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Abstract 
Background 
In 2006 the National Institute for Health and Clinical Excellence 
(NICE) made a controversial decision to restrict the availability of 
Anti-cholinesterase Inhibitors (AchI) to patients with Alzheimer‟s 
Disease (AD) who score within the „moderate‟ range (10-20 points) 
on the Mini-Mental State Examination (MMSE). A high court judge 
found NICE to have acted illegally by not providing specific guidance 
for individuals whose first language was not English, hence for whom 
the MMSE was not administrable. There is currently a lack of 
alternative objective measures of cognitive functioning that are 
equivalent to the MMSE, which can be used for people who do not 
speak English. This could result in inequalities within assessment and 
treatment practices.  
 
Aim 
The aim of this study was to explore whether cognitive tests that did 
not require spoken English (by patients) could provide equivalent 
information to that obtained from the MMSE. The second aim was to 
explore if these alternative cognitive tests could differentiate between 
those who were eligible for treatment with AchI from those who were 
not. This research would provide preliminary data about the utility of 
the chosen tests to decide on treatment eligibility based on the cut-
offs on the MMSE proposed by NICE. This would inform research in 
the future which would select non-English speaking samples to 
explore the cultural equivalence of the measures selected for this 
study. 
 
Objectives 
The two objectives of this study were firstly to explore the correlation 
between participants‟ total scores on the MMSE and their total scores 
on the Rey Complex Figure Test (RCFT), Raven‟s Colour Progressive 
Matrices (RCPM), Symbol Digit Modalities Test (SDMT), Brixton test, 
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Clock Drawing Test (CDT), and the Colour Trails Test (CTT). Secondly 
to explore if participants‟ performance on each of the alternative 
cognitive tests, namely the RCFT, RCPM, SDMT, Brixton test, CDT or 
the CTT would differentiate those eligible for treatment with AchI (10-
20 score on MMSE) from those who were not. 
 
Methods 
Twenty participants (aged 65-90 years), whose first language was 
English, were recruited from two older people‟s Mental Health Service 
sites based in two cities in England. All participants were assessed as 
having the capacity to consent using a structured assessment of 
capacity. The seven cognitive tests were administered to all 
participants. The duration of the testing ranged from 1 hour to an 
hour and half.   
 
Results 
The relationship between the MMSE and the six alternative cognitive 
tests was assessed using correlation analysis. There was a 
statistically significant linear relationship between the MMSE and the 
RCFT visual construction trial (r= .609; P<.006), the RCFT 
recognition trial (r= .496; P<.031), RCPM (r= .452; p<.045), the 
SDMT (r=.670; P<.001), the CDT (r=-.577; P<.008) and the CTT 1 
(rho=-.576; P<.012). 
 
In order to assess whether or not measures were able to identify 
those eligible for treatment or not, the measures that significantly 
correlated with the MMSE, were further analysed using Receiver 
Operating Characteristic (ROC) analysis. The area under the ROC 
curve values were as follows: RCFT visual construction (0.750, 95%, 
CI .524 - .976), RCFT recognition memory (0.801, 95%, CI .590 – 
1.012), RCPM (0.573, 95%, CI 0.298 – 0.848), SDMT (0.708, 95%, 
CI 0.469 – 0.947), CTT1 (0.818, 95%, CI 0.610 – 1.027) and the 
CDT (0.734, 95%, CI 0.479 – 0.990). All AUC values indicated that 
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the above measures had moderate to high accuracy apart from the 
RCPM, which had accuracy that was equal to chance.  
 
Cut-off scores with adequate sensitivity and specificity were identified 
for all the above measure apart from the RCPM. The cut-off scores 
with their respective sensitivity and specificity were: RCFT Visual 
constructions <20.5 (sen 87%, spec 64%); RCFT recognition memory 
<14.5 (sen 87%, 72%); SDMT <11 (sen 75%, spec 66%); CTT1 > 
144 seconds (sen 86%, spec 64%) and the CDT >9 (sen 75%, spec 
75%).   
 
Conclusion 
Cognitive tests that do not require spoken language had adequate 
predictive value and have utility in identifying those who are and are 
not eligible for treatment with AchI. The unequal prevalence rates of 
positive cases in this sample resulted in reduced PPV values for all the 
measures. An additional finding was that 80% of the participants in 
this sample who were not eligible for treatment with AchI according 
to NICE guidelines, were being treated with an AchI. Further research 
into the cross-cultural equivalence of the selected tests is necessary.  
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research with older people and had an international readership. Therefore, 
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the cross-cultural assessment of dementia.  
 
Cognitive assessment of Dementia severity using non-verbal 
cognitive tests 
Sobia Tbsum Khan a, Roshan Das Nair a, David Connelly b, Helen 
Philpott c, Nadina Lincoln a.  
a University of Nottingham UK; b Nottinghamshire NHS Trust UK; c 
Derbyshire Mental Health Services Trust UK 
ABSTRACT 
Objective: To explore the utility of cognitive tests, that did not rely 
on spoken language from participants for decision making about 
eligibility for treatment with Anti-cholinesterase Inhibitors (AchI).  
 
Methods: A cross-sectional design was used. Data was collected 
from 20 participants, aged 65 to 90 years (M, 77.6: SD, 7.2), with 
dementia, or cognitive difficulties. The sample comprised of eleven 
males and nine females. The Mini-Mental State Examination (MMSE), 
and six alternative cognitive tests were administered, these were; the 
Rey Complex Figure Test (RCFT), Ravens Colour Progressive Matrices 
(RCPM), Symbol Digit Modalities Test (SDMT), Brixton Test, Clock 
Drawing Test (CDT), and Colour Trails Test (CTT).    
 
Results:  
There was statistically significant correlations between the MMSE and 
the following cognitive tests: RCFT visual construction subtest        
(r= .609; P<.006), the RCFT recognition subtest (r= .496; P<.031), 
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RCPM (r= .452; p<.045), the SDMT (r=.670; P<.001), the CTT 1 
(Rho=-.576; P<.012) and the CDT (r=-.577; P<.008).  
 
The area under the ROC curve values were as follows: RCFT visual 
construction (0.750, 95%, CI .524 - .976), RCFT recognition memory 
(0.801, 95%, CI .590 – 1.012), RCPM (0.573, 95%, CI 0.298 – 
0.848), SDMT (0.708, 95%, CI 0.469 – 0.947), CTT1 (0.818, 95%, 
CI 0.610 – 1.027) and the CDT (0.734, 95%, CI 0.479 – 0.990). Cut-
off scores with adequate sensitivity and specificity were identified for 
all the above measures apart from the RCPM, which had predictive 
accuracy that was equal to chance.  
 
Conclusions 
Cognitive tests which do not require spoken language have utility in 
differentiating between those who are and are not eligible for 
treatment with AchI, as defined by the cut-off (<20) on the MMSE in 
the National Institute for Clinical Excellence guidelines (NICE, 2007).  
 
Key words: Anti-cholinesterase Inhibitors, Dementia, NICE, MMSE, 
„Non-verbal cognitive assessment, non-English speakers. 
 
 
 
 
 
Details for correspondence to lead author: Sobia Khan, Trent 
Doctorate in Clinical Psychology, Institute of Work Health and 
Organisations, University of Nottingham, International House, B 
Floor, Jubilee Campus, Nottingham NG8 1BB. Email: 
lwxstk@nottingham.ac.uk.  
 
 
 
 
 
 
 
  Page 12 of 209       
 
INTRODUCTION 
Dementia is an acquired degenerative neurological condition, which 
manifests itself in progressive deterioration of global cognitive 
functioning, activities of daily living and behaviour; with significant 
consequences for families and carers (Green, 2000; Rockwood et al., 
2007). For the most part, their aetiology is unknown or only partially 
understood (Lezak et al., 2004; Robillard, 2007). Even with 
recommended „gold standard‟ diagnostic criteria, cases are under-
diagnosed, missed or misclassified (Cairns et al., 2004; see 
Extended paper section 1.1 to 1.1.4 for further discussion 
regarding the challenges in dementia assessment and 
diagnosis). This situation is further compounded by the limited 
progress made in developing curative or preventative treatments 
(Pryse-Phillips, 1999). However, Anti-cholinesterase Inhibitors (AchI), 
which aim to halt and reverse decline in both cognitive abilities and 
activities of daily living (Foy & Starr, 2000), have led to benefits, if 
somewhat modest, for some (Birks & Harvey, 2006; Starr & Lonie, 
2008), and have generated considerable interest in recent years 
(Melzer, 1998; Doyle, 2001; Singh & O‟Brien, 2009; see Extended 
paper section 1.3 to 1.3.1 for further discussion regarding the 
evidence base for AchI). 
 
It is estimated that 24.3 million people around the world have 
dementia, with higher numbers in developed countries (Ferri et al., 
2005). Of the 683,597 people with dementia in the UK, 11,392 are 
from Black and Minority Ethnic (BME) backgrounds (Albanese et al., 
2007). However these could be underestimations due to scarce 
epidemiological studies in developing countries (Ferri et al., 2007), 
the lack of culturally appropriate cognitive assessments (Chen, 
2004), and differences in cultural beliefs about ageing (Ganguli et al., 
1995; Lin & Lee, 1997; Rait et al., 2000; Richards et al., 2000; Butt 
& O‟Neil, 2004; Purandare et al., 2007; Ramsey et al., 2009;  see 
  Page 13 of 209       
 
Extended paper section 1.2 to 1.2.4 for further discussion 
about international and UK specific prevalence estimates and 
challenges to establishing prevalence estimates in developing 
countries and BME groups within western countries). 
 
Most BME elders migrated to the UK as young adults, and relatively 
few have gained fluency and literacy in English (Lindesay et al., 
1997; Parker & Philip, 2006). The most commonly used cognitive 
measures have been validated only among English speaking 
Caucasians, and require fluency in English and spoken language to be 
completed (Lampley-Dallas, 2001; Manly & Jacobs, 2001). Hence, 
there is a need for cross-cultural neuropsychological assessments, 
which has been repeatedly emphasised (Maj et al., 1993; Nell, 1999; 
Chesters, 2007; Manly & Echemendia, 2007; see Extended paper 
section 1.6 and 1.7 for further discussion about cognitive 
assessment with minority groups). 
 
The National Institute for Health and Clinical Excellence (NICE) 
decided to restrict the availability of AchI to patients with Alzheimer‟s 
Disease (AD) of moderate severity (NICE, 2007). This corresponds to 
a score of 10-20 points on the Mini-Mental State Examination (MMSE, 
Folstein et al., 1975). This decision was met with widespread 
controversy and disagreement (Pelosi et al., 2006; Rodda & Walker, 
2009). The debate is over the magnitude of the effect and whether 
benefits are cost-effective for the state (Singh & O‟Brien, 2009; see 
Extended paper section 1.4 to 1.4.1 for further discussion). 
Furthermore, despite being the most frequently used and highly cited 
assessment for screening cognitive functioning in older people 
(Tombaugh & McIntyre, 1992; MacKenzie et al., 1996; Davey & 
Jamieson, 2004; Nilsson, 2007; Mitchell, 2009), the MMSE is 
confounded by multiple sources of score variance resulting in its 
psychometric instability, which is well documented (Brayne & 
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Calloway, 1990; Strauss et al., 2006 - see Extended paper section 
1.5 for critique of the MMSE). 
 
A High Court judge ruled that NICE had acted illegally by not 
providing specific guidance for groups for whom the MMSE was not 
administrable, such as those with language impairments or for whom 
English is not a first language (Syrett, 2007). The lack of progress 
made in developing alternative objective assessment procedures for 
these groups has resulted in inequalities in assessment practices and 
limits clinician‟s capacity to deliver evidenced based treatments (see 
Extended paper section 1.4.2 for more detailed discussion). 
BME and non-English speakers are also under-represented in 
Randomised Controlled Trials (RCT) for AchI and dementia research 
in general (Hussain-Gamble et al., 2004; Lopez et al., 2008 – see 
extended paper section 1.3.2 for further information about 
exclusion of BME groups in research).   
 
Subsequently, the aim of this study was to explore whether 
alternative objective cognitive tests, which did not rely on spoken 
language from participants, could provide equivalent information to 
the moderate range on the MMSE. In addition, to explore whether 
optimum cut-off scores could be identified on these cognitive tests, 
which where equivalent to the cut-offs on the MMSE that infer 
eligibility for treatment with AchI. 
 
METHODS 
 
2.1   Design 
This study employed a cross-sectional design in which all participants 
completed six index tests as well as the MMSE as the reference 
standard (described in the next section). 
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2.2   Sample 
The sample consisted of 20 participants aged between 65 and 90 
years. The initial sample size was n=30. Six subjects were excluded 
because they did not have capacity to consent; two because they 
withdrew consent; one because a carer did not consent and finally 
one because they were presenting with high levels of anxiety. Thus, 
the sample size reduced to n= 20. To be included participants needed 
to be >65 years, have a diagnosis of a dementia type illness, or were 
presenting with age related cognitive difficulties, and were fluent in 
English. Participants were excluded if they had a mood disorder, 
lacked capacity to consent, had fine motor difficulties, or if they had 
visual, or hearing impairments which would have prevented them 
from completing the cognitive tests (see Extended paper section 
2.3 for further details about the exclusion criteria).  
 
2.3 Procedures 
Participants were recruited with the approval of the regional ethics 
committee and Research and Development approval from two NHS 
sites in the UK. Participants who met the inclusion criteria were 
referred by Health Care Professionals (HPCs) working within older 
people‟s Mental Health Services. Initial appointments were arranged 
via telephone. All measures were administered during this 
appointment, taking approximately 1 to 1.5 hours. Tests were 
administered in participant‟s homes or in day hospital settings. All 
tests were administered using standardised procedures outlined in 
respective published manuals (see Extended paper Appendix 13 
for flow diagram of recruitment, and section 2.5.1 and 2.5.2 
for more detailed information about recruitment and data 
collection).  
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Measures 
The University of San Diego Brief Assessment of Capacity to Consent 
(UBACC; Jeste et al., 2007): assessed using ten items assessing 
participants‟ understanding and appreciation of the study information. 
Those unable to answer questions with sufficient detail were excluded 
(see Extended paper section 2.4.1 for further information 
about this measure; extended paper Appendix 7).  
 
Demographics Questionnaire  
Descriptive information about the sample, such as age, gender, 
education, ethnicity, relationship status, diagnosis, medication, 
history of head injury and accommodation were collected from the 
participant or carer (see Extended paper Appendix 10).  
 
MMSE (Folstein et al., 1975; Folstein, et al., 2000): consisted of 11 
items assessing orientation to time, and place, registration and recall, 
concentration, naming objects, repeating a phrase, following verbal 
and written directions, writing and constructional praxis. It took 15 
minutes to complete (see Extended paper section 2.4.3 for 
further details on the administration and psychometric 
properties for this test).  
 
Index tests 
Instruments were selected on the basis of their value in assessing 
cognitive domains, which are affected by dementia, with sufficient 
reliability. They did not rely on participants‟ spoken language, 
requiring either drawing or pointing to communicate their responses 
instead. All instructions were delivered verbatim in English by the first 
author. No studies have explored the predictive utility of the selected 
measures to identify positive and negative cases for treatment with 
AchI.  The index tests were: 
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Rey Complex Figure Test (RCFT; Meyers & Meyers, 1995): consisted 
of four items assessing visual and spatial constructional ability, visual 
speed of processing, immediate, delayed and recognition memory, in 
the visual modality only. This involved copying a figure whilst being 
timed, then drawing it from memory following a 3, then 30 minute 
delay. This test took 15-20 minutes to complete (minus 30 min 
delay; see Extended paper section 2.4.4 for further details on 
the administration and psychometric properties for this test).  
 
Ravens Colour Progressive Matrices (RCPM; Raven et al., 2003): 
assessed fluid intelligence through reasoning ability and is a 
frequently used test in gerontological research (Cockburn & Smith, 
1991; Smits et al., 1997). The test took a maximum of 25 minutes to 
complete - see Extended paper section 2.4.5 for further details 
on the administration and psychometric properties for this 
test). 
 
Symbol Digit Modality Test (SDMT; Smith, 1991): assessed attention, 
visual scanning, concentration, and motor and psychomotor speed. 
Participants were instructed to fill in as many blank spaces under a 
nonsense symbol with the correct matching numbers according to a 
code. They were given 90 seconds to fill as many gaps as possible, 
and this took 5 minutes to complete -see Extended paper section 
2.4.6 for further details on the administration and 
psychometric properties for this test).   
 
Brixton Test (Burgess & Shallice, 1997): assessed behavioural 
regulation, or concept (or „rule‟) attainment ability, which is related to 
executive functioning. Deficits in executive functioning are a notable 
area of cognitive decline in dementia (Brennan et al., 1997; Rainville, 
2002; Bielak et al., 2006). This test took approximately 15-20 
minutes to complete in this sample (see Extended paper section 
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2.4.7 for further details on the administration and 
psychometric properties for this test). 
 
Clock Drawing Test (CDT; Tuokko et al., 1995): assessed 
visuospatial, constructional and executive difficulties. Participants 
were instructed to draw the numbers in a pre-drawn clock face and 
then asked to draw in the hands to read ten past eleven. The test 
took five minutes to complete (see Extended paper section 2.4.8 
for further details on the administration and psychometric 
properties for this test). 
 
Colour Trails Test (CTT; D‟Elia et al., 1996): assessed speed for visual 
scanning, divided attention, cognitive flexibility, motor function and 
speed of information processing. It has been used to assess cognitive 
functioning in cross-cultural settings (Maj et al., 1993; Dugbartey, 
2000; Elkin-Franston et al., 2007), and can be completed in 5- 10 
minutes (see Extended paper section 2.4.9 for further details 
on the administration and psychometric properties for this 
test). 
 
Statistical analysis was conducted using correlation and Receiver 
Operating Characteristic (ROC) curve analysis (Altman & Bland, 
1994; Swets, 1988). Data was analysed using SPSS for windows 
(Version 16). 
 
RESULTS 
 
Characteristics of the sample 
The initial sample size was n=30. Six subjects were excluded because 
they did not have capacity to consent; two because they withdrew 
consent; one because a carer did not consent and finally one because 
they were presenting with high levels of anxiety. Thus, the sample 
size reduced to n= 20. Eleven (55%) males and nine (45%) females 
took part in this study. The mean age of participants was 77.6 years 
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of age (SD=7.2), ranging from 65 to 90 years. The mean years of 
education was 10.7 years (SD = 3.3), ranging from 9 to 23 years. All 
20 participants were living in their own homes. Eighteen (90%) of the 
participants classified themselves as White British, one as White Irish 
(5%) and one (5%) as White Scottish. 
 
Fifteen subjects (75%) were diagnosed with AD, three (15%) were 
diagnosed with mixed AD and Vascular Dementia, and two were 
presenting with mild cognitive impairment. The mean score on the 
MMSE was 22 (SD = 4.4), ranging from 14 to 29 points. Only three 
participants who scored within the severe range on the MMSE (0-9) 
were referred to this study and these three were unable to provide 
informed consent. Hence, it was not possible to explore the 0-9 cut 
off.  
 
There were 8 (40%) positive cases (scored <20 on MMSE, eligible for 
AchI) and 12 (60%) negative cases (scored >21 on the MMSE, not 
eligible for AchI) in this sample. In the 8 positive cases the score 
range was 14 to 20 points on the MMSE, and all were being treated 
with an AchI. In the twelve negative cases, the score range was 21 to 
29 points on the MMSE, and ten (83%) were being treated with an 
AchI. In total 18 (90%) participants were being treated with an AchI 
(n=16, 80%, with Aricept; n=2, 5%, Exelon).  
 
Following normality analysis, Pearson product moment coefficient was 
calculated between scores on the MMSE and scores on the RCFT-
visual construction, RCFT-speed of process, RCFT-recognition 
memory, RCPM, SDMT, Brixton test, CDT and CTT2. Spearman 
correlation coefficient was calculated between scores on the MMSE 
and the RCFT – immediate memory, RCFT-delayed memory and CTT1 
(see Extended paper section 3.4 to 3.5 for details regarding 
exploration of distribution of scores). The correlations obtained 
are shown in Table 1.  
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Table 1: Pearson and Spearman correlation coefficients for MMSE and 
index tests 
Index tests‡ N MMSE Significance 
RCFT VC 19 r= .609** .006 
RCFT SP 19 .128 .602 
RCFT I 19 .131 .594 
RCFT D 19 .370 .119 
RCFT R 19 r= .496* .031 
RCPM 20 r= .452* .045 
SDMT 20 r= .670** .001 
Brixton Test 18 -.403 .098 
CDT 20 r= -.577** .008 
CTT1 18 r= -.576* .012 
CTT2 12 -.372 .234 
‡ RCFT VC, Rey Complex Figure Test Visual Construction 
Trial; RCFT SP, Rey Complex Figure Test Speed of 
Processing; RCFT I, Rey Complex Figure Test Immediate 
Memory; RCFT D, Rey Complex Figure Test Delayed 
Memory; RCFT R, Rey Complex Figure Test Recognition 
Memory; RCPM, Ravens Colour Progressive Matrices; SDMT, 
Symbol Digit Modalities Test; CDT, Clock Drawing Test; 
CTT1 & 2, Colour Trails Test 1 & 2.  
 
** = Correlation is significant at p< 0.01 level, 2-tailed 
* = Correlation is significant at p< 0.05 level, 2-tailed 
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ROC analysis was carried out with measures that significantly 
correlated with the MMSE. ROC curves were plotted to show the trade 
off between sensitivity and specificity for all scores, allowing for the 
choice of most appropriate cut-off. Particular regions of the ROC 
plane correspond with particular type of diagnostic performance. The 
extreme lower left corner represents a measure that classifies all 
participants as not being eligible for AchI. The extreme top right 
corner represents a measure that classifies all participants as eligible 
for AchI. The diagonal line crossing through the plane represents 
chance. Performance below this line is worse than chance. The ROC 
curves are presented in Fig 1, 2 and 3 (see Extended paper 
section 3.9 to 3.9.3 for more details about ROC analysis).  
   
The area under the ROC curve values were as follows: RCFT visual 
construction (0.750, 95%, CI .524 - .976), RCFT recognition memory 
(0.801, 95%, CI .590 – 1.012), RCPM (0.573, 95%, CI 0.298 – 
0.848), SDMT (0.708, 95%, CI 0.469 – 0.947), CTT1 (0.818, 95%, 
CI 0.610 – 1.027) and the CDT (0.734, 95%, CI 0.479 – 0.990). Cut-
off scores with adequate sensitivity and specificity were identified for 
all the above measure apart from the RCPM, which had predictive 
ability that was equal to chance. The sensitivity, specificity, Positive 
Predictive Value, Negative Predictive Value and overall Discriminant 
Ability (DA) for chosen cut-offs were calculated using cross 
tabulations and kappa analysis. The results are shown in Table 2 
(see Extended paper section 3.10 to 3.15 for a detailed 
description of how ROC analysis was carried out for each 
measure that significantly correlated with the MMSE).    
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Table 2: Optimum cut-off scores on index test which are equivalent to 
the cut-off (<20) on the MMSE 
Index 
tests * 
Cut-off 
score 
Sen 
% 
Spec 
% 
PPV 
% 
NPV 
% 
Discriminant 
ability % 
RCFT VC <20.5a 87 64 64 87 75 
RCFT R <14.5a 87 72 70 89 79.5 
SDMT <11a 75 66 60 80 70.8 
CTT1 >144.5 
secondsb 
86 64 60 88 75 
CDT >9b 75 75 60 80 71 
   *  RCFT VC, Rey Complex Figure Test Visual Construction; 
RCFT R, Rey Complex Figure Test Recognition; SDMT, 
Symbol Digit Modalities Test; CTT1, Colour Trails Test 
1; CDT, Clock Drawing Test; Sen, Sensitivity; Spec, 
Specificity; PPV, Positive Predictive Value, and NPV, 
Negative Predictive Value.  
   a lower score indicated greater impairment 
   b Higher score indicated greater impairment 
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RCFT- Visual Construction  
                   
 
 
 
 
 
 
 
 
 
 
 
 
RCFT- Recognition Memory  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig1. ROC curves for RCFT visual construction and 
recognition memory subtests 
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Ravens Colour Progressive Matrices 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Symbol Digit Modalities Test 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig2. ROC curves for RCPM and SDMT 
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Clock Drawing Test  
 
 
 
 
 
 
 
 
 
 
Colour Trails Test 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig3. ROC curves for CDT and CTT1 
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DISCUSSION 
The aim was to explore the utility of alternative cognitive tests, which 
do not rely on spoken language, to address the lack of objective 
cognitive assessments for people who are not fluent in English and 
those who are non-verbal, to decide if they are eligible for treatment 
with an AchI (NICE, 2007).  
 
Relationship between MMSE and index tests 
High correlation coefficients were found for five of the six index tests 
(see Table 1). Out of 11 items in total, the MMSE had high 
statistically significant correlations with six items assessing:  visual 
construction (RCFT); recognition memory (RCFT), reasoning ability 
(RCPM); attention, visual scanning, motor speed (SDMT); visual 
construction and executive difficulties (CDT); attention, speed for 
visual scanning, divided attention, cognitive flexibility, motor function 
and speed of information processing (CTT1). In line with previous 
studies we found a high correlation between the MMSE and the CDT 
(Mendez et al., 1992; Schramm et al., 2002). We did not find a 
statistically significant correlation between the MMSE and specific 
tests of executive functioning, such as the Brixton test and CTT2, 
which is a key limitation of the MMSE as a dementia screen. However, 
the Brixton test is confounded by short term memory difficulties 
(Rainville et al., 2002). Participants reported forgetting of previous 
items, which was not surprising due to the 55 trials. Furthermore, 
participants‟ reported difficulty comprehending instructions for CTT2, 
which led to missing data from eight participants. However, 
difficulties with the CTT2 could also be explained by order effects, as 
it was the last measure to be administered, thus performance may 
have been confounded by fatigue (see extended paper section 4.1 
for further discussion related to the utility of index tests). 
 
The high correlations with the other common tests of cognitive 
functioning were a somewhat surprising finding given that the MMSE 
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has previously had weak coefficients with cognitive tests measuring 
similar constructs (Strauss et al., 2006). These findings provide 
partial evidence that as a screening tool the MMSE performs quite 
well (Tombaugh & McIntyre, 1992; Han et al., 2000; Strauss et al., 
2006).  However, a limitation of this study is that a clinical sample, 
which was being treated with an AchI, was used. These two variables 
could have been confounding variables. Therefore, it is unclear 
whether the correlations between the MMSE and the index tests were 
due to a true relationship between the domains that were being 
measured, or due to the effect of the medication or diagnosis. This 
could be rectified in a future study, where these two variables are 
controlled and a non-clinical sample is used (see extended paper 
section 4.4 for further discussion regarding the limitations of 
this study).    
 
Predictive accuracy of index tests & cut off scores 
All measures, apart from the RCPM, obtained AUC values above .708, 
which demonstrates moderate accuracy (Bewick et al., 2004; Linden, 
2006). A previous study has obtained the same finding in relation to 
the RCPM (Blake et al., 2002). AUC values were highest for RCFT 
recognition memory (.801) and the CTT1 (.818), which is moderate 
to high in predictive accuracy (Fischer et al., 2003). The SDMT had 
the lowest AUC value (.709).  
 
It was possible to identify cut-off scores which were equivalent to the 
<21 point cut off on the MMSE. Therefore, clinicians would be able to 
use these cut offs to aid decision making about prescribing AchI. An 
optimum cut-off of <20.5 for the RCFT visual construction, had good 
sensitivity (87%) and moderate specificity (64%). Therefore, 87% of 
participants scored 20.5 or below on this measure, which was the 
indicator for eligibility for treatment with AchI, and 64% scored above 
this cut-off.  However the usefulness of a test is judged by whether or 
not those who tested positive using this cut-off were classified 
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correctly (Altman & Bland, 1994; Linden, 2006). For this test, the PPV 
was moderate (64%) and the NPV (87%) was good. This suggested 
that only 64%, who were below the cut-off on the RCFT visual 
construction trial, actually had a MMSE score within the moderate 
range, and 87% of those who scored above the cut-off on the RCFT, 
also obtained above the cut-off on the MMSE. A similar pattern was 
observed for the four other index tests (see Table 2). The PPV for all 
the cut-offs for the index tests were adequate. However, these 
results have to be viewed in light of the limitations of this study, 
namely the small sample size and the unequal prevalence of positive 
(8, 40%) and negative cases (12, 60%). This would have reduced the 
PPV and increased the NPV as they are sensitive to unequal 
prevalence rates (Bewick et al, 2004).  In addition, it is possible that 
the cut-off scores for all five index tests (see Table 2) could have 
been different with a none clinical sample, or if there were more 
participants who scored within the moderately severe range (10-15). 
Therefore further research which manipulates these variables would 
enable us to learn more about how they impact on the predictive 
utility of the chosen measures and their cut-off scores.  
 
The higher sensitivity and lower specificity values could reflect the 
high level of cognitive impairment in this sample. The cut-offs chosen 
were all within the impaired range for their respective measures. For 
measures such as the SDMT and RCFT recognition trial the cut-off 
score was so low that it is likely that if this study included more 
people who scored within the severe (0-9) or moderately severe (10-
15) range on the MMSE, they may have scored zero. Hence it may be 
less meaningful to use these tests for these groups in clinical practice 
to monitor change.   
 
Furthermore, the RCFT recognition trial had the highest PPV and NPV, 
however all subtests of the RCFT would need to be administered in 
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clinical practice to obtain the recognition score. Any alternative test to 
the MMSE would need to balance high predictive accuracy with the 
preference for it being quick and require minimal training (Glasser, 
1993; Mitchell, 2009). Therefore, the SDMT, CDT, CTT1 and RCFT 
visual construction may be adequate alternatives to the MMSE in 
terms of time.  
 
The implications of these results are potentially considerable for GPs, 
older people‟s Mental Health Services and memory clinicians. This is 
because clinicians carry out cognitive assessments with people with 
dementia routinely. However, the findings of this study are only 
preliminary and further research needs to be carried out before the 
index tests can be used to make decisions about eligibility for 
treatment with AchI  (see extended paper section 4.3 for further 
discussion regarding the clinical implications of this research).  
 
In relation to clinical practice, this study also found that in this 
sample 80% who were not eligible for AchI, according to their MMSE 
score, were being treated with an AchI. Therefore, providing partial 
evidence that clinicians may not be adhering strictly to guidelines 
(NICE, 2007). Further research exploring treatment practices is  
needed to establish how prevalent this is across services and also the 
evidence base that is informing such decisions (See Extended paper 
section 4.2 for further discussion related to the prescription of 
AchI). 
 
Finally, it is important to bear in mind that this research was based 
on the assumption that the MMSE is a gold standard assessment. 
There is limited empirical evidence to support that the „moderate‟ 
range on the MMSE is a valid construct on which to base decisions 
about treatment eligibility (Olin & Zelinsky, 1991). This was going 
beyond its intended use as a dementia screen (Folstein et al., 1975). 
Further research about the neurological, neuropsychological and 
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functional parameters of the „moderate‟ range is warranted, if the 
guidelines are to remain valid (Cerejeire & Mukaetova-Ladinska, 
2007; see extended paper section 4.6 for further discussion 
about expanding on this research).  
 
Four key points 
1. Cognitive tests that do not require spoken language may have 
utility in assessing for eligibility for treatment with AchI.  
2. Research exploring the cross cultural equivalence of these 
measures is necessary.  
3. The clinical parameters of the “moderate” range remain unclear. 
4. AchI are prescribed to people who score above the cut-off on the 
MMSE.  
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1. Extended Introduction 
Chapter Overview 
This section will present additional background literature related to 
the aetiology, assessment, diagnosis and drug treatments for 
dementia type illnesses. The literature will firstly be reviewed to 
describe the evidence-base currently informing clinical decision 
making, and how this can be applied to people who do not speak 
English (such as ethnic minority groups). The implications of the 
National Institute for Health and Clinical Excellence (NICE) guidance 
(NICE, 2007) for the prescription of Anti-cholinesterase Inhibitors 
(AchI) for people with Alzheimer‟s Disease (AD), and the role of the 
Mini-Mental State Examination (MMSE; Folstein, Folstein & McHugh, 
1975) within these, will be critically discussed. The objective here 
being to highlight the limitations of this guidance for older people in 
general and then more specifically for older people who have limited 
proficiency in spoken English. Finally, literature will be drawn from 
the field of cross-cultural neuropsychology to consider the potential of 
alternative cognitive assessments for people who do not speak 
English.    
 
This paper will focus on the most common forms of dementia, namely 
AD and Vascular dementia (VaD). This is because AchIs have been 
approved for treatment of AD. Although they have not been approved 
by NICE to treat Vascular Dementia (VaD) it is common for AD and 
VaD to be present at the same time, and if AD is assessed as being 
the dominant condition of the two, AchI can be prescribed (NICE, 
2007).  
 
1.1   What is dementia? 
Dementia is a progressive decline in cognitive or behavioural 
functioning from a prior level of functioning, which is associated 
within decline in one or more functions, such as: short and long term 
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memory, abstract thinking, executive processes, language, attention 
and concentration, visual processing and personality changes. The 
progressive decline can be gradual or step-wise and eventually is 
severe enough to interfere with day-to-day functioning, employment 
or relationships (American Psychiatric Association, 2000). It is an 
incurable condition of major significance due to the worlds ageing 
population. Deterioration is associated with a continuous change in 
patient and care-giving problems and needs. Thus, it is imperative 
that ongoing efforts are made to carry out research with the aim of 
improving existing National Health Service (NHS) guidelines in the 
areas of assessment and care management that are consistent and 
also applicable to minority populations (National Audit Office, 2007).   
 
1.1.1   Classification of dementia 
The diagnosis of dementia is based on a careful case history. 
Laboratory and imaging tests as yet only provide supportive evidence 
(Rockwood, Bouchard, Camicioli & Leger, 2007). According to Stuss 
and Levine (1996) there are four ways to define and classify the 
dementias, 1) histologic/ neuropathologic; 2) causal risk factors (e.g. 
vascular, genetics, infections etc.); 3) brain region involved and 4) 
clinical profile (e.g. early onset, step-wise progression). To construct 
a differential diagnosis of the cause of dementia, the starting point is 
typically the clinical presentation.  The usual question is whether the 
presentation conforms to the usual pattern seen with each dementia. 
However, the process of diagnosis can be confounded by many other 
factors such as health related co-morbidities and limitations of 
assessment methods for particular populations, such as people who 
do not speak English. Therefore a thorough clinical history, 
examination and longitudinal follow-up are important (Rockwood et 
al. 2007).  
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Having an indication of the pattern of progression can also give 
clinicians some capacity to predict the likely pattern of decline and 
decide upon what interventions may be most suitable. However, in 
later stages of the disease there is little difference in the symptoms 
experienced; hence diagnosis tends to become less meaningful for 
the individual and more difficult to differentiate for clinicians. 
Furthermore, even after completing assessment in all of the key 
areas identified by Stuss and Levine (1996) it becomes apparent that 
diagnosis is not straightforward. Different types of comorbidity and 
pathology can exist simultaneously, and the clinical decision must be 
made judiciously to establish the predominant pathology contributing 
to the dementia syndrome (Cerejeira & Mukaetova-Ladinska, 2007).  
 
The first case of pre-senile dementia was reported in 1906 by Alois 
Alzheimer, a German Psychiatrist and Neuropathologist (Whitehouse, 
Mauer & Ballenger, 2000). Alzheimer used histology (the microscopic 
examination of the anatomy of diseased cells and tissues) to identify 
amyloid plaques, neurofibrillary tangles and arteriosclerotic changes 
in a female patient. This marked the first case of dementia and these 
early findings are consistent with histological examinations today. 
Until the 1960s differential diagnosis of memory difficulties within the 
older adult population could function with some certainty, especially 
with differentiating age-related benign and malignant changes 
(especially with AD). This could be validated against autopsy, which 
represented the gold standard for definitive diagnosis.  
 
However, neurofibrillary tangles and senile plaques alone do not infer 
a dementia type illness as they are also present in the brains of older 
people without dementia (Lezak, Howieson & Loring, 2004).  In 
addition, people with apparently identical lesions can differ widely in 
their cognitive functioning. Furthermore, differing sets of 
neuropathologic criteria yield differing estimates of dementias in the 
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same brains. Crystal et al (1988) showed that some elderly people 
met neuropathologic criteria for dementia but in fact were not 
showing signs of dementia (Crystal, Dickson, Fuld, Masur, Scott, 
Mehler et al, 1988).  
 
1.1.2   Alzheimer’s Disease 
There are two sets of criteria for diagnosing AD. These are specified 
within the DSM-IV-TR (American Psychiatric Association, 2000) and 
those established by the working group on the diagnosis of AD, 
established by the National Institute of Neurologic and 
Communicative Disorders and Stroke (NINDS) and the Alzheimer‟s 
Disease and Related Disorders Association (ADRDA; McKhann, 
Drachman, Folstein, Katzman, Price & Stadlan, 1984). AD is 
characterised by a gradual onset and gradual progressive decline of 
memory and at least one additional cognitive domain. Diagnosis is 
made on the basis of exclusion of other possible aetiologies for the 
progressive decline.  
 
In light of the uncertainties around diagnosis and the need to develop 
better defined criteria for research participants the NINDS/ADRDA 
distinguishes between definite, probable and possible AD. Although 
the NINCDS-ADRDA criteria is widely used in research and is 
applicable in clinical settings, when interpreted strictly they select 
only so-called pure cases of AD, so exclude patients with mixed 
disorders, which are common. Nevertheless, in comparison to other 
causes the diagnostic criteria has good sensitivity (average, 81%; 
range, 49% to 100%), at the expense of specificity (average, 70%; 
range, 47% to 100%). 
 
No single marker or set of markers for reliable positive identification 
of AD in living patients has yet been found (Lezak et al, 2004). 
Examinations of brain tissue at autopsy show the accumulation of 
amyloid plaques and neurofibrillary tangles. The additional 
  Page 45 of 209       
 
neuropathological hallmarks of AD are inflammation, neuronal loss 
and depletion of neurochemicals such as acetylcholine (Whitehouse, 
Price, Struble, Clark, Coyle & Delong, 1982; Shah & Reichman, 
2006).  
 
1.1.3   Vascular Dementia 
Four diagnostic classification systems are in use for VaD, these are 
the California criteria, the DSM-IV-TR, the NINDS-AIREN criteria and 
the Hachinski Ischemic Score. In studies comparing diagnostic criteria 
and neuropathologic findings the NINDS-AIREN, DSM-IV-TR and 
California criteria had very low sensitivity (average 50%; range, 20% 
to 80%) but higher specificity (average 87%; range, 64% to 98%). 
The decreased sensitivity of diagnostic criteria is due to the 
considerable overlap between vascular and degenerative pathology. 
Some vascular pathology exists in 29% to 41% of dementia cases 
coming to autopsy. Pure vascular pathology accounts for dementia in 
only 9-10% of cases, leading some to propose that pure VaD or AD is 
rare.     
 
Vascular Dementia (VaD) is a decline in cognitive functioning which 
can result from any of a number of vascular aetiologies. Vascular 
disorders such as stroke, Cerebrovascular Accident (CVA) and 
Transient Ischemic Attacks (TIA) are caused by pathological 
processes within cerebrovascular circulation. This is the supply of 
blood and nutrients (primarily oxygen and glucose) to the brain 
(Lezak et al, 2004). A disruption of normal blood flow (infarction) 
deprives the nervous tissue of oxygen, thus creating an area of 
damaged or dead tissue; an infarct. There is considerable overlap in 
the symptoms and presentation of vascular dementia and 
cerebrovascular disease. Therefore, there is an ongoing debate about 
the symptoms necessary to differentiate vascular dementia from 
vascular disease. Furthermore, the term “vascular-dementia” lacks 
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agreed diagnostic criteria, which results in significant differences in 
classification (Chen, 2004). VaD progresses in a similar way to AD, in 
that it gets worse over time, however progression is often „step-wise‟ 
rather than gradual, declining slowly as the person has a new stroke. 
Progression of VaD can be slowed by the identification of underlying 
risk factors such as blood pressure.  
 
1.1.4 Neuropsychological assessment of Dementia  
One of the major roles of neuropsychological assessment is to 
determine whether a patient is experiencing cognitive dysfunction 
and to contribute to identification of aetiology so treatment can be 
offered (Green, 2000). When all the data of a comprehensive 
neuropsychological assessment – patient history, background and 
presenting problems, qualitative observations and quantitative scores 
are taken together, the examiner should have a realistic 
understanding of the deficits and the likely causes. Repeated testing 
in the dementia population can signal the pattern of progression and 
the type of dementia they have. Repeated testing can also be used to 
assess the effects of drug treatments.  However, neuropsychological 
differences between the dementias typically show up in early stages 
of the disease process, hence in later stages of the disease patients 
become neuro-psychologically indistinguishable (Green, 2000). 
 
A distinction has been made between cortical and subcortical 
dementia. Subcortical dementia describes a clinical syndrome 
associated with dysfunction in subcortical grey matter structures 
including the basal ganglia, thalamus, subthalamus, brain stem and 
their frontal lobe projections, as contrasted with cortical structures 
such as the frontal and temporal lobes (Green, 2000). Aphasia, 
amnesia, agnosia, and apraxia have been described as more 
characteristic of cortical dementias, and AD is described as the typical 
representation of a cortical disease. Vascular dementia is seen more 
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as being prototypical of a subcortical disease. However, there has 
been considerable debate concerning the validity of this distinction, 
with increasing recognition that both cortical and subcortical changes 
occur in most dementia disorders (Whitehouse, 1986).  
 
In comparison to AD memory impairment in VaD may be more subtle 
and largely dominated by other cognitive dysfunctions (Sellal, Woltt & 
Marescaux, 2004). The cognitive pattern changes according to the 
type of VaD. In multi-infarct dementia cortical lesions may cause loss 
of instrumental functions manifested by aphasia, amnesia, apraxia, or 
agnosia. Compared to patients with AD, VaD patients typically 
perform better on verbal learning and memory tasks and have better 
delayed recall and lower rates of forgetting. Subcortical ischaemic 
dementia frequently impairs executive functions, attention, and speed 
of information processing. The clinical hallmark of VaD is 
dysexecutive syndrome. In addition, language is one of the first skills 
to be affected by dementia (Green, 2000). Therefore, the difficulty 
with expressive and receptive language becomes a significant barrier 
for communication.   
 
1.2      Prevalence of dementia 
1.2.1 International Estimates 
Alzheimer‟s Disease International, the umbrella organisation for 
national Alzheimer‟s associations, convened an international group of 
experts to generate up-to-date evidence-based estimates for the 
prevalence and numbers of people with dementia in all regions of the 
world (Ferri, Prince, Brayne, Brodaty, Fratiglioni, Ganguli, et al, 
2005).  Twelve international experts used the Delphi method to 
provide prevalence estimates for every World Health Organisation 
(WHO) world region and the results are considered the best estimates 
currently available. The Delphi method involves experts 
systematically reviewing the evidence base independently. The 
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results are collated to compare estimates generated by each expert, 
and they then reach a consensus to provide the prevalence rates.  
 
The numbers affected will double every 20 years to 81.1 million by 
2040 (Ferri et al, 2005). These estimates were derived with the 
assumption that there will be no changes in mortality rates, and no 
preventative or curative treatments will be developed. A point of 
interest is that most people with dementia were noted as living in 
developed countries (60% in 2001, rising to 71% by 2040). It is 
possible that this is an under-estimation of prevalence in developing 
regions. Possible explanations for this are scarce epidemiological 
surveys in these regions (Ferri et al, 2005).There are also differences 
in cultural beliefs, with some traditional approaches to health and 
well-being conflicting with western values (Butt & O‟Neil, 2004). The 
effects of ageing may also be experienced and treated differently in 
these cultures (Ramsey, Stevens, Bryan, Binder & Cockle-Hearne, 
2009). For instance, some cultures remove responsibility from their 
elderly by taking over the older persons‟ responsibilities and treating 
them with respect. Thus the symptoms of dementia may be less 
obvious or tolerated as part of ageing (Rait, Burns, Baldwin, Morely, 
Chew-Graham & Leger, 2000; Purandare, Luthra, Swarbrick & Burns, 
2007).  
 
Finally, the lower life expectancy in some regions, such as Africa, 
could also account for lower rates of dementia, because people may 
not live into old age, therefore decreasing their potential to develop 
clinical conditions which have increased incidence in later life.  Chen 
(2004) suggests that there may be methodological issues such as 
study design and differences in language, social customs and 
educational levels impacting  on the validity of cognitive instruments 
which presume literacy, numeracy and knowledge of (and interest in) 
current events. 
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Thus, confirmation and elaboration of discrepancies in prevalence in 
developing countries require more prospective studies, using 
appropriately harmonised diagnostic procedures (de Silva & 
Gunatilake, 2002). However, if this difference in disease frequency is 
genuine, it might suggest geographical variation in the distribution of 
critical risk and protective factors for and against dementia (Chen, 
2004).  
 
1.2.2   Prevalence rates in the UK 
In 2006, the Alzhiemer‟s Society commissioned the London School of 
Economics and the Institute of Psychiatry at Kings College London to 
produce a report on dementia specifically in the UK (Albanese, 
Banerjee, Dhanasiri, Feernandez, Ferri, Knapp et al, 2007).  Ten 
leading UK and European experts systematically reviewed the data. 
Using the Delphi method, they estimated that there are 683,597 
people with dementia in the UK. This number is forecast to increase 
to 940,110 by 2021 and 1,735,087 by 2051, an increase of 35% over 
the next 15 years and 154% over the next 45 years. Early onset 
(onset before age of 65 years) dementia is comparatively rare, 
accounting for 2.2% (15,034) of all people with dementia in the UK. 
However, this could again be an under-estimation, since these people 
present much later into services.  
 
The report estimates that 416,967 people with dementia (62%) have 
AD in the UK. The next most common forms are Vascular dementia 
(VaD) and mixed dementias, accounting for 27% of all cases. 
However, the „mixed dementia‟ classification is an anomaly, and it 
highlights the challenges of differential diagnosis in this area 
(Rockwood et al, 2007). In addition, Sellal et al (2004) state that 
current measures used to assess cognitive functioning place most 
emphasis on the domains that are typically impaired in patients with 
AD, therefore measures that fail to screen for executive functioning 
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and language deficits are likely to result in an underestimation of the 
incidence of VaD.  
 
1.2.3   Older adult ethnic minority groups in the UK 
The report estimates that there are 11,392 people from Black and 
Minority Ethnic (BME) groups with dementia, accounting for 1.7% of 
all people with dementia. In contrast, studies suggest that BME 
groups have a greater incidence of dementia, the cause attributed to 
unidentified genes or other risk factors (Tang, Stern, Marder, Bell, 
Gurland, Lantigua et al, 1998). Indeed, the UK incidence estimates 
note that 6.1% of all people with dementia among BME groups are of 
younger onset compared with only 2.2% for the population as a 
whole, which possibly reflects the younger age profile of BME 
communities living within the UK. However, the „BME community‟ is a 
heterogeneous group composed of different religions, languages and 
cultures, therefore it is unlikely that genetic factors will account for 
early onset dementia in all of these ethnic groups. There is also 
evidence to suggest that measures used to assess cognitive decline, 
such as the MMSE, in older people from ethnic minority groups have 
high rates of false positives. There is also the possibility that 
dementia is under-diagnosed in minority ethnic groups due to their 
reluctance in accessing services (Eolas, 1999).  
 
According to the 2001 census study there are an estimated 4.6 
million (or 7.9 per cent) people in the UK belonging to non-White 
ethnic groups (ONS; Office of National Statistics, 2003). Indians were 
the largest of these groups (1.8 %), followed by Pakistanis‟ (1.3%), 
those of mixed ethnic backgrounds (1.2%), Black Caribbean (1%), 
Black Africans (0.8 %), Bangladeshis‟ (0.5%) and Chinese (0.4%). 
The remaining minority ethnic groups each accounted for less than 
0.5% of the UK population and together accounted for a further 
0.9%. The numbers and proportions of older people from BME groups 
  Page 51 of 209       
 
are rising and will continue to rise for the foreseeable future. 
However, people from BME groups have a slightly younger age 
profile. Nine per cent of people from Black and Caribbean ethnic 
backgrounds are aged 65 and over and six percent of Indians are 
aged 65 and over. These proportions are expected to expand as 
people from minority ethnic groups who migrated to the UK in the 
1960s and 1970s reach retirement age (ONS, 2003).  
 
Unfortunately there is no data which breaks down the incidence of 
AD, VaD or any other dementia type illness within BME groups. It is 
hypothesised that the incidence of VaD would be higher for BME 
groups since they are a high risk for developing cardiovascular-
related difficulties (Chen, 2004; Purandare, Luthra, Swarbrick & 
Burns, 2007).  
 
1.2.4   Literacy and fluency of English language amongst 
ethnic minority groups in the UK 
One barrier to implementing routine practices for minority ethnic 
groups is language. There are no consistent or conclusive statistics 
for rates of literacy and fluency in English within minority ethnic 
groups. Within migrant groups, older people are least likely to have 
acquired faculty in the dominant language and integrated into the 
new nation‟s culture (Johnson, Owen, Blackburn, Rehman & Nazroo, 
2000). In a 1999 survey, among the 50 to 74 age group, 67% of 
Pakistani women, 46% of Pakistani men, 100% of Bangladeshi 
women and 64% of Bangladeshi men stated they could speak „only a 
little English‟ (Johnson et al, 2000).  
 
In addition, cognitive testing relies on linguistic competence. 
Therefore, whether a person understands English or not, tests which 
are reliant on spoken language to assess cognitive functioning, would 
limit their usefulness with those who are non-verbal in general. For 
non-English speakers, clinicians may be dependent on an interpreter; 
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however, interpreting test instructions is simpler to do than 
interpreting verbal responses. The reason being that the test 
responses are the main source of measurement and changing 
requirements for verbal responses to make them more culturally 
specific may cause them to be less equivalent to the original test 
designed for English speakers. Therefore, measures that are not 
reliant on spoken language can assist the patient to communicate 
their responses by drawing or pointing to answers (Olsson, 2004).  
 
1.3   Anti cholinesterase Inhibitors (AchI) 
The use of AchI for AD has generated controversy in recent years and 
attracted attention from the scientific community and various non-
statutory agencies and consumer groups. In dementia, especially AD, 
the production of acetylcholine is decreased. As a result, nerve 
communication becomes less efficient, with consequent problems of 
cognitive and behavioural functioning. AchI prevent the breakdown of 
Acetylcholine and can improve nerve function; however the damage 
to brain cells cannot be halted or reversed. 
 
There are three types of AchIs that are licensed for the symptomatic 
treatment of people with mild to moderately severe dementia. These 
are: 1) Aricept (Donepezil), 2) Reminyl (Galantamine) and 3) Exelon 
(Rivastigmine). In 2003, 77% of prescriptions for AchIs were for 
Donepezil (NICE, 2007). 
 
1.3.1   Evidence for effectiveness of AchI 
Dementia severity is classified in terms of mild (21-26 points), 
moderate (10-20 points), moderately severe (10-14 points) and 
severe (0-9 points) based on cut-offs on the MMSE. It is important to 
be aware of these cut-offs because the evidence base refers to the 
effectiveness of drug treatments for each of these stages of severity 
of dementia. However, it is unclear whether RCTs are stratifying their 
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samples in this manner because NICE has chosen these cut-offs or if 
NICE has generated their cut-offs on the basis of how samples have 
been stratified within RCTs. If the latter is the case, it makes logical 
sense for NICE to only recommend treatments for groups for which 
they have been proven to be effective. Either way, there is limited 
information of why these cut-offs have been used as oppose to 
alternative cut-offs proposed in the literature (Folstein, Folstein & 
Fanjiang, 2000). 
 
NICE reviewed the clinical and cost effectiveness of AchI for mild to 
moderately severe AD. The outcomes were explored in terms of 
cognitive functioning, functional ability, quality of life, behavioural 
symptoms, adverse events, cost effectiveness, benefits to carers, 
mortality rates and delay of residential care (NICE, 2007).  The use of 
these drugs is surrounded by controversy and whilst most accept that 
there is a modest benefit, others insist that they simply do not match 
up to expectations (Starr & Lonie, 2008; Rodda & Walker, 2009). It 
was recognised that although measures used to explore the benefits 
of AchI to carers, functional and behaviour assessments did not show 
any effects of the treatments. However, this could be due to the lack 
of appropriate and sensitive measures rather than a lack of effect 
(NICE, 2007). Furthermore, not all patients do benefit and there are 
no reliable predictors of who is more or less likely to benefit from 
these drugs (Starr & Lonie, 2008).  
 
A systematic review to assess the effects of AchIs in delaying the 
conversion from Mild Cognitive Impairment (MCI) to AD concluded 
that treatment for periods ranging from less than 4 months to three 
years, was not associated with any delay in the onset of AD or 
dementia (Raschetti, Albanese, Vanacore & Maggini, 2007). The eight 
trials included within this review ranged in the primary and secondary 
measures used to measure treatment outcomes. Some studies used 
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global cognitive assessments such as the MMSE as a primary 
measure and more detailed neuropsychological assessments as 
secondary measures, such as the Clock Drawing Test, Symbol Digit 
Modalities Test and Trail Making Test. Although significant treatment 
effects were not found in the primary efficacy measures, outcomes on 
secondary measures suggest promising directions for further 
evaluation of Aricept treatment in patients with MCI (Salloway, Ferris, 
Kluger, Goldman, Griesing, Kumar et al, 2004). However, Birks & 
Harvey (2006) report changes of 1 point on the MMSE in some trials, 
yet this could be accounted for by error variance alone. This suggests 
that measures such as the MMSE are not sensitive to change and in 
fact any change of less than 4 points on the MMSE is not informative 
in terms of the degree of cognitive and functional change.  
 
Birks and Harvey (2006) conducted a meta-analysis to assess 
whether Aricept improves the wellbeing of patients with dementia due 
to AD. All unconfounded, double-blind, RCTs in which treatment with 
Aricept was compared with placebo for patients with mild, moderate 
or severe dementia due to AD were included. Outcome data covered 
domains of cognitive function, activities of daily living, behaviour, 
global clinical state, adverse events and healthcare costs. The MMSE 
was frequently used to measure severity and was also used as an 
outcome measure to assess the effect of the treatment on cognitive 
functioning. People with mild, moderate or severe dementia due to 
AD treated for a period of 12, 24 or 52 weeks experienced benefits in 
cognitive function, activities of daily living, and behaviour (Birks & 
Harvey, 2006).  
 
A meta-analysis for treatment of VaD with AchI concluded that they 
resulted in small benefits in cognition, with uncertain clinical 
significance in patients with mild to moderate VaD (Kavirajan & 
Schneider, 2007). However, the study highlighted the challenges in 
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designing clinical trials for vascular dementia. The heterogeneity of 
the clinical group leads to differing clinical presentations and course 
of disease, therefore they may respond differently to the drugs. 
Furthermore, the small effects shown in trials for vascular dementia 
could be accounted for by the effects on coexisting AD, rather than 
the VaD (Kavirajan & Schneider, 2007). In addition, the outcome 
measures used are ones that are designed for AD populations, 
therefore may not be sufficiently sensitive to clinical changes in VaD 
patients.  
 
1.3.2   Minority ethnic groups excluded from clinical trials 
RCTs are the most effective method for evaluating healthcare 
treatments (Altman, 1996). However, there are concerns about the 
generalisability of findings to ethnic minority groups (Hussain-
Gambles, Atkin & Leese, 2004). A review of exclusion criteria used in 
RCTs found that many had blanket exclusions for ethnic minority 
groups without any justification (Britton, 1999), even in the UK 
(Heiat, Gross & Krumholz, 2002). This has important repercussions 
regarding the safety and efficacy of new drug use in these groups, 
especially since drug metabolism, concurrent diseases and counter-
indications have been shown to vary considerably between different 
ethnic groups (Krecic-Shepard, Park, Barnas, Slimko, Kerwin & 
Schwartz, 2000).  
 
Apart from being poor science this undermines the UK Government‟s 
plan for addressing inequalities, and its core principle of providing 
culturally appropriate and accessible care for all in the NHS 
(Department of Health, 2000). Hussain et al (2004) suggest that the 
exclusion of ethnic minority groups who do not speak English 
amounts to institutional racism and efforts should be made to make 
research-related information and measures accessible to these 
groups also (Hussain-Gambles, Atkin & leese, 2004). However, there 
  Page 56 of 209       
 
are challenges to including people who do not speak English in AchI 
trials. Although solutions are possible, they are complicated. The lack 
of cross-culturally appropriate cognitive measures for dementia is a 
significant barrier. Clinical trials of AchIs use quantitative cognitive 
assessments, which have only been validated within western cultures, 
as primary and secondary outcome measures. It is assumed that 
comprehension and expression of English would be required to 
administer the assessments; therefore those who are not fluent in 
English would need to be excluded.  
 
Including people who are non-fluent in English may be unethical, 
especially if outcome measures are administered with the knowledge 
that they will not lead to any results which would be scientifically or 
clinically valid due to increased error variance (Emanual, Wendler & 
Grady, 2000). This is especially concerning in the context of drug 
trials, which can result in adverse affects. If non-English speakers are 
to be included within clinical trials then more appropriate cognitive 
measures need to be developed, that are cross-cultural and are 
equivalent to the measures used for English speakers from the 
majority ethnic groups. This could aid in making more accurate 
comparisons of dementia disorders across different countries and 
cultures (Gibbons, van Belle, Yang, Gill, Brayne, Huppert et al, 2002).  
 
1.4 National Institute for Health and Clinical Excellence (NICE) 
NICE decides what treatments are supplied on the NHS in England 
and Wales, and are asked to look at particular drugs and devices 
when there is confusion or uncertainty over the value of a drug or 
device, or when prescribing practices vary across the country. NICE 
have been under pressure to approve AchI for AD since they were 
first introduced in 1996 in the US. Between 1997 and 2000 various 
inconsistencies became apparent in the prescription of Aricept. 
Patients could receive different treatments depending on where they 
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happen to live, and the clinician treating them rather than on the 
state of their health (Doyle, 2001). The Merton, Sutton and 
Wandsworth Health Authority was cited as an example by Doyle 
(2001). In 1997 the authority concluded that the benefits of AchI 
were insufficient to warrant funding. However, some general 
practitioners were prescribing the drug in primary care and patients 
were buying it privately (Doyle, 2001). There is evidence that due to 
abundance of guidance from various institutes, clinicians may not 
view them as being worthwhile (llife, & Manthorpe, 2007). 
 
In general NICE is widely admired as a model for decision-making on 
the introduction of new technologies to a healthcare system because 
they balance clinical effectiveness with cost effectiveness, which is 
essential to ensure equity in service provisions (Syrett, 2007). Cost-
effectiveness analysis is a tool for arriving at a “cut-off” point for 
what is valuable, and what society should pay for, and what should 
not be covered. The Quality Adjusted Life Years (QALY) is the model 
used by NICE to compare different drugs and measure their cost 
effectiveness relative to clinical effectiveness.  
 
1.4.1   NICE guidance for treatment of AD with AchI 
AchI had first been the subject of NICE Guidance in 2001. These had 
approved AchI for mild and moderately (a score over 12 points on 
MMSE) severe AD only. NICE updated their guidance and provided 
„restricted‟ guidance for clinicians prescribing AchIs for AD. NICE 
based this decision on evidence suggesting that AchIs were not a 
clinically effective or cost effective treatment for people with mild or 
severe AD and that evidence supports effectiveness only with people 
with moderate AD (NICE, 2007). Updated guidance stated that 
patients were eligible for treatment with AchI only if their cognitive 
functioning falls within the „moderately‟ severe range (10-20 points) 
on the MMSE (NICE, 2007). Therefore patients within the „severe‟ (0-
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9 points) and „mild‟ range (21-26 points), as measured by the MMSE, 
should not be prescribed the medication even if clinicians disagree 
with the guidance (NICE, 2007). The MMSE is also used to monitor 
patients on this medication, and the medication is to be stopped if it 
does not appear to be having an effect, or if the patient‟s scores fall 
below 10 points on the MMSE.   
 
It was inevitable that restricting access to expensive drugs that have 
modest benefits would lead to public protest (Doyle, 2001; Godley, 
2006). This is even more likely to happen in an area where there is 
already a lack of alternative preventative drug treatment options 
available (Melzer, 1998). Thompson et al (1997) argued that the 
recommendations were wrong because the AchIs are all that doctors 
have to offer. Subsequently in 2006 NICE was faced with its first High 
Court challenge (Dyer, 2006; Kmietowicz, 2006; Syrett, 2007). A 
pharmaceutical company (Eisai) which is the licence holder for Aricept 
applied for a judicial review to challenge NICE‟s decision. The judge 
ruled that NICE were not irrational in concluding that there is no 
cumulative benefit to patients after six months treatment, that they 
did  take into account benefits the drugs bring to carers, and they did 
not breach principles of procedural fairness. 
 
NICE cannot be held solely accountable for insufficient evidence that 
the drugs are cost effective in early stages of dementia (Godley, 
2006). Furthermore, drug companies and their marketing strategies 
can open the NHS to exploitation through their efforts to gain 
unrestricted access to the NHS as part of a free market. NICE is in a 
position to regulate this using evidence (Melzer, 1998; Kmietowicz, 
2006). Drug companies have been known to misinform the public 
about the efficacy of AchI (Melzer, 1998; Doyle, 2001). It is possible 
that this initial misinformation contributed to the impetus to challenge 
NICE on their decision and accuse them of ageism and stigmatising 
people with dementia (O‟Brien & Ballard, 2001; Dening, 1992). Other 
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key contributory factor are misconceptions of NICE‟s role and an 
over-estimation of the effectiveness of the drugs for any stage of 
dementia (Doyle, 2001). 
 
1.4.2   NICE guidance & non-English speakers 
NICE was found to have acted unlawfully in one respect. Both 
guidance issued by the institute and the decision of the appeals panel 
were found to be flawed in that there had been a failure to show 
proper consideration to NICE‟s statutory duties under the Race 
Relations Act (1976) and the Disability Discrimination Act (1995), to 
promote equal opportunities and to eliminate discrimination. This 
difficulty arose as a result of the failure of the guidance to address 
the position of those for whom English is not a first language, those 
with learning disabilities, and those with sensory difficulties such as 
individuals who are blind, deaf or non-verbal. The administration and 
interpretation of the MMSE is problematic within these populations. 
What is also of concern was NICE‟s decision to advocate that the 
MMSE should be used as a measure to decide about treatment 
eligibility. Although NICE advises that healthcare professionals should 
not rely on the MMSE score alone in these circumstances, Cerejeira & 
Mukaetova-Ladinska (2007) argue that one should not rely on the 
MMSE score alone in any circumstance.  
 
In acknowledgement of this, NICE stated that these groups should 
have equal access to treatment and should not be discriminated 
against if unable to complete the MMSE (NICE, 2007). The guidelines 
suggest that in these instances alternative measures should be 
selected, although, they do not provide suggestions for alternative 
assessments. This is probably because there are no validated 
measures which are appropriate for non-English speakers, which are 
also equivalent to the MMSE, and have proven utility in decision 
making regarding treatment with AchI.  
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Following the judicial review, NICE was directed to amend their 
guidance. Their amended guidance stated that if the patient is judged 
to have AD of moderate severity, as determined by other forms of 
assessment, they should be prescribed AchI.  However, this merely 
reinforced the limitations of the guidance as there are no objective 
means of interpreting what AD of moderate severity would look like in 
terms of cognitive, behavioural, functional or neurological 
characteristics. The MMSE is what defines the stages of severity and 
research which aims to illuminate what the parameters of the 
„moderately severe‟ range is in terms of patient characteristics and 
cognitive profile is of critical importance if these guidance are to 
remain applicable in routine clinical practice, in general, and for 
people who do not speak English. 
 
1.5 Mini-Mental State Examination 
Cognitive screening is an integral part of assessing for cognitive 
decline to establish the health care needs of older adults (Wilkins, 
Wilkins, Meisel, Depke, Williams & Edwards, 2007). The MMSE 
(Folstein, Folstein & McHugh, 1975) is the most frequently used and 
highly cited assessment for screening cognitive functioning in older 
people (Tombaugh & McIntyre, 1992; MacKenzie, Copp, Shaw & 
Goodwin, 1996; Davey & Jamieson, 2004; Nilsson, 2007; Mitchell, 
2009). Although it was originally developed in hospital settings, it has 
been applied widely in clinical practice, clinical research and 
epidemiological studies (Huppert, Cabelli & Mathews, 2005). It was 
devised as a short, convenient, quantitative assessment of cognitive 
performance and was viewed as being a more suitable measure for 
older people in comparison to alternative more lengthy assessments 
due to their difficulties in sustained attention. There is a preference 
for brief, sensitive screening measures which are easily accessible, 
inexpensive and which can be administered by non-specialists. Thus, 
making them more practical for routine assessment in primary care 
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settings, although many in these settings still consider the MMSE too 
time consuming to administer (Glasser, 1993; Mitchell, 2009).  
 
The distribution of scores across the eleven items of the tests are not 
weighted equally, therefore the measure does not screen for decline 
equally across these cognitive domains. Thus, it is not sensitive to 
impairments in memory, which is the most affected of cognitive 
domains in AD. A criticism of this measure is also that it does not 
directly measure executive functioning, which is another key domain 
affected within the dementia population. Given that it is a screening 
measure, it can be forgiven for not being a comprehensive 
assessment of any domain; however this is not always appreciated in 
practice. Tombaugh and McIntyre (1992) in their review concluded 
that in general the MMSE fulfilled its original goal of providing a brief 
screening tool that assesses the severity of cognitive decline and 
documents change over time. However, content analyses revealed 
the MMSE was highly verbal, and not all items were equally sensitive 
to cognitive impairment. Items measuring language were judged to 
be relatively easy and lacked utility for identifying mild language 
deficits. Overall, MMSE scores were affected by age, education, and 
cultural background, but not gender (Tombaugh & McIntyre, 1992; 
O‟Connor, Pollitt, Hyde, Fellows, Miller, Brook et al, 1989; Brayne & 
Calloway, 1990; Fratiglioni, Jorm, Grut, Viitanen, Holmen, Ahlbom et 
al, 1993; Wind, Schellevis, Stavernen, Scholten, Jonker & Van Eijk, 
1997).  
 
Nevertheless, a score between 0-9 indicates severe cognitive decline, 
10-20 moderate, 21- 26 mild and 27-30 is considered to be within 
the „normal‟ range (NICE, 2007). These distinctions between separate 
levels of severity have been found to be useful for clinical and 
research purposes. Staging in this way has enabled clinicians to 
categorise and hence communicate information rapidly about the 
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disease. Staging is also required when deciding about treatments that 
have been approved for different levels of disease severity (NICE, 
2007). In research, staging has been used to select „homogenous‟ or 
comparable patient samples.  
 
However, there are two fundamental theoretic and empirical 
misconceptions underlying current clinical and research practices. 
Firstly, the MMSE is a screening tool used to identify cognitive 
difficulties, therefore by definition it identifies symptoms of cognitive 
decline to support the need for further neurological, 
neuropsychological, functional and laboratory examinations (Folstein, 
Folstein & McHugh, 1975). It should not be used on its own to make 
a diagnosis of any neurological pathology or specify the underlying 
clinical condition which is causing cognitive decline (Field, Jackson, 
Hassett & Pattison, 1995; Bird, Canino, Stipec & Shrout, 1987; 
Mitchell, 2009). In addition, it is not sensitive enough to identify 
milder levels of cognitive decline in dementia (Peterson, Stevens, 
Ganguli, Tangalos, Cummings & DeKoski, 2001; Mitchell, 2009).  
 
In the original paper, Folstein and colleagues highlighted that a key 
advantage of the MMSE was that the items measured had clearer 
implications on patient‟s capacity to care for themselves and manage 
daily affairs. Whether or not the MMSE scores always correlate with 
functional abilities is debateable, but the measure was viewed as 
being useful for identifying social support that the patients may need, 
not advocated as a quantitative measure whose cut-offs could be 
used to decide on eligibility for drug treatments. It could be argued 
that the utility of the MMSE has advanced since the measure was first 
developed, but the evidence has repeatedly called for more 
appropriate use and in particular for age and education adjusted 
norms. This has not made an impact on clinical guidance. NICE in 
their guidance do state that age and education should be taken into 
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account when interpreting scores. However, without normative data it 
is unclear how clinicians should interpret scores.  
 
Furthermore, although a cut-off score of 24/30 is recommended by 
Folstein and colleagues, NICE guidance use 26/30 as a cut off. 
Folstein and colleagues (1975) state that psychiatric in-patients with 
dementia invariably scored 23 points or less out of 30, compared to 
normal controls, all of whom scored above this cut-off point. 
However, in-patient populations are likely to be experiencing 
difficulties that are in the more severe end of the spectrum compared 
to those who remain at home (O‟Conner, Pollitt, Hyde, Fellows, Miller, 
Brook & Reiss, 1989). Therefore, these cut-offs are likely to 
discriminate less accurately between those with dementia in normal 
community populations. Numerous other cut-offs have been 
calculated from Receiver Operating Characteristic (ROC) analysis of 
specific populations together with adjustments for age and education 
(Kahle-Wrobleski, Corrada, Li & Kawas, 2007; Mitchell, 2009). This 
was in response to the ample evidence that age and education were 
confounding factors (Crum, Anthony, Bassett et al, 1994; Grigoletto, 
Zappala, Anderson & Lebowitz, 1999; Mitchell, 2009).  
 
There are additional sources of psychometric instability for the MMSE. 
Classical Test Theory indicates that obtained scores consist of two 
components: the true score and the error variance. Longitudinal 
testing is a hallmark of dementia assessment and the MMSE is 
administered repeatedly (Pelosi, McNulty & Jackson, 2006; NICE, 
2007), this can result in practice effects (Hinton & Withers, 1971). 
The limited use of standardised assessment instructions (Meyers & 
Meyers, 1995) results in differences in administration practices across 
clinicians. This results in reduced inter-rater reliability, even amongst 
specialists (Davey & Jamieson, 2004).  
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There are also item-specific problems which can introduce error 
variance. For instance the attention subtest has two very different 
items and the patient is expected to complete only one of them. If 
they will not or cannot perform the calculations item, they have the 
option of spelling „world‟ backwards (Davey & Jamieson, 2004). The 
item administered can vary from different clinicians and also there is 
evidence to suggest that the backward spelling task is easier, and so 
less sensitive in comparison to calculations (Galasko, Klauber, 
Hofstetter, Salmon, Lasker & Thai, 1990). Therefore, a change in 
scores could reflect psychometric instability, which has been found to 
be the case in a normative sample (Olin & Zelinski, 1991). 
Furthermore, a change in the environment in which the test is 
conducted may affect responses to the orientation subtest. A client 
who is asked to name the geographical location of where they are or 
name the building they are in, may respond incorrectly when 
assessed during an outpatient appointment compared to when being 
assessed in a familiar environment (i.e. their own home).  
 
Thus, although the cut-off scores can provide useful screening 
information to inform clinical decision making for further assessment, 
there is no consistent findings within the research literature to 
evidence that it is scientifically reliably, valid or clinically meaningful 
to use these cut-offs alone to decide on treatment eligibility. 
Unfortunately, the psychometric limitations of the MMSE have not 
diminished its popularity and paradoxically, research has attempted 
to extend its usage beyond that of a dementia screening (Olin & 
Zelinsky, 1991). 
 
Secondly, although theoretically it would seem sensible that all those 
who fall within the mild, moderate or severe range would present 
with comparable cognitive and functional difficulties to their 
counterparts, this is not always observed in clinical practice. The 
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„mild‟, „moderate‟ or „severe‟ ranges lack construct validity and 
criterion validity. Patients can vary on what items they score lower 
points on and still fall within the same level of severity. Therefore, 
research, especially RCTs, that categorises participants when trying 
to evaluate the efficacy of drugs for specific levels of severity are 
confusing. When selecting samples, RCTs should include functional, 
behavioural, alternative cognitive and neurological measures to 
inform their inclusion criteria and ensure that the sample is 
comparable in terms of level of severity, rather than relying on the 
MMSE alone.  
 
The use of the MMSE as an outcome measure also demonstrates a 
lack of appreciation for the multiple sources of error variance. The 
many confounding factors influencing the MMSE cause it to be an 
unstable measure and consequently makes it difficult to know if an 
increase in scores were indicative of a genuine treatment effect, or if 
a reduction in scores was indicative of decline. Therefore, outcomes 
need to be balanced by a design which attempts to control 
adequately for confounding variables. This is especially important if 
drug treatments will then be approved only for specific levels of 
severity (NICE, 2007). A failure to do this could lead to erroneous 
conclusions being made both in research and clinical settings (Olin & 
Zelinski, 1991). However, this is by no means an easy task, which is 
perhaps why the dominant trend has been to use the MMSE. Patients 
with dementia of any type are not homogenous and without a better 
understanding of the underlying aetiology of the disease, to inform 
diagnostic criteria, it will be a challenge to identify a measure that will 
fit for all. Furthermore, cognitive, behavioural and functional abilities 
are strongly influenced by cultural, educational and life experiences 
and it is not possible to control for all of these variables, especially 
within a much older sample.  
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1.6 MMSE and BME groups 
Research suggests that where the original MMSE has been used with 
ethnic minority groups there has been an increased risk of false 
positives (Parker & Philip, 2006), hence substantially increasing the 
risk of them being diagnosed with dementia. In one study 6% of non-
impaired White people and 42% of non-impaired Black people were 
wrongly classified by the MMSE (Fillenbaum, Heyman, Williams, 
Prosnitz & Burchett 1990). One factor which could account for this 
variance is years of education. There is a well-documented influence 
of education on performance on cognitive tests (Tombaugh & 
McIntyre, 1992). However, even when years of education have been 
accounted for, there remains an effect, related to ethnicity and 
culture. To support this further, people from the White ethnic group 
in USA and UK performed differently on MMSE, which demonstrates a 
clear effect of culture rather than race (Gibbons et al, 2002).  
 
One approach to developing equivalent measures to the MMSE has 
been to adapt items for cultural equivalence. Helms (1997) suggested 
that to control for cultural bias in neuropsychological assessment the 
tests should be matched according to (1) functional equivalence 
(extent to which the tests measure the same psychological constructs 
with equal accuracy within these groups), (2) conceptual equivalence 
(level of familiarity with the test items); (3) linguistic equivalence, 
(extent to which language used in the tests has equivalent meaning 
across cultures); (4) psychometric equivalence (extent to which the 
tests measure the same thing at the same level across cultures); (5) 
testing condition equivalence; (6) contextual equivalence, (evidence 
that the cognitive ability being assessed is comparable across 
environments; and (7) sampling equivalence (samples of subjects 
representing cultural groups should be comparable).  
 
In an attempt to develop culturally appropriate assessments the 
MMSE has been translated in various languages, such as Spanish 
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(Escober, Burnam, Karno, Forsythe, Landsverk & Golding, 1986), 
Chinese (Katzman, Zhang, Qu, Wang, Liu, Yu  et al, 1988) Korean 
(Park, Park & Ko, 1991), Hindi (Ganguli, Ratcliff, Chandra, Sharma, 
Gilby, Pandav et al, 1995), Japanese (Larson et al 1992), Gujarati 
(Lindesay, Jagger, Mlynik-Szmid, Sinorwala, Peet & Moledine, 
1997a), Urdu (Rait et al, 2000) and Sinhalese (de Silva & Gunatilake, 
2002). Many of the studies involve translation of the instructions and 
test items, and some aspects of the tests are modified to be more 
culturally appropriate. For example in the Sinhalese translated MMSE 
for the Sri Lanka population, they replaced „season‟ with „time of day‟ 
for orientation to time, because there are no major seasonal 
variations in Sri Lanka (de Silva & Gunatilake, 2002). Translations 
require equivalence in terms of word meaning and therefore in order 
to do this accurately measures are translated and then back 
translated to ensure that correct translations are being used. 
However there are occasions when another language does not have 
an equivalent word and therefore it will be replaced with an 
alternative word. Hence, reducing the equivalence of the MMSE with 
translated measures.  
 
The studies that are based in the UK (Lindesay et al, 1997; Rait et al, 
2000), have small sample sizes, therefore the measures are not 
validated in the UK and results cannot be generalised, hence the lack 
of normative data. Furthermore, clinicians who are English speaking 
would not be able to administer translated MMSEs and would still 
require access to an interpreter. It is also difficult for clinicians to 
supervise translators, ensuring that correct translations and 
procedures are being followed (Nell, 1999). One would have to 
question the appropriateness of interpreters administering cognitive 
assessments with the absence of specialist training, knowledge and 
the skills required to assess the outcomes. A trained clinician is able 
to consider all possible sources of score variance such as, vision, 
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mood, environment, demand characteristics, fine motor skills, speech 
and language difficulties to name a few.  
 
In addition, it is unclear whether translated MMSEs are actually 
utilised within services once they have been developed. There is also 
a continuing debate over the suitability of instruments developed in 
one culture (e.g. MMSE) being used in another culture. Factors such 
as language, literacy and ethnicity, acculturation, age and education 
have been shown to have an effect (Tombaugh & McIntyre, 
1992;Baird, Ford & Podell, 2007; Boone, Victor, Wen, Razani & 
Ponton, 2007).  
 
Nevertheless, there remains a need to develop standardised 
assessment procedures that are objective, especially when making 
decisions about treatment and to monitor change following drug 
treatments. Despite the limitations of using existing cognitive tests, it 
may be easier to adapt existing tests, especially when they are 
needed imminently in clinical settings such as when deciding if a 
person is eligible for medication. In addition, translated MMSEs can 
be used in combination with cognitive tests that do not require 
spoken language and their combined evidence could provide more 
reliable insights into a patients cognitive functioning. The combination 
of multiple assessment modalities is best practice in 
neuropsychological assessment (Lezak et al, 2004).  
 
1.7 Cross Cultural Neuropsychology 
Chesters (2007) suggests that only a limited kind of 
neuropsychology, appropriate to only a fraction of the world‟s 
population, is being presented to the rest of the world as if there 
could be no other kind of neuropsychology. Much can be learned from 
studying diverse cultural groups, to add to our understanding of 
dementia, rather than depending only on research that tends to be 
Eurocentric. Cross-cultural analysis may give us a better 
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understanding of brain organisation and treatment efficacy, and we 
are limited because our knowledge is based on research evidence 
from western civilisations only (Ardila, 1993). What is also urgently 
needed is the increase in the knowledge base of, and provision of 
appropriate tools for clinicians to enable them to carry out culturally 
competent and clinically relevant neuropsychological evaluations 
(Perez-Arce, 1999). Indeed, if the field is to remain scientifically 
credible, it needs to address the effects of language and culture on 
cognition, and provide access to neuropsychological assessment and 
rehabilitation services to all (Ivnik, 2005). 
 
In the last decade there has been an increase in the number of 
publications addressing the relevance of cultural factors to 
performance on neuropsychological measures (Agranovich & Puente, 
2007). Factors such as degree of acculturation, cultural experience, 
literacy level and quality of education influence test performance 
(Manley, Jakobs, Sano, Merchant, Small & Stern, 1998). There are 
also different norms in different cultures in terms of attitudes towards 
testing (Agranovich & Puente, 2007). It is also suggested that cultural 
difference can also affect lateralisation of language and spatial 
disturbance (Ardila, 1995) and thus have a profound effect on non-
verbal behaviour and language.  
 
The increase in demands for neuropsychological assessment of 
persons with limited or no English language background has been the 
impetus for developing instruments written in the patient‟s language 
and standardised for persons from a specific cultural or for a specific 
language (Uzzell, Ponton & Ardila, 2007). The use of interpreters is 
only a second best partial solution (Ardila, 1995; Lezak et al, 2004). 
The next important goal for neuropsychological assessment should be 
the dissemination of evidence-based language and culture 
appropriate neuropsychological examination techniques and skills 
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(Lezak et al, 2004). There are large variations between individuals 
and diseases and it is unlikely that a single test will be appropriate for 
everyone; however examination in specific areas should lead to some 
simplification and generalisation in procedures. Therefore, a series of 
relatively short fixed batteries designed for particular disorders, 
specific domains (e.g., memory, attention, executive functions), that 
answer specific questions and meet particular needs are what we 
should be working towards (Lezak et al, 2004).  
 
1.8   Aims 
Preliminary data was collected from participants whose first language 
was English to establish the utility of the cognitive measures, to aid in 
decision making regarding eligibility for treatment with AchI. 
Therefore the data collected will not, and did not intend to, provide 
information regarding the cultural equivalence of the chosen 
measures. It is hoped that the conclusions drawn from this study 
would be used to inform the design of a study in the future to explore 
the cross-cultural utility of these cognitive tests in establishing 
treatment eligibility in a non-English speaking sample. 
The hypotheses were: 
1. There would be a significant correlation between participants‟ 
total scores on the MMSE and their total scores on the Rey Complex 
Figure Test (RCFT), Raven‟s Colour Progressive Matrices (RCPM), 
Symbol Digit Modalities Test (SDMT), Brixton test, the Clock Drawing 
Test (CDT), and the Colour Trails Test (CTT). 
The participants‟ performance on the RCFT, RCPM, SDMT, Brixton 
test, CDT, and the CTT would differentiate those eligible for treatment 
with AchI (10-20 score on MMSE) from those who are not. 
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2. Extended Methodology 
2.1   Ethical Considerations 
An application for ethical consideration was made to the National 
Health Service (NHS) Central Office for Research Ethics Committees.  
Ethical approval was obtained prior to commencement of the study. 
Following this, further approval was obtained from the Research and 
Development departments of the two NHS sites. Three key ethical 
considerations were highlighted by the ethics committee, 1) to ensure 
that participants had the capacity to consent and this was assessed 
formally by the lead researcher, 2) to maintain participant anonymity 
and 3) to allow participants to take breaks as and when needed from 
testing. The ethical issues raised were taken into consideration in the 
methodology of this study (see Appendix 2 for NRES approval).  
 
2.2   Sample size and power 
A priori sample size calculation was conducted for this study. The 
sample size is calculated on the basis of the desired effect or power 
that is hoped to be achieved. A power of .80 is the standard 
adequacy level (Dancey & Reidy, 2007). The effect size is to be 
informed by previous research in the area (Field, 2000). However, 
this can be an arbitrary process if there are no previous studies which 
have explored the strength of a relationship between variables of 
interest. In addition, when a study involves the exploration of the 
strength of a relationship between multiple variables or measures, 
the expected effect can vary within a study, for each measure. For 
this study, there were no prior studies which had explored the 
correlation between the MMSE and the RCFT subtests, RCPM, SDMT, 
Brixton test or the CTT. However, previous research has reported that 
the CDT correlated moderately/ highly (.41 to .80) with the MMSE 
(Strauss, Sherman & Spreen, 2006). Therefore, it would be 
appropriate to conduct a priori sample size calculation based on a 
large expected effect. However, even though the MMSE has not been 
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correlated with the Brixton test, the MMSE is reported to be a poor 
measure of measure of executive functioning, therefore a small 
relationship would be expected between the MMSE and the Brixton 
test. Nonetheless, due to the nature of this study, which is interested 
in identifying measures that can aid in decision making about 
treatment with AchI, a strong effect is desired. Therefore, for a large 
effect (0.5, Cohen, 1992), standard adequate power of .80, and 
significance level of P<0.05, the minimum sample size required was 
29 participants. This was calculated using G-Power analysis 
(Erdfelder, Faul & Buchner, 1996).  
 
2.3   Exclusion criteria 
Patients were excluded if: 
1. They were blind or deaf or had difficulties with fine motor skills: 
This is because the assessments could not be administered to 
these patients in a standardised way. The tests that were 
administered required participants to be able to draw and write 
therefore they needed to have intact fine motor skills. Participants 
who were blind or deaf were also excluded as these modalities 
were needed to carry out the tests. This was assessed by asking 
the participant prior to commencing the study. If they indicated 
that they experienced difficulties in these areas they were 
excluded.  
2. They did not consent to take part. 
3. They did not have the capacity to consent 
4. Anxiety or mood related difficulties: Mood related difficulties such 
as depression and anxiety can impact on test performance. 
Therefore, if participants indicated that they felt distressed or 
were unable to concentrate due to mood related difficulties they 
were excluded from this study. No formal psychiatric assessment 
was conducted with participants. In addition, participants who 
appeared distressed during testing would be excluded, especially 
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if this was likely to have impacted on their performance and would 
also have been unethical to continue testing. This was assessed 
using observation.  
5. Participants who had a recent (1 year) head injury were also 
excluded following the initial visit. This was assessed on the basis 
of participants self-report.    
 
2.4 Measures 
2.4.1   The University of San Diego Brief Assessment of 
Capacity to Consent (UBACC, Jeste, Palmer, Appelbaum, Golshan, 
Glorioso, Dunn et al, 2007) 
One reason for the paucity of research in dementia is ethical concerns 
around capacity to consent (Agarwal, Ferran, Ost & Wilson, 1996; 
Warner & Nomani, 2008). The assessment of capacity has been 
codified in law (DOH, 2005) and there is increasing demand for 
formal capacity assessments of potential participants with dementia 
(Kim & Caine, 2002). What is also concerning is that many individuals 
with dementia participate in research but are likely to lack capacity 
(Warner, McCarney, Griffin, Hill & Fisher, 2008).  
 
Participants should be able to understand salient information provided 
to them, retain this information for sufficient time to be able to weigh 
the information in the balance, and to form a decision (without 
coercion), and to communicate that decision. However, there is no 
„gold standard‟ capacity assessment and there is considerable 
heterogeneity within diagnostic groups. Factors (such as cognitive 
impairment) that have the most significant association with impaired 
capacity explain no more than 25% of the variance (Jeste & Saks, 
2006; Church & Watts, 2007). The MacArthur Competency 
Assessment Tool for Clinical Research [MacCAT-CR] (Appelbaum & 
Grisso, 2001) and the University of California, San Diego Brief 
Assessment of Capacity to Consent [UBACC] (Jeste et al, 2007) are 
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two frequently used instruments used to assess for capacity to 
consent in research settings. Kim and Caine (2002) used ROC 
analysis to examine the utility of the MMSE in discriminating capacity 
status, against the MacCAT-CR. They found that the MMSE did not 
discriminate capacity status well, which is supported by a more 
recent study (Warner et al, 2008). They suggested that a cut-off of 
26 would have sensitivity of 91-100% and low specificity of 35.7%. 
Indeed, this leads to suggestions that people with moderate and 
severe dementia as measured by the MMSE, have limited, if any 
capacity to give informed consent (Sugarman, Roter, Cain, Wallace, 
Schmechel & Welsh-Bohmer, 2007).  
 
Carpenter et al (2000) in their study found that participants should 
not automatically be excluded from studies if they perform poorly on 
the MacCAT-CR, as participants are able to provide informed consent 
if additional educational information is provided (Carpenter, Gold, 
Lahti, Queern, Conley, Bartko et al, 2000). If people were excluded 
purely on the basis of this measure, which does not take into account 
the unequal thresholds of competence across different studies with 
varying risk-benefit ratios, dementia research would be halted 
(Warner & Nomani, 2008). Carpenter et al (2000) suggested that 
retention of key elements, rather than detailed knowledge is critical 
during research. The key elements include awareness that 
participation is voluntary, and that withdrawal can be done without 
penalty. Remembering the name of drugs and the full list of adverse 
effects is less important.  
 
When appraising the literature for guidance regarding seeking 
informed consent for this study, it was apparent that the focus of the 
literature base was on participation in RCTs. Therefore, it is difficult to 
apply this evidence to studies which do not involve drug treatments. 
Nonetheless, a formal assessment of capacity was incorporated in 
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this study and the measure chosen was the UBACC (Jeste et al, 
2007). The reason being that it takes less time to complete compared 
to the MacCAT-CR, and has standardised procedures for 
administration and scoring. The items or questions can be re-worded 
to make them more applicable to the specific study. However, the 
items reflect the key areas that need to be assessed (see Appendix 
7).  A response is scored either 0 (in-appropriate response), 1 
(warrants further information to assist participant, or further 
assessment of capacity is required), or 2 (appropriate response 
indicating capacity to consent). An additional advantage of this 
measure was that the participant is allowed to refer to written 
information (such as the participant information sheet (see Appendix 
6) to answer the questions, hence they do not need to rely on 
memory alone. This is more appropriate for participants with 
dementia.  
 
2.4.2  Demographic questionnaire  
This information was collected from carers only when the participant 
provided consent. This information was documented separately for 
each participant on a demographic questionnaire sheet (see Appendix 
10). 
 
2.4.3   MMSE (Folstein et al, 1975):  
The MMSE measured orientation to time and place (date, time, town 
– 10 points), memory (remembering three objects immediately – 3 
points; a recall trial– 3 points), comprehension (following instructions 
– 3 points), language (naming objects -2 points; following 
commands, reading and writing a sentence – 3 points), attention 
(subtract 7 from 100 or spell WORLD backwards – 5 points) and 
visual spatial abilities (copying a drawing- 1 point). The average time 
taken to complete the test was 15 minutes and the scores range from 
0 to 30 points (0-9 severe, 10-20 moderate, 21-26 mild, 27- 30 
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normal range). A lower score indicated cognitive impairment (Folstein 
et al, 2000). Many of the items or domains assessed in the MMSE are 
similar to those assessed in neuropsychological tests. However, the 
MMSE is considerable to be less sensitive. As a screening measure, it 
has good criterion validity for people with severe to moderate levels 
of cognitive decline (100% sensitivity and 85% specificity), but is less 
predictive of people with milder levels of cognitive decline. A cut-off 
of 23 and 24 points optimizes its predictive validity (Tombaugh & 
McIntyre, 1992).  
 
The internal consistency of the MMSE tended to be lower for 
community samples compared to clinical samples, ranging from a 
coefficient of .77 (Holzer, Tischler, Leaf & Myers, 1994), to a modest 
coefficient of .62 (Tombaough, McDowell, Kristjansson & Hubley, 
1996). This is likely to be because the MMSE is not a sensitive 
measure of cognitive decline in community samples, as they score 
higher on the MMSE.  
 
The MMSE is also designed to assess a variety of cognitive domains, 
therefore resulting in lower alpha levels in comparison to more 
detailed neuropsychological assessments (Strauss et al, 2006). 
Concordance rates between the individual MMSE tasks (orientation, 
memory, attention) and neuropsychological measures of the 
corresponding domains can be low (Jefferson, Consentino, Ball, 
Bogdanoff, Kaplan & Libon, 2002).  
 
Age and education affect performance on the MMSE. Lower 
educational levels increase the likelihood of misclassifying non-
impaired people as cognitively impaired. Furthermore, race, ethnicity 
and language also affect MMSE performance. Despite this there are 
over 100 translations of the MMSE, but few have been validated and 
lack normative data (Auer, Hampel, Moller, & Reisberg, 2000). In 
addition there is considerable variability in reliability estimates, which 
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suggests that for conditions which can fluctuate or there are high 
rates of comorbidity, the MMSE is less reliable (Jorm, Scott, Cullen, & 
MacKinnon, 1991). For heterogeneous clinical populations, such as 
those with dementia, the test-retest reliability ranges from .56 to .98 
(Folstein, et al, 2000). Studies have reported adequate levels of 
inter-rater reliability in clinical and community samples, with 
reliability coefficients ranging from .83 to .95 (Molloy, Alemayehu, & 
Roberts, 1991). However, inter-rater reliability estimates in research 
settings are likely to be higher than those found in clinical practice, 
due to variations in administration practices. Therefore, some caution 
is needed when interpreting MMSE scores in clinical practice.   
    
 
2.4.4   Rey Complex Figure Test (RCFT, Meyers & Meyers, 1995): 
The RCFT consists of four subtests assessing five mental processes, 
1) visual spatial construction ability; 2) speed of processing of visual 
information, 3) immediate memory, 4) delayed memory, and 5) 
recognition memory. All standardised instructions were 
communicated verbally and although the participant could speak 
during administration, the test did not require spoken language by 
the participants to be completed.  The immediate memory trial is 
administered after three minutes. Then, 30 minutes after the 
participant has completed the copy trial, the delayed memory trial 
begins. The recognition trial commenced immediately after the 
delayed memory trial was completed. This involved them looking 
through 24 geometric figures, 12 of which were correct elements of 
the figure they were asked to copy and 12 were distracters. The 
participants were asked to indicate which of the 24 items they 
recognised as being from the stimulus figure (see Appendix 10 for 
standardised instructions given to each participant).   
 
The standardised approach to scoring within the manual was used. 
Here the complex figure is divided into 18 units and each unit is 
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scored separately for both accuracy and placement. A score of 0, 0.5, 
1 or 2 was assigned to each unit of the figure based on accuracy and 
placement criteria. Thus, raw scores range from 0 to 36. For the 
speed of processing trial, participants were timed on how long they 
took to copy the drawing. Higher time to copy scores indicated 
reduced speed of cognitive processing. Lower copy scores indicated 
reduced visual-perceptual and visuomotor integration skills. Reduced 
immediate and delayed recall scores suggest reduced visuospatial 
recall ability, while recognition total correct measures the ability to 
retrieve visuospatial material when given retrieval cues (Meyers & 
Meyers, 1995). There are no cut-off scores and participants scores 
were compared to norms based on their age (Meyers & Meyers, 
1995).  
 
Research analyzing inter-rater reliability of scoring of drawings, 
indicate that the manual instructions are sufficiently detailed to obtain 
good inter-rater reliability when the raters are experienced clinicians 
(Strauss et al, 2006; Allen, Brechin, Skilbeck & Fox, 2007).  
 
Evaluation of internal consistency demonstrated adequate reliability 
for the copy condition (.60) and higher for the recall conditions (.80), 
which suggests that all the details of the figure tap into a single factor 
(Fasteneau, Bennett, & Denburg, 1996). The test is sensitive to 
individuals with disorders which are known to affect memory and 
executive functioning such as dementia type illnesses (Ardila, Lopera, 
Rosselli, Moreno, Madrigal, Arango-Lasprilla et al, 2000; Strauss et al, 
2006). Correlations with tests of executive functioning were 
moderate, providing evidence of convergent validity, and correlations 
with tests of general cognitive ability were low, providing evidence for 
discriminant validity (Strauss et al, 2006). However, age influences 
copy performance, especially after 70 years (Tombaugh & McIntyre, 
1992; Boone, Lesser, Hill-Gutierrez, Berman & D‟Elia, 1993), and is 
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also positively correlated with education. However, Chervinsky et al, 
(1992) found that correlations with IQ are modest, which suggests 
that the RCFT provides a large amount of information not accounted 
for by education and IQ (Chervinsky, Mitrushina, & Satz, 1992). 
 
2.4.5   Raven’s Colour Progressive Matrices (RCPM, Raven, & 
Court, 2003):  
This measure assessed inductive reasoning ability in the visual 
modality. The test consisted of 36 items, grouped into three sets (A, 
Ab, B) of 12 items each. In each item participants were presented 
with an incomplete design and six alternatives among which one 
must be chosen that best completes the design. Every correctly 
solved item resulted in a score of one. Items became progressively 
more difficult and easier items at the beginning of each set acted as 
learning experiences to be used to inform performance on more 
difficult items as the test progressed. This indirectly assessed 
intellectual efficiency by observing if learning increased efficiency and 
accuracy (Mills, Ablard, & Brody, 1993). The standardised instructions 
within the published manual were used to administer the tests (see 
Appendix 10). The test did not require spoken language from 
participants and verbal instruction from the administrator was kept to 
a minimum (Zaidel, Zaidel, & Sperry, 1981). Scores ranged from 0 to 
36 points, and a lower score indicated greater impairment. This was 
an untimed test and took up to 25 minutes to complete.  
 
The RCPM is moderately correlated with other tests of intelligence, 
such as the Wechsler, Stanford-Binet tests, and the NART, which 
suggests that it has concurrent validity (Strauss et al, 2006). 
However, age is correlated with the Ravens test, and increasing age 
is related to decline in performance. A number of studies have also 
demonstrated strong correlations with working memory with older 
people, which suggest that memory loss, can be a confounding factor 
(Salthouse, 1993). Speed of processing also correlates with test 
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performance, with higher scores associated with rapid processing 
(Bates & Rock, 2004). However, people with dementia experience 
global decline in their cognitive functioning, therefore, it is difficult to 
identify a test which will not be confounded by the multiple domains 
that are affected. For instance, difficulties with executive functioning 
can impair the participants‟ ability to comprehend test instructions. In 
clinical settings, when a comprehensive neuropsychological 
assessment is completed with a dementia patient, these multiple 
domains are assessed, and the interpretation of performance will take 
these factors into account (Green, 2000).   
 
RCPM was developed for older people and can be used with people 
who cannot understand English, or have impairment in verbal 
language or hearing ability (Raven et al, 2003; Strauss et al, 2006). 
It is considered more culture fair than the Wechsler test for assessing 
reasoning ability (O‟Leary, Rusch & Guastello, 1991). In addition, the 
minimal instructions make it an easier test to translate. However, this 
does not mean that the RCPM is culture free, as even non-verbal 
tests are culturally biased.  
 
2.4.6 Symbol Digit Modalities Test (SDMT, Smith, 1991): 
The SDMT is a widely used measure of neurological impairment 
(Sheridan, Fitzgerald, Adams, Nigg, Martel, Puttler et al, 2006). The 
brevity and ease of administration, and its unambiguous scoring, 
contribute to its widespread use (Strauss et al, 2006). This test took 
five minutes to complete and did not require verbal language to be 
completed. The participants were shown a sheet of paper with rows 
of abstract symbols. Above this row of symbols is a coding key which 
shows nine abstract symbols with a corresponding number. The 
participants were instructed to scan the sheet of symbols and assign 
their respective numbers, as quickly as possible (see Appendix 10 for 
instructions). The participants are timed and are allocated a time limit 
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of 90 seconds to match up as many symbols with numbers as 
possible. The more they completed correctly, the higher the score 
and the maximum score is 110.  
 
Test-retest reliability was reported by Smith (1991) with an average 
retest interval of 29 days. Correlations were .90 for the written 
version and similar values were reported in other studies (Strauss et 
al, 2006). Uchiyama et al (1994) reported no significant practice 
effects with the written version following yearly intervals over two 
years (Uchiyama, D‟Elia, Delinger, Selnes, Becker, Wesch et al, 
1994). This suggests that the measure would have utility with 
dementia patients who are tested repeatedly to monitor the 
progression of the disease.  
 
The SDMT is similar in format to the Wechsler digit symbol/ coding 
subtest, and correlations ranged from .62 to .91 (Sheridan et al, 
2006; Strauss et al, 2006) which suggests good construct validity. 
However, the SDMT is considered to be more difficult than the 
Wechsler version. The SDMT also assesses similar constructs to the 
Trail Making Test (TMT) and PASAT (Royan, Tombaugh & Rees, 
2004). However, the PASAT requires spoken language to be 
completed by the participant and the TMT requires knowledge of the 
Latin alphabet, therefore reducing their utility with those not fluent in 
English.  
 
Deficits in attention abilities are a known symptom of dementia 
(Green, 2000). It is one of the most sensitive tests of attention in 
neuropsychology (Strauss et al, 2006). However, there are 
demographic effects on performance on the SDMT. Scores decline 
with advancing age (Bowler, Sudia, Mergler, Harrison & Cone, 1992) 
and performance improves with increasing IQ (Uchiyama et al, 1994). 
However, Sheridan et al reported that age did not significantly affect 
performance on the SDMT.  
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2.4.7   Brixton Test (Burgess & Shallice, 1997): 
Participants were presented with a 56-item stimulus book. Each page 
showing the same basic array of 10 circles set in two rows of five, 
with each circle numbered from one to 10. On each page one of the 
circles was filled with the colour blue. The position of the blue circle 
changed from one page to the next and the participant was instructed 
to guess the position of the blue circle on the next page. The blue 
circle moved according to a simple rule and the participant was 
expected to reason what the rule was in order to guess where the 
blue circle will appear on the following page. The changes were 
governed by a simple rule that changed without warning. The total 
number of errors across 55 trials was the outcome measure, and a 
higher score indicated greater impairment of executive functioning. 
This test is reported to take five minutes to complete (Burgess & 
Shallice, 1997; Strauss et al, 2006), however in this sample; the 
approximate time taken to administer this test was 15-20 minutes.  
 
Split-half reliability in healthy individuals is .62 and test retest 
reliability was marginally better at .70 (Burgess & Shallice, 1997; 
Strauss et al, 2006). The Brixton test does correlate with other 
measures of executive functioning, such as the Tower of London (.58) 
and part B of the Trail Making Test (Tchanturia, Andreluh, Morris, 
Rabe-Hesketh, Collier, Sanchex et al, 2004).  
 
Duncan et al (1995) showed that performance on executive tests 
were well predicted by fluid intelligence, leading to suggestions that 
fluid intelligence may be a more general measure of executive 
function (Duncan, Burgess & Emslie, 1995). Burgess and Shallice 
(1997) recommend that tests be used with caution with individuals 
with relatively low educational attainment, or who pre-morbidly fell 
below the bottom 15% of the population on measures of general 
intelligence. In addition, older age is also shown to have a negative 
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impact on performance (Andres & Van der Linden, 2000; Bielak, 
Mansueti, Strauss, & Dixon, 2006). However, when fluid intelligence 
was controlled for, executive performance on no longer correlated 
with age (Rabbitt & Lowe, 2000). Nevertheless, executive processes 
are one notable area of cognitive functioning that decline with age 
(Brennan, Welsh & Fisher, 1997). As a consequence, normative data 
for a typical ageing population has recently been published for this 
test (Bielak et al, 2006).   
 
This test did not require verbal responses and the participant could 
give their answer by pointing to where they expected the circle to be 
on the next page. The Hayling test is also an appropriate measure of 
executive function, but is reliant on patients spoken English for 
administration. There are no studies reporting the relationship 
between the MMSE and the Brixton test. The cross-cultural 
equivalence of this measure has not been explored. However, the 
limited reliance on spoken language from participants may make it 
easier to translate (Strauss et al, 2006).  
 
2.4.8   Clock Drawing Test (CDT, Tuokko, Hadjistavropoulos, Miller, 
Horton & Beattie, 1995):    
A higher score indicated greater impairment in cognitive functioning. 
The drawing was scored on the basis of what errors were made in the 
domains of omissions, perseverations, rotations, misplacements, 
distortions, substitutions, and additions. The test manual was used to 
score clock drawings. A maximum of 31 errors could be obtained,, 
and a higher error score indicated greater impairment.  
 
The CDT is frequently recommended as a screening test for dementia 
(Libon, Swenson, Barnoski & Sands, 1993; Storey, Rowland, Basic & 
Conforti, 2001; Richardson & Glass, 2002) There are more than a 
dozen different versions of the clock-drawing test (Strauss et al, 
2006). In addition, scoring systems have been proposed without 
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agreement on which is best for specific clinical settings (Storey et al, 
2001; Strauss et al, 2006). Storey and colleagues used ROC analysis 
to report the accuracy of five clock scoring methods for dementia 
detection. The results showed that the Shulman CDT (Shulman, 
Shedletsky & Silver, 1986) had high inter-rater reliability (.93), intra-
rater reliability (.96), and explained the largest Area Under the Curve 
(.79). However, the Tuokko et al (1995) has similar inter-rater 
reliability values but provides a comprehensive scoring system and 
standardised administration materials, which is vital in research 
settings to minimise confounding variables. This is especially of 
importance when many different types of errors are present for 
different reasons, and scoring of drawings become ambiguous.  Also, 
different scoring methods are highly correlated with each other 
(Tuokko, Hadjistavropoulos, Rae & O‟Rouke, 2000; Strauss et al, 
2006).  
 
Test-retest reliability coefficient was .70, which indicates that the 
scores obtained are quite stable (Tuokko, Hadjistavropoulos, Miller & 
Beattie, 1992).  In terms of validity the CDT is not as sensitive in 
measuring visuospatial, constructional and executive difficulties. 
However Kurzman (1992) examined the convergent validity of the 
CDT with neuropsychological measures. Validity correlations ranged 
from .04 to .27, and validity was higher with dementia patients 
compared to those with no cognitive difficulties. However, 
Hadjistavropoulos et al (1991) reported statistically significant 
correlations with language subtests from the WAIS-R, such as with 
similarities (r= -.41; P<.001), visuaspatial subsets such as the Digit 
Span (r= -.43; P< .001), and the Block Design (r= -.57; P<.001). In 
addition, there were significant correlations with memory subtests 
(Hadjistavropoulos, Tuokko & Beattie, 1991). Furthermore, errors on 
the CDT have been found to relate to conceptualization and semantic 
knowledge (Rouleau, Salmon & Butters, 1996). This suggests that 
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although the CDT is not a measure of memory, executive functioning 
or language abilities, the underlying constructs of the CDT tap into 
these domains, especially in dementia populations where there is 
global cognitive decline. The CDT also correlates with global 
measures of cognitive functioning, such as the MMSE with 
correlations ranging from .41 to .80 (Strauss et al, 2006).  
 
The Tuokko CDT has sensitivity of 92% and specificity of 86% in 
detecting dementia (Tuokko et al, 1992). Further studies have 
suggested that although patients with AD and Huntington‟s Disease 
have similar quantitative patterns on the CDT, there is a qualitative 
difference in the type of errors they make (Rouleau, Salmon, Butters, 
Kennedy & McGuire, 1992). However, the validity of the CDT in terms 
of its ability to differentiate between different disorders has not been 
found consistently by research (Suhr, Grace, Allen, Nadler & 
McKenna, 1998; Strauss et al, 2006).  
 
In comparison to other dementia screening assessments, the CDT is 
not dependent on verbal responses from patients. In addition, clock 
faces are familiar to most cultures and the CDT does not require 
Arabic numerals and participants can use their own culture specific 
numerical systems to indicate the hours in the clock face (Tuokko et 
al, 1995). It has been validated in mild AD non-English speaking 
older people in Taiwan (Chiu, Li, Lin, Chui & Liu, 2008). In addition, 
Borson and Colleagues (1999) concluded that the CDT was as 
effective as the MMSE as a first level dementia screen for multilingual 
samples, even when interpreters were bilingual interpreters were not 
available (Borson, Brush, Scanlon, Vitaliano, Chen, Cashman et al, 
1999).  
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2.4.9   Colour Trails Test (CTT, D‟Elia, Satz, Uchiyama & White, 
1996):  
The standard Trails Making Test is one of the most frequently 
administered measures in neuropsychological practice (Lezak et al, 
2004). The CTT consisted of two parts. Part 1 and 2 consist of several 
numbered circles coloured in vivid pink or yellow. All odd numbered 
circles are coloured in pink, and all even numbered circles are 
coloured in yellow. In part 2 each number is printed twice, once in 
pink and once in yellow.  In part 1 the participants were instructed to 
link in ascending order a series of 25 numbers (1-2-3....). 
Participants were instructed to perform the task as quickly as possible 
without making errors.  In Colour Trails Test 2, the participants were 
instructed to draw a line between numbered circles, maintaining the 
sequence of numbers but altering between pink and yellow colours as 
they proceed (see Appendix 10 for full instructions). The score is time 
in seconds and a higher score indicated increased impairment.  
 
Tests of attention and information processing are of particular use 
when assessing dementia (Pachana, Boone, Cummings & Berman, 
1996). However, increasing education enhances performance on CTT 
2, but less on CTT1 (Mitrushina, Boone, Razani & D‟Elia, 2005). The 
test-retest reliability is moderate (.64) for part 1, and higher (.79) for 
part 2 (Strauss et al, 2006). The CTT has not been validated against 
other cognitive tests as much as the TMT (Strauss et al, 2006). 
However results comparing TMT part A and CTT 1 found that they 
were correlated significantly (r= .408; P<.05) (D‟Elia et al, 1996).  
 
The CTT was designed as a culture fair analogue to the original Trail 
Making Test (TMT). The CTT is however free of the language 
demands of the TMT. Although it has been suggested that 
acculturation may exert minimal effects on TMT performance (Arnold, 
Montgomery, Castaneda & Longoria, 1994), its reliance the English 
alphabet stimulus in part B, severely limit its application in cross 
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cultural settings. The CTT was developed on the premise that the TMT 
had limited utility across cultures. It has been used in cross-cultural 
research to assess driving ability in older people with cognitive 
difficulties (Elkin-Frankson, Lebowitz, Kapust, Hollis & O‟Conner, 
2007), with Turkish non-impaired adults to explore the equivalence of 
the CTT and the TMT (Dubartey, Townes & Mahurin, 2000) and within 
with cognitive impairment due to HIV-1 n different cultures (Maj, 
D‟Elia, Satz, Janssen, Zaudig, Uchiyama et al, 1993).  Furthermore, 
Cheung et al (2000) that the CTT and TMT were generally fair across 
Chinese and English (Cheung, Chan, Yip, Cheung & Chan, 2000). 
However, it further research is required to establish the cross-cultural 
equivalence of the CTT and TMT (Razani, Burciaga, Madore & Wong, 
2007; Strauss et al, 2006). 
 
2.5   Procedure  
2.5.1   Recruitment 
The lead researcher approached service managers and Health Care 
Professionals (HCPs) based at older people‟s Mental Health Services 
within two NHS Trusts in two large cities in England. Potential 
participants were identified through a network of professionals 
working in two memory clinics, four Community Mental Health Teams 
(CMHT) and two Day Hospitals. The lead researcher provided 
information about the aims, hypotheses and study methodology. 
Various methods were used to disseminate this information such as 
presentations in multi-disciplinary meetings/ specialty meetings, 
handouts, and communicating through service managers. This 
provided an opportunity for referrers to meet with the lead 
researcher, and have questions regarding the study answered. In 
total the lead researcher made face-to-face contact with 73 mental 
health professionals over a period of four months. The time taken to 
present research varied from 30 minutes to an hour. This included a 
diverse mix of professionals, such as health care assistants, 
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psychiatrists, nurses, social workers, occupational therapists, speech 
and language therapists and clinical psychologists.  
 
Attempts at understanding the motivational needs of clinicians can 
lead to a more accurate perception of how to reach willing 
collaborators (Young & Dombrowski, 1989). Due to the demands of 
working in a busy NHS context, the burden on health professionals 
was minimised. The lead researcher collected all the data and 
requested only minimal information from referrers. A key incentive, 
for staff visited, was the need for improved guidlines on deciding on 
drug eligibility for people with mild, moderate and severe dementia 
who were unable to complete the MMSE. HCPs were keen for any 
results to be made available to their teams. This is strongly 
advocated by Patel and colleagues (2003), who stated that this is 
neglected by researchers and can have adverse consequences on 
future attempts to recruit participants in the region (Patel, Doku & 
Tennakoon, 2003). Hence, results will be disseminated to all 
collaborators through presentations upon completion of this study.  
 
HPCs‟ were given copies of invitation letters for participants (see 
Appendix 3), referrer information sheets (see Appendix 4), and 
referral forms (see Appendix 5). Initial patient contact was made by 
HPCs‟ who informed clients of the study and handed out invitation 
letters. HPCs‟ established if patients were interested in hearing more 
about the study and if so, they sought consent to complete a referral 
form, with the patients contact details on it, and forwarded this to the 
lead researcher. The referral forms were either posted to the 
University address or faxed to a secure site within a NHS trust. The 
lead researcher made contact after a minimum of 24 hours, via 
telephone and briefly explained the study and arranged an initial 
appointment. Memory difficulties are common in dementia, hence 
participants were encouraged to make a note of the appointment on a 
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calendar if they had one. Participants who expressed an interest in 
taking part, but who reported not having a memory aid or a strategy 
to document appointments, were given the option of having a carer, 
who was present, to make a record of the appointment and remind 
them if needed. To minimise confusion or distress due to forgetting, a 
picture of the lead researcher was included on all documents handed 
to participants. This enabled them and their carers to know, in 
advance, who to expect on the visit and also to enable them to verify, 
for their safety, that the person visiting them was the person who 
was responsible for the research. 
 
To minimise inconvenience and ensure participants would not have to 
incur any financial cost for taking part, all data was collected during 
appointments arranged at participant‟s homes. During this visit the 
lead researcher explained the studies objectives and procedures and 
ensured that the participants met the inclusion criteria. The 
participants who did not meet the inclusion criteria were excluded at 
this stage. The lead researcher talked through the Participant 
Information Sheet (see Appendix 6). A formal capacity to consent 
assessment (see Appendix 7) was conducted prior to signing the 
consent form (see Appendix 8). A copy of the consent form was 
handed to the participant and a copy was included within their clinical 
notes and their research file.  
 
2.5.2   Data collection  
The settings of the assessments varied depending on the mobility 
needs of the participants. The venues ranged from participant‟s 
homes or day hospitals.  The lead researcher endeavoured to 
maintain some consistency across the testing procedure for all 
involved. Therefore, the following rules were upheld: the lead 
researcher administered all measures, only the participant and the 
lead researcher were in the room at the time of the testing, with no 
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interruptions or distractions, and the room contained a table with two 
chairs. The lead researcher discussed this with participants and 
ensured that these conditions could be met prior to booking the 
appointment. This was done to minimise error variance through 
confounding variables, such as not having a table to write on. The 
participants were reminded that they could take a break at any time 
during the testing.  
 
The lead researcher administered the MMSE according to the 
standardized administration procedures. The six alternative cognitive 
tests were also administered. Data was collected in the initial visit for 
the majority of participants, and over two appointments for three 
participants.  The average total duration of a visit was approximately 
2 hours. This involved building rapport with participants, delivering 
information about the study, answering any questions presented by 
participants and carers, carrying out a capacity assessment, carrying 
out cognitive testing and debriefing. The administration of all 
cognitive tests took approximately one to one and a half hours for 
each participant (see Appendix 9 for order and instructions for 
testing).  
 
The measures were scored using published scoring guidelines for 
each test. All responses were documented on record forms for each 
test. Each participant had a separate „Research File‟ this contained 
seven test record forms for the measures they had completed, 
consent form, demographic sheet and scoring sheets.  The storage of 
research files was arranged with the Trent Doctorate of Clinical 
Psychology course and the data was stored in a secure office at the 
University of Nottingham. The referral forms were the only sheets 
which contained participant identifiable information and these were 
stored separately in another cabinet within the University of 
Nottingham. Each participant was assigned a number to match their 
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contact details with their research files, so that results could be sent 
to them. Participants were given feedback on their performance in 
the form of a letter outlining their scores on each measure (see 
Appendix 11). Referrers were also provided with feedback if the 
participant provided consent (see Appendix 12 for a sample feedback 
report for a referrer).  
3   Extended Results 
3.1   Results 
Plan of analysis 
The overall aim of the statistical analysis was to determine if the 
RCFT, RCPM, SDMT, Brixton Test, CDT or CTT could provide 
equivalent information to the MMSE. This was explored using 
correlation analysis. Therefore, this analysis explored if changes in 
participants‟ performance (scores) on the RCFT, RCPM, SDMT, Brixton 
Test, CDT or CTT were met with similar changes in the scores 
obtained on the MMSE.  
 
The second aim was to explore whether or not the RCFT, RCPM, 
SDMT, Brixton Test, CDT or CTT would differentiate between those 
eligible for treatment with AchI from those who were not. This was 
explored using Receiver Operating Characteristic (ROC) analysis. ROC 
analysis was carried out on the measures that had a statistically 
significant correlation with the MMSE. This was carried out to explore 
if a cut-off score could be identified on any of the alternative 
cognitive tests, that was equivalent to the cut-off on the MMSE which 
determined eligibility for AchI (<20). Only the cut-off score between 
the mild and moderate range was explored as no participants in this 
sample obtained a score below 14 points on the MMSE. Therefore, in 
the absence of participants scoring within the severe range (<9), it 
was not possible to explore the utility of the alternative cognitive 
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tests to differentiate between the severe and moderate range on the 
MMSE.  
 
The mild (>21) and moderate (<20) cut-offs on the MMSE were 
taken from NICE guidance (NICE, 2007), despite the existence of 
alternative age and education adjusted cut-offs proposed within the 
literature. This was because it is the cut-offs recommended by NICE 
which clinicians are expected to use and any alternative adjusted cut-
offs advised in the literature are not used consistently across 
services. The cut-offs identified using ROC analysis would ascertain 
what score a patient would need to score on any of the alternative 
cognitive tests, in order to be eligible for AchI.  
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3.2   Descriptive statistics of performance on cognitive tests 
 
Table 1: Descriptive statistics of performance on cognitive tests 
Test‡ n Score range 
on test 
Range Mean Std. 
Deviation 
MMSE 19 0-30 14-29 22.4 4.2 
RCFT VC 19 0-36 2-36 19.8 10.8 
RCFT IM  19 0-36 0-23.5 3.1 6 
RCFT 
SP*  
19 Time in 
seconds 
108-537 326.3 143.4 
RCFT DM 19 0-36 0-22.5 2 5.4 
RCFT R 19 0-20 12-20 14.4 4.4 
RCPM 20 0-36 5-35 17.5 8.2 
SDMT 20 0-115 0-31 14 8.6 
Brixton* 18 0-55 11-52 37.2 10.1 
CTT 1* 18 Time in 
seconds 
55-370 146.1 83.1 
CTT 2* 12 Time in 
seconds 
143-430 251 99.6 
 CDT*  20 0-31 0-24 10.6 8 
‡ RCFT VC, Rey Complex Figure Test Visual Construction; RCFT IM, 
Rey Complex Figure Test Immediate Memory; RCFT SP, Rey 
Complex Figure Test Speed of Processing; RCFT D, Rey Complex 
Figure Test Delayed Memory; RCFT R, Rey Complex Figure Test 
Recognition Memory; RCPM, Ravens Colour Progressive Matrices; 
SDMT, Symbol Digit Modalities Test; CDT, Clock Drawing Test; 
CTT1 & 2, Colour Trails Test 1 & 2. 
 
* Higher score indicates increased levels of impairment. 
 
 
3.3   Missing data 
Pairwise deletion of missing values was used in SPSS version 16. This 
is appropriate because there were particular tests which participants 
were unable to complete, such as the Colour Trails Test 2. This was 
important information because there was a pattern in what tests 
participants were unable to complete. This demonstrated that certain 
measures may be too difficult and therefore this may reflect the 
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appropriateness of using this measure to assess for cognitive 
functioning in the dementia population. The alternative to this was to 
use listwise deletion, where the case is excluded from all analyses. 
This option was not considered appropriate as it would have 
decreased the sample size for the analyses (Field, 2000). Missing 
values could have been replaced with the mean value for the sample, 
but this would have biased scores towards the mean.  On certain 
measures the standard deviation of the mean was so large that a 
mean score would not have been an accurate reflection of the true 
score that the participant may have gained on this test. 
  
3.4   Exploring the distribution of scores  
Initially the data was explored to establish patterns within it. This was 
used to see whether the data met the criteria necessary for statistical 
procedures that were to be conducted for each stage of the analysis. 
Exploration of the data was carried out using a range of methods on 
SPSS Version 16. This included pie charts for plotting frequencies and 
percentages, scatter plots to show relationships to inform correlations 
and histograms for checking the distribution of scores (Field, 2000; 
Pallant, 2007).  
 
In order to select the appropriate inferential statistical test, the 
distribution of scores was explored. Statistical tests make 
assumptions about how the data is distributed (Field, 2000). 
Parametric tests assume that scores are normally distributed. When 
this assumption is violated, non-parametric alternatives are to be 
used to analyse the data. The analysis of interest here was 
correlation, so analysing the strength of the relationship between the 
MMSE and the alternative cognitive tests. To decide which statistical 
test would be used, the distribution of the data for each cognitive test 
was explored using histograms (Field, 2000; Pallant, 2007; Dancey & 
Reidy, 2007). In order to explore if the histograms met the 
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characteristics of a normal distribution, the following criteria was 
used: 
 That the distribution of scores should be symmetrical about the       
mean 
 The tails should meet the x axis at infinity 
 The mean, median and mode are all the same value 
 It should be bell-shaped 
 
When exploring the distribution using histograms all measures 
appeared to show that the distribution of the data was not normally 
distributed. However, the subjective nature of this type of analysis 
warranted further analysis. Therefore, Skewness and Kurtosis values 
were also calculated for each variable to verify what was observed 
from the histograms (Field, 2000). Table 2 presents the skewness 
and kurtosis values for each measure.  
 
There is an option to transform scores to normalise them. However, 
there are no consistent guidelines for what level of skewness is 
problematic and guidelines for when to transform data are mixed 
(Norris & Aroian, 2004). However, there can be a loss of data which 
results in inaccurate interpretation of the data because transformed 
data becomes a step removed from the original measurement (Field, 
2000).  
 
The value for skewness and kurtosis should be 0 in a normal 
distribution (Field, 2000; Dancey & Reidy, 2007). The further away 
values are from zero (either positive or negative) the more likely it is 
that the data are not normally distributed and therefore a non-
parametric statistical test should be used. However, Field (2000) 
suggests that the actual values of skewness and kurtosis are not in 
themselves informative and instead the values need to be converted 
into z scores. The z –skew is calculated using (S – 0)/ SE Skew 
(where S is Skew, and SE is the standard error of the Skew), and 
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values above 1.96 or below -1.96 are significantly different from that 
expected by a normal distribution (p<.05) and may be problematic 
(Field, 2000). The z skew and z kurtosis for all cognitive measures 
are shown in table 2.  
 
Table 2:   z skew for all cognitive measures 
Measure‡ Skewness Z 
skew 
Kurtosis Z 
Kurtosis 
MMSE -.198 -.4 -.733 1 
RCFT VC -.173 -.3 -.992 1 
RCFT I 2.991 5.7 9.445 1 
RCFT SP .095 .2 -1.515 1 
RCFT D 3.809 7.3 15.331 1 
RCFT R .756 1.4 -.159 1 
RCPM .449 0.9 -.627 1 
SDMT .643 1.3 .018 1 
Brixton -.780 -1.5 2.586 1 
CTT 1 1.518 2.8 2.916 1 
CTT 2 .376 0.5 -1.405 1 
CDT .495 1 -1.044 1 
‡ RCFT VC, Rey Complex Figure Test Visual Construction; 
RCFT IM, Rey Complex Figure Test Immediate Memory; 
RCFT SP, Rey Complex Figure Test Speed of Processing; 
RCFT D, Rey Complex Figure Test Delayed Memory; 
RCFT R, Rey Complex Figure Test Recognition Memory; 
RCPM, Ravens Colour Progressive Matrices; SDMT, 
Symbol Digit Modalities Test; CDT, Clock Drawing Test; 
CTT1 & 2, Colour Trails Test 1 & 2. 
 
3.5  Justification for use of parametric and non-parametric 
analysis 
On the basis of z-scores for skewness and kurtosis the distribution of 
scores on the MMSE, RCFT visual construction trial, RCFT speed of 
processing trial, RCFT recognition memory, RCPM, SDMT, Brixton 
test, CTT2 and CDT were normally distributed. However, to verify this 
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Kolmogorov-Smirnov (K-S) and Shapiro-Wilk statistic was used (see 
Table 3). A significant value (p<0.05) indicates a deviation from 
normality (Pallant, 2007). On the basis of this analysis the scores on 
these tests appeared to be normally distributed therefore parametric 
statistical analysis was used. Pearsons product moment correlation 
analysis was used to explore the relationship between the above 
measures and the MMSE. 
 
On the basis of the z-scores for skewness and kurtosis the 
distribution of scores on the RCFT immediate and delayed memory 
trial, and the CTT1 were not normally distributed. The K-S test test 
verified this, with the exception of the CTT1. However, the Shapiro-
Wilk value was statistically significant (.018) and evidence suggests 
that the K-S test can be too stringent for small samples (Pallant, 
2007). Therefore non-parametric statistical analysis, specifically 
spearman correlation was used to explore the relationship between 
these measures and the MMSE.  
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Table 3: Kolmogorov-Smirnov & Shapiro-Wilk significance 
values for each test 
Test‡ Kolmogorov-Smirnov 
(K-S) 
Shapiro-Wilk 
MMSE .200 .628 
RCFT VC .200 .305 
RCFT SP .125 .112 
RCFT I .000* .000* 
RCFT D .000* .000* 
RCFT R .200 .048* 
RCPM .200 .387 
SDMT .200 .049* 
Brixton test .200 .151 
CDT .200 .100 
CTT1 .200 .018* 
CTT2 .200 .173 
‡ RCFT VC, Rey Complex Figure Test Visual Construction; RCFT 
IM, Rey Complex Figure Test Immediate Memory; RCFT SP, Rey 
Complex Figure Test Speed of Processing; RCFT D, Rey Complex 
Figure Test Delayed Memory; RCFT R, Rey Complex Figure Test 
Recognition Memory; RCPM, Ravens Colour Progressive 
Matrices; SDMT, Symbol Digit Modalities Test; CDT, Clock 
Drawing Test; CTT1 & 2, Colour Trails Test 1 & 2. 
* = A significant result (p<0.05) indicating that the distribution 
of scores deviate from normality.  
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3.6 Effect size  
The effect size is an objective and standardised measure of the 
magnitude of observed effect. The fact that the measure is 
standardised means that the effect size can be compared across 
different studies that have measured different variables, or have used 
different scales of measurement. Many measures of effect size have 
been proposed. The most common is Cohen‟s d and Pearson‟s 
correlation coefficient (r). The correlation coefficient is one of the 
most common effect size measures and it is incredible versatile 
(Field, 2000). A correlation coefficient of 0 means there is no effect, 
and a value of 1 means that there is a perfect effect, or strong 
relationship. Cohen (1992) has made some widely accepted 
suggestions about what constitutes a large or small effect in terms of 
Persons r, these are:  
 
r = 0.1-.23 (small effect) 
r = 0.24-.36 (medium effect) 
r = 0.37 (large effect) 
 
These guidelines can be used to assess the importance of correlations 
between the MMSE and the alternative cognitive tests, regardless of 
the significance of the test statistic (Field, 2000). This is because 
statistical significance is the probability that that the observed 
relationship could be due to chance (assuming the null hypothesis is 
correct), it does not tell you about the strength of any relationship 
found (Field, 2000).   
 
3.7 Bonferroni corrections 
Bonferroni corrections were not carried out prior to conducting the 
correlation analysis, despite recommendations to do so when multiple 
comparisons are being made (Cabin & Mitchell, 2000). Bonferroni 
corrections are employed to reduce Type 1 errors, however they also 
increase the likelihood of type 2 errors (Perneger, 1998). In addition, 
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Bonferroni corrections reduce the power of a study below the .80 
standard. This intern would require larger sample sizes to detect 
large effects (Cohen, 1988; Nakagawa, 2004). This is not always 
practical or possible when carrying out time limited, low-cost research 
within the NHS. In the context of this research, it would also be 
difficult to establish which correlations were due to chance and which 
were not. For instance all the cognitive measures were administered 
to a sample which was experiencing significant, often global decline in 
their cognitive functioning. Hence, their performance on each 
measure could not be entirely isolated from the domain that was 
assessed in another measure. Furthermore, there is no formal 
consensus on when Bonferroni corrections should be applied.  
 
3.8   Correlations  
Parametric and non-parametric correlation analysis was conducted to 
explore the relationship between the MMSE and the six alternative 
cognitive tests. The results showed that there was a statistically 
significant relationship between the following measures: 
The MMSE and the RCFT visual construction trial: 
There was a positive linear correlation between these two measure, 
which suggests that a higher score on the MMSE was associated with 
a higher score on the RCFT visual constructional task (r= .609; 
p<0.006; strong relationship). 
The MMSE and the RCFT recognition trial  
There was a positive linear correlation between the MMSE and the 
RCFT recognition trial, which suggests that a higher score on the 
MMSE was associated with a higher score on the RCFT recognition 
trial (r=.496; p<0.031; strong relationship). 
The MMSE and the Ravens Colour Progressive Matrices  
There was a positive linear correlation between the MMSE and the 
RCPM, which suggests that higher scores on the MMSE was 
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associated with higher scores on the RCPM (r= .452; p<0.045; large 
strong relationship). 
The MMSE and the Symbol Digit Modalities test  
There was a positive linear correlation between the MMSE and the 
SDMT. This suggests that higher scores on the MMSE was associated 
with higher scores on the SDMT (r=.670; p<0.001; strong 
relationship). 
The MMSE and the Colour Trails Test 1  
There was a negative linear correlation between the MMSE and Colour 
Trails Test 1. This suggests that higher scores on the MMSE was 
associated with lower time to complete the CTT1 (Spearman‟s rho=-
.576; p<0.012; strong relationship). 
The MMSE and the Clock Drawing Test  
There was a negative linear correlation between the MMSE and the 
CDT. This suggests that a higher score on the MMSE was associated 
with lower error rates on the CDT (r=-.577; p<0.008; strong 
relationship). 
 
3.9 Receiver Operating Characteristic (ROC) analysis 
When considering the predictive accuracy of a test, statistics derived 
from the ROC analysis are the preferred indices of predictive accuracy 
and effect size (Swets, Dawes, & Monahan, 2000; Harris, 2003; 
linden, 2006; Craig, Browne, Stringer, & Hogue 2008). ROC curves 
are valuable tools for the assessment of the accuracy of a test by 
comparing it with a definitive „gold standard‟ (reference standard) 
test (Obuchowski & McClish, 1997). The „gold standard‟ test will 
specify a cut-off point which distinguishes between normal values 
(negative cases) from abnormal values (positive cases). Thus, 
indicating absence and presence of disease. If a less extreme cut-off 
is used, more patients are indicated as positive cases, thus improving 
the sensitivity of the test (i.e. the probability of rightfully concluding 
the disease is present in diseased patients), but at the expense of 
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deteriorating specificity (i.e. the probability of rightfully concluding 
the disease is absent in healthy patients). ROC curves are used to 
describe the possible combinations of sensitivity and specificity, 
depending on the cut-off point that is chosen (Hout, 2003).  
 
In this study the „gold standard‟ test was the MMSE. The accuracy of 
the alternative cognitive tests (index tests) was compared to MMSE in 
terms of identifying those who are eligible for treatment with AchI 
and those who are not.  
 
3.9.1   Classifier performance 
Generally, both the sensitivity and specificity of a test need to be 
known in order to assess its usefulness for a diagnosis (Fawcett, 
2006). When selecting a cut-off point the trade off between 
sensitivity and specificity was considered. This was as follows: 
 
 If the threshold for identifying those eligible for AchI, from the 
index test, is lowered then the number of false positives 
increases (the percentage of participants who were not eligible 
for AchI who were incorrectly classified as being eligible for 
AchI) 
 If the threshold for identifying those eligible for AchI, from the 
cognitive tests, is heightened then the number of false 
negatives or misses increases (the percentage of participants 
who are incorrectly classified as not being eligible for AchI).  
 
A perfect measure would have 100% sensitivity and 100% specificity, 
thereby correctly identifying everyone and never misclassifying 
people (Bewick, Cheek, & Ball, 2004). In reality few measures are 
that accurate (Linden, 2006).  The cut-off identified from each of the 
index tests needed to balance high specificity (>80%) with the least 
acceptable rate of false positives (>60%). However, there is no clear 
standard set for what percentage of sensitivity and specificity is 
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acceptable. The standards used in this research have also been used 
in a previous studies (Barr, 1997; Blake, McKinney, Treece, Lee & 
Lincoln, 2002; Bewick et al, 2004; Lepeleire, Heyrman, Baro & 
Buntinx, 2005; Linden, 2006; Mitchell, 2009).  
 
A limitation of ROC analysis is that the predictive values of the 
cognitive tests are highly sensitive to the prevalence rate of the 
observed outcome in the population being evaluated (Altman & 
Bland, 1994; Linden, 2006). When the sample has a high prevalence 
of the outcome the Positive Predictive Value increases (PPV), however 
the Negative Predictive Value (NPV) decreases. Conversely, when the 
prevalence of positive cases (those who are eligible for AchI) in the 
sample is low, the PPV decreases and NPV increases.  The prevalence 
of participants who were eligible for AchI in this sample was 40%, 
therefore, the predictive accuracy of all the measures evaluated in 
this study was lower, due to the unequal prevalence rates.  In 
addition, due to missing data the prevalence rate of those eligible for 
AchI for each ROC analysis varied according to the index test being 
evaluated. The prevalence of those eligible for AchI was calculated for 
each measure using the following metric: (A+B)/ (A+B+C+D) x 
100%.  
 
Cut-offs were identified for all the measures that correlated with the 
MMSE and these will be presented individually below. Once an 
appropriate cut-off was identified based on a balance between 
sensitivity and specificity, the variables were transformed with these 
cut-offs, within SPSS, using cross tabulations. A kappa analysis was 
conducted to establish the rate of true negative and false positives 
identified using these cut offs. Given each measure, there are four 
possible outcomes. If the instance is positive and it is classified as 
positive it is counted as a true positive; if it is classified as negative, 
it is counted as a false negative. If an instance is negative and it is 
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classified as negative, it is counted as a true negative, if it is 
classified as a positive, it is counted as false positive. Given each 
measure and the test set, a two-by-two contingency table can be 
constructed representing the dispositions of the set of instances 
(Fawcett, 2006) see Table 4. Once this data has been completed, it is 
possible to calculate the false positive rate, the true positive rate, the 
sensitivity, specificity, and the overall positive predictive value of the 
cut-offs on the cognitive tests, using the metrics presented in Table 
5.  
 
Table 4: Contingency table  
 Reference standard test 
Index test Positive 
 
Negative 
 
Total 
Positive 
 
 
True 
positives 
A 
 
 
False positives 
B 
 
 
A + B 
Negative 
 
 
False 
Negatives 
C 
 
 
True 
negatives 
D 
 
C+D 
Total A + C 
 
B + D A+B+C+D 
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Table 5: Metrics 
 
 Metrics 
 
False 
positive rate 
 
B/ Total negatives 
 
 
True 
positive rate 
 
A/ Total positives 
 
Sensitivity  A/ (A+C) x 100 
 
Specificity D/ (B + D) x 100 
 
 
Positive 
predictive 
Value(PPV) 
 
 
 
A/ (A + B) 
 
Negative 
Predictive 
Value (NPV) 
 
                    D / (C 
+ D) 
Discriminant 
Ability 
Sensitivity + 
Specificity / 2 
 
3.9.2   Area under the curve (AUC) 
A ROC analysis plots the tests true positive rate (sensitivity) against 
its false negative rate (1-specificity) and is constructed by estimating 
the sensitivity and specificity of each test for each of the participants 
test score. This produces a line of data points across a graph making 
up the “curve”. This graph is a technique for visualising, organising 
and selecting classifiers based on their performance (Fawcett, 2006). 
The AUC is a popular summary measure of the accuracy of a test. It 
serves as an index to describe the discriminatory property of a test, 
so one does not have to rely solely on visual inspection to determine 
how well the test performs (Bewick et al, 2004; Linden, 2006). An 
AUC of 0.5 is a random, an AUC between 0.5 and 0.7 represents 
moderate, between 0.9 and 1 represents high accuracy, and an AUC 
of 1 would represent the ideal test (Fischer, Bachmann & Jaeschke, 
2003). However, the full AUC has been criticised because it is the 
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function of both the sensitivity and specificity, therefore the AUC 
represents the entire range of error rates and gives equal weight to 
all false positive rates. The volume under the ROC surface of 1/6 
corresponds to a test without discriminatory power, and the value of 
1 indicates a perfect test.  
 
The AUC value of two or more tests can be used to make 
comparisons of their predictive accuracy. If one test has a higher AUC 
value than another, this suggests that it has better predictive value 
and can be selected. However, caution must be taken when doing 
comparisons between two ROC volumes, because it is not possible to 
establish if there is a statistically significant difference between the 
AUC of two or more different measures, without appropriate 
computer software (Stephen, Wesseling, Schink & Jung, 2003; Chi & 
Zhou, 2008; Erkel & Pattynama, 2008).  
 
3.9.3 Positive and Negative Predictive Values  
The positive predictive value (PPV) of a test is the probability that a 
patient has a positive outcome given that they have a positive test 
result. This is in contrast to sensitivity, which is the probability that a 
patient has a positive test result given that they have a positive 
outcome. Similarly, the negative predictive value (NPV) is the 
probability that a patient has a negative outcome given that they 
have a negative test result, in contrast to specificity, which is the 
probability that a patient has a negative test result given that they 
have a negative outcome. The PPV and NPV were calculated for each 
measure and the metrics are presented in Table 5.   
 
3.10   ROC analysis for Rey Complex Figure Test – Visual 
Construction subtest 
The prevalence of those eligible for AchI in this analysis was 42% (8 
positive & 11 negative). The best cut-off score was selected (see 
table 6). A score equal or below 20.5 (<20.5) would identify 
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participants who were eligible for treatment with Achi, with good 
sensitivity (87%) and adequate specificity (64%). A lower score on 
this test infers greater impairment in visual constructional and 
perceptual ability. The new cut-offs identified 11 positive cases.  
 
Table 6: Coordinates of the ROC Curve for RCFT Visual construction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In order to calculate the PPV and NPV of this cut-off, the scores for 
RCFT construction were redefined within SPSS v16 into binary 
classifiers. Therefore, a score of <20.5 was assigned a value of one 
(eligible for AchI) and a score equal or above 21 was assigned a 
value of two (not eligible for AchI). These were cross tabulated with 
the MMSE; „eligible‟ for AchI and „not eligible‟ for AchI.  To measure 
the agreement and calculate the metrics presented in Table 5, Kappa 
measure of agreement is used (see Table 7). Cohen's kappa 
Positive if 
Less Than 
or Equal 
To 
Sensitivity 1 - 
Specificity 
1.0000 .000 .000 
2.2500 .000 .091 
5.7500 .250 .091 
10.0000 .375 .091 
12.7500 .375 .182 
14.7500 .500 .182 
16.0000 .625 .182 
18.0000 .625 .273 
19.2500 .625 .364 
19.7500 .750 .364 
20.2500 .875 .364 
22.7500 .875 .455 
26.5000 .875 .545 
28.7500 .875 .636 
30.7500 1.000 .636 
32.5000 1.000 .727 
34.5000 1.000 .909 
37.0000 1.000 1.000 
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measures the agreement between the evaluations of two raters when 
both are rating the same object. A value of 1 indicates perfect 
agreement. A value of 0 indicates that agreement is no better than 
chance. A kappa coefficient of .5 for represents moderate agreement, 
above .7 represents good agreement, and above .8 represents very 
good agreement (Pallant, 2007). The agreement between the MMSE 
and RCFT visual construction was moderate (kappa= -.511; p<.026).   
Table 7: Contingency table showing positive and negative predictive 
values of cut-off of <20.5 on RCFT Visual construction  
 
 MMSE 
RCFT- 
Visual 
construction 
 Eligible for 
Aricept 
(<20) 
 
Not eligible 
for Aricept 
(>21) 
 
Total 
(n) 
Positives 
<20.5 
 
True 
positives 
7 (sensitivity 
= 87.5%) 
 
False positives 
4 (35.4%) 
 
 
11 
Negatives 
>21 
 
False 
Negatives 
1 (12.5%) 
 
True negatives 
7 (Specificity = 
63.6%) 
 
 
 
8 
Total (n) 8 11 19 
 
The cut-off (<20.5) identified 11 positive cases, (participants who 
were eligible for AchI) and identified eight negative cases 
(participants who were not eligible for treatment with AchI). The PPV 
of the RCFT visual construction trial is 7/ (7+ 4) = 0.636 (64%), and 
the NPV is 7/ (1 + 7) = 0.875 (87%). Therefore, 64% of participants 
scored <20.5, and were within the moderate range on the MMSE, and 
thus were correctly classified as being eligible for AchI. 87% of the 
participants‟ who scored above 21, also scored above the cut off for 
treatment with AchI. 
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The discriminant ability of the cognitive tests can be calculated to 
summarise the performance of the test (see table 5 for the metric). 
This tells us how much information the cognitive test provides 
compared to the MMSE, which is assumed to provide perfect (100%) 
information.  The discriminant ability of the RCFT visual construction 
trial is: (87% + 64%) / 2 = 75%.  The AUC = .750 (CI= .524, .976), 
suggesting moderate accuracy (see Figure 1 and Table 8). 
 
Figure 1: ROC curve for Rey Complex Figure Test- Visual 
construction 
 
 
 
 
 
 
 
 
 
 
 
 
Table 8: Area Under the Curve RCFT Visual construction 
 
AUC Standard 
Error 
Significance 
(p<.05) 
95% Confidence Interval 
Lower 
Bound 
Upper Bound 
.750 .115 .069 .524 .976 
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3.11 ROC analysis for Rey Complex Figure Test – Recognition 
memory subtest 
The prevalence of those eligible for AchI in this analysis was 42% (8 
positive & 11 negative). The cut-off score selected was <14.5 (a 
score of 14.5 or below), which identified participants who were 
eligible for treatment with AchI, with good sensitivity (87%) and good 
specificity (72%) (see Table 9). This cut off identified 11 positive 
cases. A lower score on this test infers greater impairment in visual 
recognition memory.  
 
Table 9:  Coordinates of the ROC Curve for RCFT Recognition 
memory 
 
Positive if 
Less Than 
or Equal To 
Sensitivity 1 - 
Specificity 
11.0000 .000 .000 
12.5000 .375 .091 
13.5000 .625 .182 
14.5000 .875 .273 
15.5000 .875 .455 
16.5000 .875 .636 
18.5000 1.000 .818 
21.0000 1.000 1.000 
 
 
The kappa measure of agreement was moderate (kappa= -.592; 
p<.009). The PPV = 7/ (7 + 3) x 100=70%. The NPV= 8/ (1 + 8) x 
100 = 89% (see Table 10). Therefore, 70% of participants scored 
<14.5, and were within the moderate range on the MMSE, and thus 
were correctly classified as being eligible for AchI. 89% of the 
participants‟ who scored above 21 also scored above the cut off for 
treatment with AchI. 
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Table 10: Contingency table showing positive and negative 
predictive values of cut-off of <14.5 on RCFT Recognition memory  
 
 MMSE 
RCFT- 
recognition 
memory 
 Eligible for 
Aricept 
(<20) 
 
Not eligible 
for Aricept 
(>21) 
 
Total 
(n) 
Positives 
<14.5 
 
True 
positives 
7 (sensitivity 
= 87.5%) 
 
False positives 
3 (27.2%) 
 
 
11 
Negatives 
>15 
 
False 
Negatives 
1 (12.5%) 
 
True negatives 
8 (Specificity = 
72.7%) 
 
 
 
8 
Total (n) 8 11 19 
 
The discriminant ability of the RCFT recognition memory trial is: 
(87% + 72%) / 2 = 79.5%. The AUC = .801 (CI= .590 to 1.012) 
which suggests moderate to high accuracy (see Figure 2 and Table 
11). 
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Figure 2: ROC curve for RCFT- Recognition memory 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 11: Area Under the Curve RCFT Recognition memory 
AUC Standard 
error 
Significance 
(p<.05)  
95% Confidence Interval 
Lower 
Bound 
Upper Bound 
.801 .108 .029 .590 1.012 
 
3.12  ROC analysis for Ravens Colour Progressive Matrices 
The AUC value for the RCPM was .573 (see Figure 3 and Table 12). 
This suggested that the measure was no better than chance at 
discriminating between positive and negative case, despite a 
statistically significant correlation (r=.452; p<.05) with the MMSE. 
Subsequently, it was not possible to identify a cut-off score, which 
had acceptable sensitivity or specificity (see Table 13).  
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Figure 3: ROC curve for RCPM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 12: Area Under the Curve for the RCPM 
 
Area 
Standard 
error 
Significance  
(p<.05) 
Asymptotic 95% 
Confidence Interval 
Lower 
Bound 
Upper 
Bound 
.573 .140 .589 .298 .848 
 
 
 
 
 
 
 
 
    Figure 3: ROC curve for RCPM 
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Table 13: Coordinates of the ROC Curve for RCPM 
Positive if 
Less Than 
or Equal To 
Sensitivit
y 
1 - 
Specificity 
5.0000 .000 .000 
8.0000 .125 .083 
10.5000 .250 .083 
12.5000 .500 .250 
14.5000 .500 .333 
16.0000 .500 .500 
18.5000 .625 .500 
20.5000 .625 .667 
21.5000 .750 .667 
24.0000 .750 .750 
26.5000 .750 .833 
28.5000 .875 .917 
32.5000 1.000 .917 
36.0000 1.000 1.000 
 
3.13   ROC analysis for Symbol Digit Modalities Test 
The prevalence of those eligible for AchI in this analysis was 40% (8 
positive & 12 negative). The cut-off score selected was <11 (a score 
of 11 or below), which identified participants who were eligible for 
treatment with AchI, with good sensitivity (75%) and adequate 
specificity (66%) (see Table 14). This cut off identified 10 positive 
cases. A lower score on this test infers greater impairment in global 
cognitive functioning. 
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Table 14: Coordinates of the ROC curve for SDMT 
 
Positive if 
Less Than 
or Equal To Sensitivity 
1 – 
Specificity 
-1.0000 .000 .000 
.5000 .250 .167 
1.5000 .375 .167 
3.0000 .375 .250 
6.5000 .500 .250 
10.0000 .625 .250 
11.5000 .750 .333 
12.5000 .875 .417 
14.5000 .875 .583 
17.0000 .875 .750 
19.0000 .875 .833 
25.0000 1.000 .833 
30.5000 1.000 .917 
32.0000 1.000 1.000 
 
The kappa measure of agreement was moderate (kappa= -.400; 
p<.068). The PPV = 6/ (6 + 4) x 100=60%. The NPV= 8/ (2 + 8) x 
100 = 80% (see Table 15). Therefore, 60% of participants scored 
<11, and were within the moderate range on the MMSE, and thus 
were correctly classified as being eligible for AchI. 89% of the 
participants‟ who scored above 21 also scored above the cut off for 
treatment with AchI. 
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Table 15: Contingency table showing positive and negative 
predictive values of cut-off of <11 on SDMT  
 
 MMSE 
SDMT  Eligible for 
Aricept 
(<20) 
 
Not eligible 
for Aricept 
(>21) 
 
Total 
(n) 
Positives 
<11 
 
True 
positives 
6 (sensitivity 
= 75%) 
 
False positives 
4 (33.3%) 
 
 
10 
Negatives 
>12 
 
False 
Negatives 
2 (25%) 
 
True negatives 
8 (Specificity = 
66.6%) 
 
 
 
10 
Total (n) 8 12 20 
 
The discriminant ability of the SDMT trial is: (75% + 66.6%) / 2 = 
70.8%. The AUC= .708 (CI= .469 to .947), which suggests moderate 
accuracy to high accuracy (see Figure 4 and Table 16).  
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Figure 4: ROC curve for SDMT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 16 Area Under the Curve 
Area Standard 
error 
Significance 
(p<.05) 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
.708 .122 .123 .469 .947 
 
3.14 ROC analysis for Colour Trails Test 1 
The prevalence of those eligible for AchI in this analysis was 39% (7 
positive & 11 negative). On the Colour Trails Test 1 a cut-off of 
>114.5 seconds (a score of 114.5 or higher) would identify 
participants who were eligible for treatment with AchI, with good 
sensitivity (86%) and adequate specificity (64%) (see table 17). A 
higher score on this test infers greater impairment in attention and 
executive functioning.  
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Table 17: Coordinates of the ROC curve for CTT1 
 
Positive if 
Greater 
Than or 
Equal To 
Sensitivit
y 
1 - 
Specificity 
54.0000 1.000 1.000 
56.0000 1.000 .909 
65.0000 1.000 .818 
75.5000 1.000 .727 
81.0000 1.000 .636 
88.5000 .857 .636 
95.0000 .857 .545 
100.5000 .857 .455 
114.5000 .857 .364 
133.0000 .714 .364 
144.5000 .714 .273 
149.0000 .571 .273 
153.0000 .571 .182 
165.0000 .571 .091 
176.0000 .571 .000 
206.5000 .429 .000 
238.0000 .286 .000 
305.5000 .143 .000 
371.0000 .000 .000 
 
 
The kappa measure of agreement was moderate (kappa= .458; 
p<.040). The PPV = 6/ (6 + 4) x 100=60%. The NPV = 7/ (1 + 7) x 
100 = 88% (see Table 18). Therefore, 60% of participants scored 
>114.5 seconds, and were within the moderate range on the MMSE, 
and thus were correctly classified as being eligible for AchI. 88% of 
the participants‟ who scored below 115 seconds, also scored above 
the cut off for treatment with AchI. 
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Table 18: Contingency table showing positive and negative 
predictive values of cut-off of >114.5 on the CTT1  
 
 MMSE 
CTT1 
(seconds) 
 Eligible for 
Aricept 
(<20) 
 
Not eligible 
for Aricept 
(>21) 
 
Total 
(n) 
Positives 
>114.5 
 
True 
positives 
6 (sensitivity 
= 86%) 
 
False positives 
4 (36%) 
 
 
10 
Negatives 
<115 
 
False 
Negatives 
1 (14%) 
 
True negatives 
7 (Specificity = 
64%) 
 
 
 
8 
Total (n) 7 11 18 
 
The discriminant ability of the CTT1 is: (86% + 64%) / 2 = 75%. The 
AUC =.818 (CI= .610-1.027), which suggests moderate to high 
accuracy (see Figure 5 and Table 19).   
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Figure 5: ROC curve for Colour Trails Test 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 19: Area Under the Curve for the Colour Trails Test 1 
 
Area 
Standard 
error 
Significance 
(p<.05) 
95% Confidence Interval 
Lower 
Bound 
Upper 
Bound 
.818 .106 .026 .610 1.027 
 
3.15 ROC analysis for the Clock Drawing Test 
On the Clock Drawing Test a cut-off of >9 errors (a score of 9 or 
above) would identify participants who were eligible for treatment 
with AchI, with good sensitivity (75%) and adequate specificity 
(75%) (see Table 20). A higher score on this test infers greater 
impairment.  
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Table 20: Coordinates of the ROC curve for CDT 
 
Positive if 
Greater 
Than or 
Equal To 
Sensitivit
y 
1 - 
Specificity 
-1.0000 1.000 1.000 
1.0000 1.000 .917 
2.5000 .875 .917 
3.5000 .875 .750 
4.5000 .750 .750 
5.5000 .750 .667 
6.5000 .750 .500 
7.5000 .750 .417 
8.5000 .750 .333 
9.5000 .750 .250 
12.0000 .625 .250 
14.5000 .625 .167 
15.5000 .500 .083 
18.5000 .375 .083 
21.5000 .375 .000 
22.5000 .250 .000 
23.5000 .125 .000 
25.0000 .000 .000 
 
The kappa measure of agreement was moderate (kappa= -.400; 
p<.068). The PPV = 6/ (6 + 4) x 100=60%. The NPV= 8/ (2 + 8) x 
100 = 80% (see Table 21). Therefore, 60% of participants made >9 
errors, and were within the moderate range on the MMSE, and thus 
were correctly classified as being eligible for AchI. 80% of the 
participants‟ who made <8 errors, also scored above the cut off for 
treatment with AchI. 
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Table 21: Contingency table showing positive and negative 
predictive values of cut-off of >9 on the CDT  
 
 
 MMSE 
CDT 
(errors) 
 Eligible for 
Aricept 
(<20) 
 
Not eligible 
for Aricept 
(>21) 
 
Total 
(n) 
Positives 
>9 
 
True 
positives 
6 (sensitivity 
= 75%) 
 
False positives 
4 (33%) 
 
 
10 
Negatives 
<8 
 
False 
Negatives 
2 (25%) 
 
True negatives 
8 (Specificity = 
67%) 
 
 
 
10 
Total (n) 8 12 20 
 
The discriminant ability of the CDT is: (75% + 67%) / 2 = 71%. The 
AUC= .734 (CI= .479 to .990), this suggests modest accuracy (see 
Figure 6 and Table 22). 
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Figure 6: ROC Curve for the Clock Drawing Test 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 22: Area Under the Curve for the Clock Drawing Test 
 
Area 
Standard 
error 
Significance 
(p<.05) 
95% Confidence Interval 
Lower 
Bound 
Upper 
Bound 
.734 .130 .083 .479 .990 
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4. Extended Discussion 
4.1 Utility of alternative cognitive tests 
It is possible to use each of the index tests together to assess for 
cognitive functioning, or to select individual tests. In order to decide 
which cognitive test to use, clinicians will need to consider the 
advantages and disadvantages of using a specific test based on the 
test properties and the client‟s experience. Dementia patients 
experience global decline in cognitive functioning (Green, 2000), 
therefore it is important to select measures which are tolerated well 
by this client group. In terms of the Brixton test of executive 
functioning, Burgess and Shallace (1997) reported that it was 
tolerated well by older people with dementia. However, observations 
of participant‟s behaviour during this research suggested that caution 
should be taken when administering this test with people with 
dementia. This is because the test involved presenting the 
participants with 55 items and there was a lack of a discontinue rule. 
This meant that all 55 test items needed to be administered 
according to standardised procedures. This was despite the fact that 
participants had difficulty comprehending the task and had already 
responded incorrectly to over 30 test items. Furthermore, when the 
blue circle did not appear in the position they had expected, they 
became aware that they were making mistakes. Subsequently, 
participants who had insight into their difficulties reported their 
frustration at being confronted with their difficulties in this way. 
Therefore, further research exploring the possibility of including a 
discontinue rule would improve the utility of this test with people with 
dementia.  
 
An additional challenge to selecting reliable and valid cognitive tests 
for people with dementia is the difficulty in isolating a cognitive 
domain within an assessment. For instance, due to the prevalence of 
memory impairment, it was difficult to assess whether performance 
  Page 125 of 209       
 
on the Ravan‟s Colour Progressive Matrices or the Brixton test was 
due entirely to impairment in the respective cognitive domain, or if it 
was due to forgetting of instructions. Some participants may continue 
to complete a task implicitly, without following any explicit rules or 
instructions. This is difficult to control for, which reinforces the need 
to carry out global assessment of cognitive functioning in clinical 
practice (Lezak et al, 2004).  
 
Finally, there is a tension between selecting tests where performance 
is judged on the basis of time (i.e. RCFT speed of processing, SDMT 
and CTT) and tests that do not have a discontinue rule (i.e. RCPM and 
Brixton Test). It is suggested that timed test are biased against older 
people, who have naturally occuring slowed psychomotor and motor 
processing (Lezak et al, 2004). There are also cultural differences in 
terms of how much emphasis people place on „working quickly‟ or 
„getting it right‟. Even when participants were told to work as quickly 
as possible, this did not appear to impact on their performance. 
However, some older people with dementia experience difficulty with 
perseveration. Hence tests which do not have specific standardised 
procedures for discontinuation will limit their utility in this client 
group.  
 
4.2 Drug treatment practices 
Cerejeira and Mukaetova-Ladinska (2007) highlighted that a problem 
with NICE guidance is that the application of the MMSE might become 
a substitute for clinical decisions rather than acting as a useful 
instrument in the clinical-decision making process. They suggested 
that by rigidly following the MMSE score clinicians would miss the 
complexity involved in making a therapeutic decision. It was also 
noted that there was a lack of empirical data about how many 
clinicians are using AchIs for mild dementia, and how beneficial they 
are in routine clinical settings. This study found that 80% of those 
  Page 126 of 209       
 
who were not eligible for treatment with an AchI (i.e. those who 
scored 21 or over on the MMSE) were still being prescribed AchI. 
However, given that the participants in this sample were already 
being prescribed AchI, it is possible that at the time of prescription 
the participants did have a score within the moderate range on the 
MMSE. Therefore, their MMSE scores could have improved due to the 
effect of the medication. However, evidence from RCTs report a 
maximum of 1 point change in MMSE scores following treatment 
(Birks & Harvey, 2006). Furthermore, the test-retest reliability of the 
MMSE is poor (Davey & Jamieson, 2004). Hence it is possible that 
variations in assessment practices could have lead to participants 
having different scores when being prescribed the medication, 
compared to when being selected for this study.  
 
Nonetheless, it would not be surprising if those scoring above the cut-
off were being prescribed AchI, as this has been observed in clinical 
practice (Doyle, 2001). However, there are no adverse implications of 
this for patients because AchI has been approved and is safe at a 
maximum dose of 10mg for people with AD or mixed AD and VaD of 
mild and severe level (Birks & Harvey, 2006). They are merely not 
deemed to be cost effective or clinically effective for each of these 
groups (NICE, 2007).  
 
One explanation proposed for why AchIs are being prescribed outside 
of guidelines is that an abundance of guidance may mean that 
clinicians place less importance in them (lliffe & Manthorpe, 2007). 
Furthermore, clinicians may be more flexible because they are taking 
into account other factors resulting in MMSE score variance, such as 
age and education (Tombaugh & McIntyre, 1992). Therefore, 
technically, they may not be prescribing outside the guidelines, rather 
they are taking other sources of evidence into account when 
interpreting scores. However, this can pose some inequalities in 
prescription practices depending on how flexible a clinician is in 
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interpreting the guidance, which can cause further confusion for 
patients and carers (O‟Brien & Ballard, 2001). Furthermore, Connelly 
and Bullock (2003) suggested that many memory specialists involved 
in the care of dementia sufferers do not feel that guidelines will 
largely influence clinical practice. 
 
4.3 Implications for clinical practice 
The lack of guidelines for people who do not speak English or who are 
non-verbal within the NICE guidelines presents unacceptable 
inequalities in assessment practices for these groups. Aside from 
being unethical, they are illegal. Although there is widespread 
controversy surrounding the guidelines, the thrust of the argument 
against the guidelines has so far been about the unfair restriction 
placed on people with mild dementia and ageism due to the cost 
effectiveness analysis (Syrett, 2007). Indeed, when NICE were taken 
to court by the pharmaceutical company, they did not highlight the 
discrimination against those who were unable to speak English, 
people with learning disabilities or people with sensory difficulties. 
This does not mean to say that clinicians were not aware that the 
MMSE was not administrable with these groups, it merely highlights 
that minority groups are not only marginalised within NICE guidance, 
but also by the bodies and organisations that are disputing the 
validity of NICE‟s decision. Hence, although the number of RCTs with 
people of severe and mild dementia has increased to disprove the 
NICE guidance, a similar empirical drive towards improving 
assessment processes for marginalised groups so far has not 
materialised. Subsequently, this study has significant implications for 
clinical practice, by providing some evidence in an area where 
progress is of critical importance.  
 
The index tests that were selected for this research can aid in clinical 
practice from the earliest stages of the assessment process. The 
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measures were selected specifically so they were easy to administer 
and were not time consuming. In busy GP practices, where clients are 
seen for brief consultations, a brief measure of cognitive functioning 
can assist them to monitor changes in those who are non-verbal 
(Glasser, 1993). The CDT and SDMT would be ideal in this setting as 
they require minimum training in the administration of tests and are 
easy to score. GPs can monitor whether their patients are scoring 
within the „moderate‟ range on these tests and then make 
appropriate referrals to memory clinics or older people‟s Mental 
Health Services for further assessment. Psychiatrists and prescribing 
clinicians in turn can use this information, alongside their own 
assessments to decide if it would be appropriate to prescribe AchI. 
This would be an improvement in assessment procedures for people 
who are non-verbal, as it would include an objective assessment 
measure.  
 
Furthermore, clinicians who work within memory clinics within 
secondary Mental Health services often refer clients to clinical 
psychologists or neuropsychologists for neuropsychological 
assessment. This is to aid in the process of diagnosis and also to 
monitor change overtime. When routine neuropsychological tests are 
not appropriate, the alternative tests can be used for those who are 
non-verbal.  
 
However, cognitive tests selected for this study are more sensitive to 
cognitive dysfunction compared to the MMSE. Therefore, whilst there 
is a ceiling effect on the MMSE, the alternative cognitive tests 
presented with a floor effect. The cut-off scores (which are equivalent 
<21 on the MMSE) for all the index tests are within the impaired 
range. Given that the mean MMSE score in this sample was 22, 
participants were more representative of those at the higher level end 
of the moderate range. This can be problematic because it means 
that those who score 10-15 on the moderate range on the MMSE may 
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floor the alternative cognitive tests. This may certainly be the case for 
the RCFT recognition trial as the cut-off score selected was <14.5, 
but a score of 12 can be obtained when a client does not recall a 
single item presented. Likewise the cut-off score selected for the 
SDMT was <14, however it is possible to obtain a score of up to 115 
on this test. In the absence of data from people within the severe 
range or moderately severe range, it is difficult to know if the index 
tests selected for this study would also be appropriate for these 
groups.  
 
Furthermore, the results of this research should be viewed as 
preliminary findings only, and further research is needed to validate 
these findings before clinicians can begin using them to decide on 
treatment eligibility. Promising as the results may be, they need to be 
understood in the context of the limitations of the study. For 
instance, there are factors related to the sample which warrant 
caution when interpreting the findings. A clinical sample which was 
already being treated with an AchI was used in this study. This is a 
significant limitation because it means that these two variables could 
have confounded the results. This is because it is unclear whether the 
correlations between the MMSE and the alternative cognitive tests 
were due to a true relationship between the measures in terms of the 
cognitive domains that were being measured, or due to the effect of 
the diagnosis and/ or the drug treatment. Subsequently, this study 
does not provide evidence that the correlations or the cut-off scores 
would be the same if a non-clinical sample was used, or for those 
who are not being treated with an AchI.  
 
Given that dementia is a complex disease and clinical population is 
heterogeneous (Rockwood et al, 2007; Robillard, 2007), the 
correlations could be unstable. This is because variations in the 
impact of the disease across the dementia population could mean 
that the same correlations (Table 1) may not be found in a repeated 
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study. Although it could also be argued that it is unlikely that the 
medication would have had a drastic impact on the MMSE scores 
(Birks & Harvey, 2006), this cannot be said for the alternative 
cognitive tests. Previous research in this area has shown that 
neuropsychological tests, such as the Symbol Digit Modalities Test, 
have demonstrated better outcomes, even when the MMSE score has 
not changed (Salloway et al, 2004).  
 
This does not invalidate the findings of this research. It does provide 
justification for further research efforts in this area, specifically using 
the index tests selected in this study. This would expand on the 
findings of this study. The limitations could be rectified by 
administering the seven cognitive tests with a non-clinical sample. In 
addition, a study using a clinical sample which is not being treated 
with an AchI would also provide further information about what effect 
the medication has on the relationship between the selected cognitive 
tests and the MMSE.  
 
Finally, there is no evidence that these measures are equivalent 
across cultural groups. Therefore the outcome of this study will not 
lead to any direct benefits for non-English speakers. Although the 
measures may result in benefits for people who are non-verbal in the 
future, it is important to differentiate between those with expressive 
and receptive language difficulties. Individuals who experience 
difficulty understanding spoken language would still experience 
difficulty completing these assessments, because all instructions are 
delivered using spoken language.  
 
4.4 Additional limitations of study 
 
Diagnosis 
There are a number of methodological issues which can arise when 
conducting research with people with dementia, when recruiting from 
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different NHS sites, and when limited by resources. The background 
literature and a period of pre-study consultation with health 
professionals highlighted potential challenges and these were taken 
into consideration when planning this study. There is considerable 
variability in cognitive and functional ability within each dementia 
type illness (Crystal et al, 1988; Rockwood et al, 2007). Although 
„gold standard‟ diagnostic criteria have been recommended by various 
bodies for each dementia type illness, there is considerable variability 
within and across services of diagnostic procedures that are being 
used (Cerejeira & Mukaetova-Ladinska, 2007). There is evidence to 
suggest that whilst there is good inter-rater reliability and appropriate 
levels of sensitivity and specificity, the diagnostic procedures reported 
within research achieve higher levels of inter-rater reliability than can 
be found in clinical practice (Crystal et al, 1988). In a resource 
limited NHS it is not always possible for clinicians to fulfil all of the 
rigorous criteria of standardised diagnostic procedures, such as 
detailed laboratory, neurological and neuropsychological 
examinations. Whilst this is imperative within the context of scientific 
research to make comparisons across studies, clinicians have to make 
best use of the resources available to them.  
 
Subsequently, this study did not set specific diagnostic criteria for 
referrers, apart from identifying participants with a diagnosis of a 
dementia type illness. Given that this research was time-limited, 
strict criteria may have compromised the rate of recruitment.  
However, this imposed restriction on the methodology as data was 
not collected to validate that the participants had been classified 
correctly, on the basis of the gold standard classifications systems 
specified for each dementia type illness (Rockwood et al, 2007). This 
will make it more difficult to make comparisons with other studies, or 
research which seeks to expand on this study.   
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Previous studies which have carried out research using an NHS 
sample have incorporated extensive diagnostic procedures within 
their study methodology. This included standardised diagnostic 
clinical interviews, carer interviews, neuropsychological assessments, 
detailed review of clinical notes, neurological/ laboratory 
examinations and assessments of activities of daily living (Robillard, 
2007). However, these studies had multiple research personnel, 
whilst the data collection for the current study was limited to one 
researcher. If this study was to be repeated, it would be improved by 
a more rigorous methodology, which should include the collection of 
detailed information about the sample as described above.  
This study recruited participants with any dementia type illness, 
despite the fact that the NICE guidelines are specific to patients with 
AD. Consultations with three psychiatrists, highlighted that recruiters 
may experience difficulty selecting pure cases of a specific dementia 
type illness because of the high rates of mixed presentations, which is 
also documented in the literature (Chen, 2004). Furthermore, 
clinicians also reported that patients with mixed presentations, 
overlapping symptoms or a moderate score on the MMSE were being 
treated with AchI, especially if AD was judged to be the dominant 
disease (NICE, 2007). This is despite the fact that NICE guidance 
specifically state that AchI should only be prescribed to patients with 
AD (NICE, 2007). However, the guidelines do state that patients with 
a mixed presentation can be prescribed Aricept if AD is judged to be 
the predominant disease (NICE, 2007). In addition, difficulties 
regarding differential diagnosis can result in uncertainty in providing 
a definitive pure diagnosis, which is perhaps contributing to the 
variability in prescribing practices (Doyle, 2001). Including only 
people with a pure diagnosis of AD would have lead to a lowered 
recruitment rate and also excluded people for whom the guidance is 
also relevant (NICE, 2007). In addition, since this research was 
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interested in how scores on the MMSE would correlate with 
alternative cognitive tests, and that even pure cases of AD are not a 
homogenous sample in terms of their cognitive functioning, this 
would not confound the results of the study. Furthermore, this study 
was not aiming to provide a profile of how people with AD perform on 
cognitive tests.  
 
4.5 Alternative cognitive tests 
When selecting tests for this study, I was limited by what tests were 
available and most commonly employed by clinicians. Furthermore, 
there are multiple cognitive tests which do not require spoken 
language to be completed; however it was not practical to include 
any additional measures or to carry out a comprehensive critical 
review of all cognitive measures prior to conducting the study. 
Therefore, in the planning stages the „compendium of 
neuropsychological tests‟ (Strauss et al, 2006) was consulted for 
identification of potential tests, which were then reviewed in more 
detail. However, given the significant findings of this study, a 
replication of this study using different measures would be of equal 
interest.  
 
4.6 Further research 
Extension of study  
The lead researcher spent considerable time consulting with 
professionals working within older peoples Mental Health Services for 
recruitment. This generated interest and formed a collaborative 
alliance between the researcher and the NHS staff.  The small sample 
size does not reflect a lack of interest from potential referrers.  The 
recruitment rate was lowered due to delays related to changes in 
clinical research supervision provisions in the area, delays in delivery 
of test materials from publishers, and time taken for ethical approval 
from three bodies.  Subsequently mental health teams are continuing 
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to refer participants and therefore data will be collected for a further 
three months to increase the sample size for an equal prevalence rate 
of negative and positive cases.  
 
Further statistical analysis 
This study did not explore whether a combination of the index tests 
could increase the predictive accuracy in identifying positive cases for 
treatment. However, given the unequal prevalence rates in this 
sample, this may be a redundant analysis to carry out at this stage. 
However, a replication of this study with a larger sample and equal 
prevalence rates would warrant further statistical analysis using 
multiple-logistical regression techniques to explore this more reliably. 
Based on literature citing that the speed and low cost attributions of 
the MMSE result in its popularity (Strauss et al, 2006), this could be 
one model which could be used to inform a regression analysis. The 
combined cumulative administration time of the SDMT, CDT and CTT1 
is 15 minutes. Therefore, the combined predictive accuracy of these 
measures would be of interest in future analysis. However, one would 
have to bear in mind that the MMSE is not a gold standard diagnostic 
test and has psychometric instability. This means that it is unlikely 
that any test will achieve 100% predictive accuracy, and this may be 
appropriate as neuropsychological tests are generally more reliable 
and valid (Lezak et al, 2004).  
 
Administering tests using non-verbal cues 
In the planning stages of this study we considered administering the 
RCPM and CTT using non-verbal cues. It has been found that both 
these measures can be administered in this way (D‟Elia et al, 1996 
Raven, 2000; Strauss et al, 2006). However, the lack of standardised 
guidelines about what gestures to use instead of verbal instructions 
makes it difficult to administer these tests in this way. Furthermore, 
any results obtained using this method, in the context of research, 
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would have made it difficult to establish whether participants‟ 
performance was an accurate measure of their cognitive functioning 
or confounded by their difficulties interpreting non-verbal 
instructions. The missing data from the CTT2 indicates that non-
verbal gestures may cause more confusion within a dementia 
population. Nonetheless, research exploring the potential of 
administering the RCPM and CTT using gestures in a dementia 
population, using quantitative and qualitative methods would expand 
on this the findings of this study. Qualitative research could explore 
the participant‟s experience of completing tests using non-verbal 
gestures. This is relevant as it may highlight additional factors which 
can influence performance, such as discomfort, frustration and/ or 
confusion. 
 
4.7 Critical Reflection 
This reflection will begin by outlining the positivist epistemological 
positioning of this research and why it is necessary for it to be so as it 
is embedded within the medical model. The strengths and 
weaknesses of the positivist scientific position will be outlined in 
relation to how these are manifested in the context of this research. 
Finally, the post-positivism epistemology is discussed as an 
appropriate alternative in the context of social research, 
neuropsychological assessment and the discovery of human 
experience.  
 
Philosophical position of this research 
All research aims to formulate or discover something new. When 
conducting research, within a clinical setting, using clinical 
populations to aim to improve assessment practices for medical 
treatments, you become bound by certain standards or „philosophical 
positions‟ from which your research will need to be based, in order for 
it to be valued. Indeed, Emanuel and colleague (2000) stated that in 
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order for research to be valuable it needs to be scientifically valid 
(Emanuel, Wendler & Grady, 2000). The techniques employed within 
this research, namely seeking ethical approval or scrutiny over study 
methodology, testing hypotheses, reviewing psychometric data of 
tests to learn about their „reliability‟ and „validity‟, and controlling for 
confounding variables during assessment are seen as embodying the 
scientific method or positivist epistemology.  
 
Much contemporary philosophical thought especially that which 
affects the social sciences, revolves around the question of whether 
„science‟ occupies a special privileged place in human thought about 
reality (Hughs & Sharrock, 1990). There is ample evidence that many 
believe it does. For instance, NICE guidelines were developed on the 
back of evidence gathered from RCTs. RCTs are considered the „gold 
standard‟ in medical research (Altman, 1996). The efficacy of the 
AchIs reported by carers, which was based largely on carer 
interviews, did not provide scientifically valid evidence of large 
enough effect to prove the drugs were effective. Thus, carer reports 
had minimal impact on guidelines. The use of the MMSE on the other 
hand as a tool to stratify and measure outcomes gained importance, 
despite reports of a 1 point change (Birks & Harvey, 2006), which can 
be due to error variance alone. Thus, this is contrary to what is 
viewed as being minimal standards in science. The bias towards 
science is clear, or at least the importance placed on quantifiable data 
over qualitative data is. Indeed, standards for what makes research 
with human subjects ethical described by Emanuel and colleagues 
(2000) stated that “the overarching objective of clinical research is to 
develop generalisable knowledge to improve health and/ or increase 
understanding of human biology” (pp. 2701). However, there is some 
logic to this, especially in the context of a National Health Service and 
due to the need to provide effective but economical healthcare to the 
masses. Therefore, research in the context of healthcare provision 
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does need to produce evidence that is generalisable. However, the 
notion that evidence from RCTs are generalisable is questionable as 
they employ restrictive inclusion and exclusion criteria, which make 
the sample unrepresentative of the population the evidence is to be 
generalised to.  
  
The initial impetus to carry out this research was about addressing 
the unacceptable inequalities posed by the scientific method to 
minority groups. This includes ethnic minority groups and those with 
disabilities. The „scientific method‟ does not cater well for these 
groups. Hence, they are excluded from RCTs (Britton, 1999) or 
excluded from essential clinical guidelines (NICE, 2007). This is 
largely because it is more difficult and costly to control for all the 
variables that could impact on how they will perform on respected 
measures. In order to impact on practice in this context, the only 
evidence which is likely to have any impact is those that are 
quantifiable and generalisable.  
 
In addition, the drive to generate „generalisable‟ results will be 
motivated in part by the economic gain of this. For instance, there is 
no financial profit to be made from developing cognitive tests for 
minority groups. Firstly the scientific enquiry would be time 
consuming, costly and will only benefit the smallest number of 
people. The lack of regard for including minority groups within RCTs 
by pharmaceutical companies for AchI trials is reflective of this. The 
current market for AchI in the UK is £65 million (Kmietowicz, 2006) 
and this is without the inclusion of minority groups. Therefore it is 
possible that making drugs more accessible for these groups is not 
seen as being worth their while, or necessary.  
 
Neuropsychology can also be described as a positivist disciple due to 
the emphasis on the scientific method of measuring behavioural 
correlates of neurological functioning. However, neuropsychology 
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does acknowledge the multiple sources of score variance, including 
the environment and culture. Therefore, the combination of 
assessment modalities such as observations, clinical interviews, carer 
interviews and a detailed history of developmental and environmental 
experiences are all equally emphasised (Lezak et al, 2004). The 
interventions also emphasise rehabilitation and compensation, rather 
than cure.   
 
There are also important insights gained about human experience 
using social constructivist methods such as Interpretative 
Phenomenological Analysis. This technique aims to understand how a 
person makes sense of their experiences and is less concerned about 
generalising findings. In the context of this research, valuable 
insights were gained through observing and engaging with 
participants. They were able to describe their experience of testing 
and what informed their performance. For instance, a participant 
reflected that they were a perfectionist and preferred to get things 
exactly right or not try at all. Hence, their difficulties with copying  
the Rey Complex Figure Test were likely to be more about their 
personality rather than impaired constructional ability. However, 
when reporting the findings of this study, greater emphasis was 
placed on findings for which there were documented quantitative 
evidence. This is because despite individual differences, the 
quantitative data also provided valuable insights. However, in clinical 
practice both these sources of evidence can be taken together to 
make more accurate interpretations of scores. When test scores do 
not correspond to what is observed in practice, further assessment is 
required. These ideas are firmly placed within the post positivist 
epistemology proposed by Karl Popper (Hughs & Sharrock, 1990).    
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APPENDICES 
Appendix 1: Instructions to Authors 
 
International Journal of Geriatric Psychiatry 
1. AIMS & SCOPE 
The rapidly increasing world population of aged people has led to a 
growing need to focus attention on the problems of mental disorder in 
late life. The aim of the International Journal of Geriatric Psychiatry is 
to communicate the results of original research in the causes, 
treatment and care of all forms of mental disorder which affect the 
elderly. The Journal is of interest to psychiatrists, psychologists, 
social scientists, nurses and others engaged in therapeutic 
professions, together with general neurobiological researchers. 
The Journal provides an international perspective on the important 
issue of geriatric psychiatry, and contributions are published from 
countries throughout the world. Topics covered include epidemiology 
of mental disorders in old age, clinical aetiological research, post-
mortem pathological and neurochemical studies, treatment trials and 
evaluation of geriatric psychiatry services. 
2. MANUSCRIPT CATEGORIES 
The International Journal of Geriatric Psychiatry invites the following 
types of submission: 
Research Articles 
Research Articles are the Journal‟s primary mode of scientific 
communication. Peer-review of Research Articles will be handled by 
the most appropriate Editor. Research Articles must not exceed 3500 
words of body text, and are limited to 6 figures/tables. 
MANUSCRIPT PREPARATION 
Manuscripts must be written in English. 
Text should be supplied in a format compatible with Microsoft Word 
for Windows (PC). Charts and tables are considered textual and 
should also be supplied in a format compatible with Word. All figures 
(illustrations, diagrams, photographs) should be supplied in jpg, tiff 
or eps format. 
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All manuscripts must be typed in 12pt font and in double space with 
margins of at least 2.5 cm. 
Manuscripts must comply with the word limits defined in section 2, 
and include: 
Title Page 
The first page of the manuscript should contain the following 
information: 
 the title of the paper  
 a running head not exceeding 50 characters  
 2–6 article keywords and up to 4 key points  
 names of authors  
 names of the institutions at which the research was conducted  
 name, address, telephone and fax number, and email address of 
corresponding author  
 the name(s) of any sponsor(s) of the research contained in the 
paper, along with grant number(s)  
 the word count of the body text 
Structured Abstracts 
Authors submitting Research and Review Articles should note that 
structured abstracts (maximum 250 words) are required. The 
structured abstract should adopt the format: Objective, Methods, 
Results, Conclusions. (Authors of Reviews may use Design instead of 
Method.) Abstracts should contain no citation to other published 
work. 
This should in general, but not necessarily, be divided into sections 
with the headings: Introduction, Methods, Results, Discussion, 
Conclusion. 
Tables and Figures 
Tables and figures should not be inserted in the appropriate place in 
the text but should be included at the end of the paper, each on a 
separate page. 
Tables and figures should be referred to in text as follows: Figure 1, 
Figure 2; Table 1, Table 2. The place at which a table or figure is to 
be inserted in the printed text should be indicated clearly on a 
manuscript. Each table and/or figure must have a legend that 
explains its purpose without reference to the text. 
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References 
 
References should be in 'Harvard' format, i.e, names and dates in 
brackets in the text (Jones, 2000; Smith and Jones, 2001; Jones et al 
., 2002), and the full reference listed at the end of the paper, in 
alphabetical order by first author, as follows: 
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(Titles of periodicals should be abbreviated according to the style 
used in Index Medicus.) 
 
5. DECLARATION 
 
Conflict of Interest 
 
Authors are responsible for disclosing all financial and personal 
relationships between themselves and others that might bias their 
work. To prevent ambiguity, authors must state explicitly whether 
potential conflicts do or do not exist. Investigators should disclose 
potential conflicts to study participants and should state in the 
manuscript whether they have done so. Authors should describe the 
role of the study sponsor(s), if any, in study design, in the collection, 
analysis and interpretation of data, in the writing of the report and in 
the decision to submit the report for publication. If the supporting 
source had no such involvement, the authors should so state. 
 
Ethics 
 
When reporting experiments on human subjects, indicate whether the 
procedures followed were in accordance with the ethical standards of 
the responsible committee on human experimentation (institutional or 
regional) and with the Helsinki Declaration of 1975, as revised in 
1983. Do not use patients' names, initials or hospital numbers, 
especially in illustrative material. When reporting experiments on 
animals, indicate whether the institution's or a national research 
council's guide for, or any national law on, the care and use of 
laboratory animals was followed. A statement describing explicitly the 
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ethical background to the studies being reported should be included 
in all manuscripts in the Materials and Methods section. Ethics 
committee or institutional review board approval should be stated. 
 
Patients have a right to privacy that should not be infringed without 
informed consent. Identifying information should not be published in 
written descriptions, photographs and pedigrees unless the 
information is essential for scientific purposes and the patient (or 
parent or guardian) gives written informed consent for publication. 
Informed consent for this purpose requires that the patient be shown 
the manuscript to be published. Identifying details should be omitted 
if they are not essential but patient data should never be altered or 
falsified in an attempt to attain anonymity. Complete anonymity is 
difficult to achieve and informed consent should be obtained if there 
is any doubt. For example, masking the eye region in photographs of 
patients is inadequate protection of anonymity. 
 
Authorship 
All persons designated as authors should qualify for authorship and 
all those who qualify should be listed. Each author should have 
participated sufficiently in the work to take public responsibility for 
appropriate portions of the content. One or more authors should take 
responsibility for the integrity of the work as a whole, from inception 
to published article. Authorship credit should be based only on 1) 
substantial contributions to conception and design, or acquisition of 
data, or analysis and interpretation of data; 2) drafting the article or 
revising it critically for important intellectual content; 3) final 
approval of the version to be published. Conditions 1, 2 and 3 must 
all be met. Acquisition of funding, the collection of data or general 
supervision of the research group, by themselves, do not justify 
authorship. All others who contributed to the work who are not 
authors should be named in the Acknowledgements section. 
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Appendix 3: Participant invitation letter 
 
 
 
Trent Doctorate of Clinical Psychology 
Institute of Work Health and Organisations  
University of Nottingham 
International House, B Floor 
Jubilee Campus 
Wollaton Road 
Nottingham 
NG8 1BB 
The assessment of dementia severity using non-verbal 
cognitive tests 
Invitation letter 
Dear Sir / Madam, 
 
We would like to invite you to participate in a research study taking 
place in your area. We would appreciate it if you would take some 
time to read the following information and share it with others if you 
like. If any aspect of this information is unclear or if you would like 
further information please contact the lead researcher on the contact 
details provided at the end of this letter.  
 
What is the purpose of the study? 
This study is interested in the assessment of older people with 
mental health difficulties as a result of dementia. The purpose of this 
study is to find alternative methods of assessing people’s difficulties 
and needs, when the usual assessment methods cannot be used.  
 
Dementia is an illness most common in people over the age of 65, 
but can also affect people under 65. Dementia can cause difficulties 
with mental abilities such as memory, attention, concentration, vision 
and reading. This can make it harder for people to remember 
information and cause them to become confused. It is important for 
health care professionals to carry out assessments to find out what 
difficulties the individual is experiencing and what treatment could be 
helpful for them. 
 
Lead Researcher:  
Sobia Khan 
Trainee Clinical Psychologist 
Picture 
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One method of assessing how individual’s memory, attention, vision 
and language are working is to use assessments that test their 
mental abilities. However, the most commonly used tests are in 
English and people need to be able to understand and speak 
English to do them. So, if a person cannot speak English or has 
difficulty with spoken language it can be difficult to test their mental 
abilities.  The aims of this research are to examine whether 
alternative tests which do not require you to be able to read, write or 
speak English can be just as useful. 
 
Why have I been chosen? 
You have been chosen because you are over 65 and you can speak 
English. You have also been chosen because you may be being 
assessed or treated by a mental health professional because you 
are experiencing difficulties with mental processes such as memory, 
attention and concentration.  
 
Do I have to take part? 
No, it is up to you whether or not you take part. If you decide to take 
part you will be given a consent form which you will need to sign if 
you decide to take part and you will be given a copy of both the 
signed consent form and an information sheet. If you decide that you 
would prefer to not take part, this would not affect the standard of 
care you receive.  
 
What will happen to me if I take part? 
If you are happy to take part, your nurse/ doctor will pass your 
telephone number to the lead researcher, who will call you to 
arrange an appointment.  The researcher will talk through the study 
with you and you can ask questions. If you choose to take part, we 
would arrange another appointment to carry out some tests or if you 
have time we could do them the same day. This will take 
approximately one hour and fifteen minutes and you will be allowed 
to take a break at any time. The tests are similar to puzzles involving 
drawing, remembering objects or carrying out tasks using 
instructions.  
 
Will my taking part in this study be kept confidential? 
Yes. We will follow ethical and legal practice and all information 
which is collected about you during the course of the research will 
be kept strictly confidential.  The research team will only have 
access to your research notes, not any medical notes.   
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Contacts for further information 
If you require any further information regarding the study please 
contact the following people who are part of the research team. If 
you would prefer independent advice from a body that is not 
involved in this study, you can contact Alzheimer’s Society or the 
Patient Advice and Liaison Services.  
 
Lead Researcher 
Sobia Khan (Trainee Clinical 
Psychologist)                                                                
University of Nottingham                                                                                                                 
Mobile:  
Academic Research Supervisor 
Dr Roshan Nair (Consultant 
Clinical Psychologist)                                                       
University of Nottingham                                    
Tel:  
Clinical Research Supervisor 
Dr David Connelly: (Consultant 
Clinical Psychologist)                                                    
Highbury Hospital  
Tel:  
 
Independent agencies who you can contact for further advice about 
taking part in this study: 
Patient Advice and Liaison 
Services (PALS) 
 
PALS 
Duncan Macmillan House 
Porchester Road, 
Nottingham 
NG3 6AA 
Freephone Helpline: 0800 
0153367 
Alzheimer's Society 
 
7 Mansfield Rd 
Nottingham, NG1 3FB 
              
 
Tel: 0115 934 8468 
 
Thank you for taking the time to read this invitation letter and 
considering taking part in this study.   
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Appendix 4: Referrer information sheet 
 
Trent Doctorate of Clinical Psychology 
Institute of Work Health and Organisations  
University of Nottingham 
International House, B Floor 
Jubilee Campus 
Wollaton Road 
Nottingham 
NG8 1BB 
 
 
The assessment of dementia severity using non-verbal 
cognitive tests 
 
Referrer Information sheet 
 
Dear Colleague,  
 
You are being invited to take part in a research study by assisting with the 
recruitment of participants. It is hoped that this information will provide you with 
the necessary details so to make an informed decision about approaching your 
patient caseloads. Please feel free to contact the lead researcher for further 
information, or if you are interested in any part of this research and should like 
to discuss it further.  
 
Who is conducting the research? 
 
I am a second year trainee clinical psychologist currently training on the Trent 
Doctorate of Clinical Psychology. I am conducting this research as part of my 
professional training and qualification.  
 
Background 
 
The National Institute of Clinical Excellence has recommended for the Mini-
Mental State Examination (MMSE) to be used to assess if a patient with 
dementia as a result of Alzheimer’s Disease may be eligible for treatment with 
Cholinesterase inhibitors such as Aricept. The guidelines state, those who score 
within the moderate range (10-20 points) on the MMSE can be prescribed 
Cholinesterase inhibitors, however, the MMSE has been designed for patients 
who are able to speak English. The NICE acknowledge that those who are 
unable to complete the MMSE due to language barriers, should not be 
discriminated against, but do not provide any additional guidance for clinicians. 
It is important to research into alternative forms of cognitive assessment for 
older people with dementia to ensure that individuals from diverse cultural and 
ethnic backgrounds and people who are non-verbal have equal access to 
services within the NHS. 
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Aims of research 
 
The aim of this study is to determine if alternative cognitive assessments, that 
do not rely on participants English speaking ability, can provide equivalent 
information to the MMSE and differentiate those eligible for treatment with 
cholinesterase inhibitors such as Aricept, from those who are not.  
 
The hypotheses are: 
 
1. There will be a significant correlation between participant’s total scores 
on the MMSE and their total scores on the Rey-Osterrith Complex Figure Test 
(ROCF), Colour Trails Test (CTT) Raven’s Colour Progressive Matrices 
(RCPM) the Clock Drawing Test (CDT), the Brixton test and the Symbol Digit 
Modalities Test (SDMT). 
 
2. The participant’s performance on the ROCF, CCT, RCPM, CDT, the 
Brixton test and the SDMT will differentiate those eligible for treatment of 
Aricept (10-20 moderate score on MMSE) from those who are not. 
 
What will my patients have to do? 
 
This will be a within groups design.  A total of 37 participants are needed in this 
study to complete all seven of the above tests either at their homes or at service 
settings. The testing will take approximately 1 hour and 15 minutes and 
participants will be allowed a break at any time during testing.  
 
Inclusion Criteria Exclusion Criteria 
Older adults (65+)                                                                                                                                                         
 
Non-English speakers                                      
Capacity to consent Bilinguals (unless 
English is their first 
language)                                                                                                        
Cognitive Difficulties – 
Patients who are 
experiencing significant 
cognitive difficulties and 
are seeking assessment, 
but it is too soon to 
confirm a diagnosis.  
Diagnosis of a mood 
disorder which is likely 
to be impacting on their 
cognitive abilities. 
Diagnosis of a Dementia 
type illness – any type 
including mix 
presentations.  
Difficulties with fine 
motor skill (unable to 
write/draw/hold a pencil) 
All English speaking                                                                                                                                       Blind
 Deaf   
 
 
 
  Page 178 of 209       
 
What do I have to do? 
 
I would appreciate it if you could identify potential participants from your case 
loads, which meet the inclusion and exclusion criteria, and find out if they may 
be interested in taking part in this research project. I will provide you with 
invitation letters to hand out to your patients and to find out if they are happy for 
you to forward their contact details to myself. I will make contact to arrange an 
informal discussion or visit to talk through the participant information sheet and 
gain informed consent.   
 
Who has reviewed the research? 
 
This study has been reviewed and given favourable opinion by a Research 
Ethics Committee in your local area. In addition to this, research supervisors 
based at the University of Nottingham will monitor the research and provide 
supervision to the lead researcher. The clinical aspects of the research will be 
supervised by a qualified clinical psychologist working in your area.  
 
What will happen to the results of the research? 
 
The participants will receive a short report outlining their performance on tests if 
they wish. If the participant provides consent, this information will also be made 
available to referrers. 
 
The results of the research will be written up as part of a doctorate thesis. It is 
hoped the research will lead to publication and that any results will be 
disseminated in an appropriate format to the staff teams who support the 
recruitment of participants, the older people’s mental health services in 
Nottinghamshire, and the ethics and R & D departments.   
 
A flow chart has been attached to the end of this information sheet to illustrate 
the process of this research project. If you would like further information please 
do not hesitate to contact myself or Dr Roshan Das Nair (Consultant Clinical 
Psychologist/ Academic research supervisor) on the numbers provided at the 
end of this information. Thank you for taking the time to read this information 
sheet and considering taking part in this research.  
 
Yours sincerely 
 
 
Sobia Khan 
Lead Researcher/ Trainee Clinical Psychologist 
 
Contact details: 
 
Lead Researcher 
Sobia Khan (Trainee Clinical Psychologist)                                                                
University of Nottingham                                                                                                                
Tel:  
Mobile:  
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Clinical Research Supervisor 
Contact details 
 
Academic Research Supervisor 
Contact details 
The assessment of dementia severity using non-verbal cognitive 
tests 
 
Flow Chart  
Explain study to health care professionals                                                                                                            
Provide referrer information sheets 
 
 
Health care professionals approach patients that meet inclusions/ exclusion criteria                                                                 
Hand out Invitation letters 
Contact details for interested patient’s are passed on to lead researcher 
 
 
Chief Investigator contacts participants and organises an initial appointment to talk through the 
details of the research and gain informed consent 
 
 
Book an appointment to carry out tests 
 
 
Testing                                                                                                                                                                   
(Administer seven tests) 
 
 
Analyse date 
 
 
Provide short summary of test results to each participant 
 
 
Write up of thesis 
 
 
Dissemination of results 
 
 
 
 
 
 
Exclude participants 
if they do not meet 
the inclusion criteria 
and meet exclusion 
criteria 
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Appendix 5: Referral form 
 
The assessment of dementia severity using non-verbal 
cognitive tests 
Lead Researcher: Sobia Khan 
Trainee Clinical Psychologist 
Tel: 07974211006 or 07805535541 
Contact Details:  
Trent Doctorate of Clinical psychology 
Institute of Work Health and Organisations 
University of Nottingham 
International House, B Floor 
Jubilee Campus 
Wollaton Road 
Nottingham 
NG8 1BB 
 
Tel:  0115 8466646 
 
Clinical research supervisor: 
Dr David Connelly 
Consultant Clinical Psychologist 
Tel: 0115 9770000 
Fax: 01158542202 
 
 
Thank you for taking the time to talk to your patients about this research project. Please 
hand the Invitation letters to your patients when you first tell them about the research. If 
they have expressed an interest in this study or would like further information, please note 
their contact details below. I would also appreciate it if you could make a note of your 
patient’s most recent MMSE score. Please ensure your patients consent to their 
information being passed on to me.   
 
Participant details 
 
Participant Name: 
 
Carer/ significant other: 
Address: Address (if different): 
  
  
  
Post code: 
 
Tel: Post code: Tel: 
 
Last MMSE score: 
 
Date MMSE was administered: 
Clinician/ Referrer name:       
 
Job title:  
Date of referral:  
Place of work: 
 
Contact Number: 
 
Thank you for the above information and your contribution to this research. Please post this 
form to the lead researcher at the address provided above or fax it to David Connelly at the 
number above.   
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Appendix 6: Participant information sheet 
 
 
 
Trent Doctorate of Clinical Psychology 
Institute of Work Health and Organisations  
University of Nottingham 
International House, B Floor 
Jubilee Campus 
Wollaton Road 
Nottingham 
NG8 1BB 
The assessment of dementia severity using non-verbal 
cognitive tests 
Participant Information Sheet 
Dear Sir / Madam, 
Thank you for considering taking part in this research. Please read 
the information in this letter for details of the research. If you would 
like further information please contact the lead researcher on the 
contact details at the end of this information.  
 
What is the purpose of the study? 
This study is interested in the assessment of older people with 
mental health difficulties as a result of dementia. The purpose of this 
study is to find alternative methods of assessing people’s difficulties 
and needs, when the usual assessment methods cannot be used.  
 
Dementia is an illness most common in people over the age of 65, 
but can also affect people under 65. Dementia can cause difficulties 
with mental abilities such as memory, attention, concentration, vision 
and reading. This can make it harder for people to remember 
information and cause them to become confused. It is important for 
health care professionals to carry out assessments to find out what 
difficulties the individual is experiencing and what treatment could be 
helpful for them. 
 
One method of assessing how individual’s memory, attention, vision 
and language are working is to use assessments that test the 
individual’s mental abilities. However, the most commonly used tests 
Lead Researcher:  
Sobia Khan 
Trainee Clinical Psychologist 
Picture 
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are in English and people need to be able to understand and speak 
English to do them. So, if a person cannot speak English or has 
difficulty with spoken language it can be difficult to test their mental 
abilities.  The aims of this research are to examine whether 
alternative tests which do not require you to be able to read, write or 
speak English can be just as useful. 
 
Why have I been chosen? 
You have been chosen because you are over 65 and you can speak 
English. You have also been chosen because you may be being 
assessed or treated by a mental health professional because you 
are experiencing difficulties with mental processes such as memory, 
attention and concentration.  
 
Do I have to take part? 
No, it is up to you whether or not you take part. If you decide to take 
part you will be given this information sheet to keep and be asked to 
sign a consent form to show you have agreed to take. You are free 
to withdraw at any time and without giving reason. This would not 
affect the standard of care you receive.  
 
What will happen to me if I take part? 
You will complete some mental ability tests with the lead researcher. 
This will take approximately one hour and fifteen minutes. The tests 
are similar to puzzles, involving drawing, remembering objects or 
carrying out tasks using instructions. We can do these tests at your 
own home or you could come to a clinic near you. We would need to 
make sure that there were no distractions so you can concentrate 
and you have a table that you can lean on to write.  
 
What are the possible disadvantages or risks of taking part? 
We do not anticipate that there will be many disadvantages or risks 
in taking part in this project.  The tests cannot harm you, however, 
some people can feel stressed when they are being tested. There is 
no need to worry about your performance on the tests. You are not 
expected to know all the answers because some of the tests are 
designed to get progressively more difficult. We are not asking you 
to do the tests to find out if you have an illness and your results on 
the tests will not affect the care you are receiving.  
 
If you have any concerns during testing you can talk to the lead 
researcher. We would also like to remind you that you have the right 
to withdraw from this study at any time and without giving a reason.    
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What are the possible benefits of taking part? 
The study will not have any direct benefit for you, but the information 
we get from this study may be helpful for the investigation into 
developing tests for people who have dementia but cannot speak 
English.  
 
What will happen to the results of this study? 
The lead researcher will write up the results of this study for her 
educational course, in the Doctorate in Clinical Psychology. It is also 
hoped that this research will also lead to publications.  If you would 
like, we will give you a short report about how you performed on the 
tests. If you wish to receive a summary of the results please contact 
the lead researcher named at the end of this information. 
 
Will any additional information be collected? 
Information about your age, gender, general health, education level, 
occupation, ethnicity and marital status will need to be collected. 
This is important when conducting research, as people often want to 
know some information about the people that were involved in the 
research. If you are unable to provide this information a relative can 
do this on your behalf. We would need for you to consent for us to 
do this.  
 
What if there is a problem? 
If you have a concern about any aspect of this study, you can 
discuss this with the lead researcher or with her supervisors. If you 
remain unhappy and wish to complain formally, you can do this 
through the NHS Complaints Procedure. Details can be obtained 
from the hospital. In the event that something does go wrong and 
you are harmed during the research and this is due to someones 
negligence then you may have grounds for a legal action for 
compensation against Nottinghamshire Healthcare Trust but you 
may have to pay your legal costs. The normal National Health 
Service complaints mechanisms will still be available to you.  
 
Who will have access to information about me? 
Only the researchers involved in the running of this study will have 
access to your information. With your consent we will send a letter to 
your consultant confirming your participation in this study. This is 
standard practice for patients who are invited to take part in 
research studies.  
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Who is organising the research? 
The study is being organised by the lead researcher and supervisors 
from the University of Nottingham.  
 
Who has reviewed the study? 
All research in the NHS is looked at by independent group of people, 
called a Research Ethics Committee to protect your safety, rights, 
wellbeing and dignity. This study has been reviewed and given 
favourable opinion by a Research Ethics Committee in your local 
area.  
In addition to this, research supervisors based at the University of 
Nottingham will monitor the research and provide supervision to the 
lead researcher. If you decide to participate you will be given a copy 
of this information sheet and a signed consent form to keep. 
 
Contacts for further information 
If you would prefer independent advice from a body that is not 
involved in this study, you can contact Alzheimer’s Society or the 
Patient Advice and Liaison Services.  
Lead Researcher 
Sobia Khan (Trainee Clinical 
Psychologist)                                                                
University of Nottingham                                                                                                                
Mobile:  
Clinical Research Supervisor 
Dr David Connelly: (Consultant 
Clinical Psychologist)                                                    
Highbury Hospital
Tel:  
Academic Research Supervisor 
Dr Roshan Nair (Consultant 
Clinical Psychologist)                                                       
University of Nottingham                                                                                            
Tel:  
 
Independent agencies who you can contact for further advice about 
taking part in this study: 
Patient Advice and Liaison 
Services (PALS) 
 
PALS 
Duncan Macmillan House 
Alzheimer's Society 
 
7 Mansfield Rd 
Nottingham, NG1 3FB 
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Porchester Road, 
Nottingham 
NG3 6AA 
Freephone Helpline: 0800 
0153367 
01            
 
Tel: 0115 934 8468 
 
Thank you for taking the time to read this information sheet and 
considering taking part in this study.   
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Appendix 7: Capacity to consent assessment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The assessment of dementia severity using non-verbal cognitive tests 
What is the research about? 
 
Why do you think you have been approached to take part in this research? 
 
Do you have to be in this study if you do not want to participate? 
 
 
What will you be asked to do if you take part in this research? 
 
 
If you withdraw from this study will you still be able to receive regular 
treatment? 
 
 
How much of your time do you think you would need to give to this 
research? 
 
Who could you ask for more information about this research? 
 
Who could you tell if you had concerns about taking part in this research? 
 
 
 
 
The assessment of participant‟s capacity to consent 
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Appendix 8: Consent form 
   
CONSENT FORM 
Title of Project: The assessment of dementia severity using non-verbal 
cognitive tests 
Name of Lead Researcher: Sobia Khan (Trainee Clinical Psychologist) 
  Please initial 
box 
1 I confirm that I have read and understand the information sheet dated 
09/09/09 (version 5) for the above study.  I have had the opportunity to 
consider the information, ask questions and have had these answered 
satisfactorily. 
 
2 I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical 
care or legal rights being affected. 
 
3 I understand that sections of any of my research notes may be looked at 
by responsible individuals from Nottinghamshire Primary Care Trust or 
University of Nottingham where it is relevant to my taking part in 
research. I give permission for these individuals to have access to my 
records. 
 
4 I confirm that you can approach my carer for some information.  
5 I confirm that you can share information about my performance on the 
tests with a clinician who is involved in my care (e.g care co-ordinator, 
key worker, social worker, psychiatrist, nurse). 
 
6 I agree to take part in the above study  
 
 
Name of patient  
 
Date 
 
Signature 
 
Researcher  
 
Date 
 
 
Signature 
1 for patient; 1 for researcher; 1 to be kept with clinical notes 
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Appendix 9: Procedure and instructions for administering cognitive 
tests 
Testing Procedure and Instructions 
1. Go through participant information sheet 
2. Capacity to consent assessment 
3. Sign consent form 
4. Building rapport 
Remind participants that they can take a break at any point during 
testing. Make a note of when break is taken in data file. 
Administered in private to ensure confidentiality, minimise 
distractions and reduce potential of discomfort.  
Order of tests  
1) Rey Complex Figure Test 
2) Demographics (Demographics and MMSE to be administered to fill 30 
minute gap until delayed trial on RCFT is to be administered) 
3) Mini-Mental State Examination 
4) Ravens Colour Progressive Matrices 
5) Symbol Digit Modalities Test 
6) Brixton Test 
7) Clock Drawing Test 
8) Colour Trails Test 
Rey Complex Figure Test 
Copy Trial: Look at this figure (point to the blank response sheet) I 
would like you to copy that figure onto this sheet of paper (point back 
to the stimulus card and say) copy it so that I know that this is the 
figure you drew. Do a good job. (After the participant has indicated 
that they have understood the instructions to the task, begin timing 
the drawing as the participant starts copying the figure.  
Note time taken and day if testing – do not tell them you will be 
asking them to recall from memory 
Note time when this task finished 
Immediate recall: 3 minutes after – A short time ago I had you 
copy a figure. I would like you to draw that figure again, but this time 
from memory. (point to the blank response sheet and say) Draw that 
figure here.  
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Note time taken and day if testing – do not tell them you will be 
asking them to recall from memory 
Delayed recall: 30 minutes after copy trial – A short time ago, I had 
you copy a figure. I would like you to draw that figure again, but this 
time from memory. (Point to the blank sheet and say) Draw that 
figure here.  
Record the time in the day the trial commenced  
Recognition Trial: Administered immediately after the Delayed 
Recall trial with no intervening task.  
Some of the designs that are printed on these pages were part of the 
larger figure that I asked you to copy earlier. Circle the figure that 
were part of the larger design you copied. Each figure on these pages 
is facing the same direction as in the original, complete design. There 
are four pages, and the designs are numbered 1 to 24. Go ahead and 
begin.  
Mini-Mental State Examination 
Begin by asking the participant if they experience any problems with 
their memory. Then ask may I ask you some questions about your 
memory? These answers are not scored, however, they serve to 
orient the participant to the nature of the examination. The 
instructions are based on standardised instructions provided  
1. Orientation to time: What is the year? 
   What is the season? 
   What is the day of the week? 
   What is the date?  
2. Orientation to place: Where are we now?  
What is the country? 
   What is the city/ town? 
   What part of the city are we now? 
   What is the name of the building we are in now? 
   What is the room we are in now? 
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3. Registration:  
Listen carefully. I am going to say three words. You say them back 
after I stop. Ready? Here they are....Apple, Pause, Penny, Pause, 
Table, Pause. Now repeat those words back to me. ........ Now keep 
these words in mind, I am going to ask you to say them again in a 
few minutes.  
4. Attention and Calculation:  
Now I‟d like you to subtract 7 from 100. Then keep subtracting 7 
from each answer until I tell you to stop. What 100 take away 7? 
If participant refuses to perform the serial 7s task, substitute it with 
the following: 
Spell WORLD forward, then backward 
5. Recall:  
What were those three words I asked you to remember? 
6. Naming: 
What is this? Point to pen 
What is this? Point to watch  
7. Repetition: 
Now I am going to ask you to repeat what I say. Read? “No ifs, ands 
or buts” now you say that. 
Repeat 5 times but only score the first trial 
8. Comprehension: 
Detach next page. Tear it in half. Use the upper half of the page for 
comprehension, reading and drawing subtests. Use the lower half for 
the reading and Drawing items.  
Listen carefully because I am going to ask you to do something. Take 
this paper in your right hand, pause, fold it, pause, and put it on the 
table.  
9. Reading: 
Please read this and do what it says. 
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10. Writing: 
Please write a sentence, if they do not respond, say write about the 
weather.  
Demographics sheet until 30 minutes lapses for RCFT 
11. Drawing: 
Please copy this design.  
Ravens Colour Progressive Matrices 
Look at this (point to upper figure) you see it is a pattern with a piece 
cut out of it. Each of these pieces (point to each in turn) is the right 
shape to fit the space, but only one of them is the right pattern. No1 
is the right shape but is not the right pattern. No2 is not the right 
pattern at all. No3 is quite wrong. No6 is nearly right but it is wrong 
here (point to the white piece). Only one is right. Point to the piece 
which is quite right.  
Now point to the piece which came out of this pattern 
Symbol Digit Modalities Test 
Please look at the boxes at the top of this page. You can see that 
each box in the upper row has a little mark in it. Now look at the 
boxes in the row just underneath the marks. Each of the boxes under 
the marks has a number. Each of the marks in the top row is 
different, and under each mark in the bottom row is a different 
number.  
Now look at the next line of boxes. Just under the top two rows. 
Notice that the boxes on the top have marks, but the boxes 
underneath are empty. You are to fill each empty box with the 
number that should go there according to the way they are paired in 
the key at the top of the page. For example, if you look at the first 
mark, then look up at the key, you will see that the number 1 goes in 
the first empty box. Now what number should you put in the second 
box? That‟s right, so write number 5 in that box. What number goes 
in the next box? That‟s right! Now for practice fill in the rest of the 
boxes until you reach the double line. Then stop!  
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Now when I say “go” write in the numbers just like you have been 
doing and keep going as fast as you can until I say stop. When you 
come to the end of the line, go quickly to the next line without 
stopping. Do not erase as it will waste time, just keep working on the 
next ones as fast as you can.   
Brixton Test 
There are many pages here which all have the same basic design on 
them. There are always ten positions, and one of them is always 
coloured blue (point to the one filled in blue). However, the coloured 
one moves around according to various patterns that come and go 
without warning. These numbers (point to numbers underneath the 
circles) are just here to refer to the position – there is nothing 
complicated or mathematical about this test.  
Now as I turn the pages, your job is to pick up on the pattern as best 
you can. And point to where you think the blue one is going to be on 
the next page. It‟s not guess work, you can work it out. For 
instances, imagine the blue one was here (point to 6) and then when 
I turn the page it goes to 7, and then to 8 and then to 9 – you might 
reasonably expect it next to go to 10.  
From time to time the pattern changes without warning and then it is 
your job to pick up on the pattern as best as you can. Do you 
understand? 
Obviously the first time you have nothing to go on, so your first 
answer will have to be a guess – have a guess as to where the blue 
one will be next.  
Clock Drawing Test 
Clock drawing 
Imagine this is the face of a clock. Put the numbers on the clock face.  
When finished, say: 
Now put the hands on the clock to indicate 10 past 11.  
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Colour Trails Test 1 
Practice Trial 
In this box are different coloured circles with numbers in them. When 
I say “begin” I want you to take this pencil and connect the circles by 
going from 1 to 2 to 3 to 4 to 5 to 6 until you reach the end.  
I want you to connect the circles in the correct order as quickly as 
you can, without lifting the pencil from the paper. If you make a 
mistake, I will point it out. When I do, I want you to move the pencil 
back to the last correct circle and continue from there. The line that 
you draw must go through the circles and must do so in the correct 
order. Do you have any questions? 
Okay lets practice. Put your pencil here where this hand tells you to 
start. When I say “begin” connect the circles in order as quickly as 
you can until you reach the circle next to the hand telling you to stop. 
Ready? Begin.  
Test Trial 
Now I have a sheet with several more numbers and circles. Connect 
the circles in order like you did just a moment ago. Again, work as 
quickly as you can, and do not lift the pencil from the paper as you 
go. Make sure that your lines touch the circles.  
You will start here where the hand tells you to start and end where 
the hand tells you to stop. Ready? Begin.  
Colour Trails Test 2 
Practice Trial 
In this box are different coloured circles with numbers in them. This 
time I want you to take the pencil and connect the circles in order by 
going from this colour 1 (point to pink 1) to this colour 2 (point to 
yellow 2), to this colour 3 (point to pink 3) to this colour 4 (point to 
yellow 4) and so on until you reach the last number next to the hand 
telling you to stop.  
Notice that the colour changes each time you go to the next number. 
I want you to work as quickly as you can. Do not lift the pencil from 
the paper once you have started. If you make a mistake, i will point it 
out. When I do, I want you to move the pencil to the last correct 
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circle and continue from there. As before, the line you draw must go 
through the circles in the correct order. Do you have any questions? 
Practice 
Okay, lets practice 
Put your pencil here next to the hand telling you to start. When i say 
begin, connect the circles in order as quickly as you can, changing 
from one colour to the next, until you reach the hand telling you to 
stop. Ready? Begin.  
Test Trial 
Now I have a sheet with several more numbers and coloured circles. 
Connect the circles like you did just a moment ago. Again work as 
quickly as you can.  
You will start here, where the hand tells you to start and end where 
the hand tells you to stop. Ready? Begin.  
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Appendix 10: Demographic questionnaire  
Demographic Questionnaire  
Title: The assessment of dementia severity using non-verbal cognitive test 
Lead Researcher:  Sobia Khan  
(Trainee Clinical Psychologist) 
Participant Code Number:  
Dob: Education: 
 
Grammer School             Comprehensive 
Age:     College                           Higher education 
Gender:  
 
Male           Female   
University          
Work based training/ apprenticeship 
Occupation / previous occupation 
(please state): 
 
Other  
Please state: 
Diagnosis: 
 
How many years of education do you have?  
When diagnosed: 
 
What age did you complete your education? 
Ethnicity: 
White 
   British     
   Irish    
   Other White 
What was the highest qualification you have 
achieved? 
 
Living arrangements:  
 
Mixed 
   White and Black Caribbean  
   White and Black African  
   White and Asian   
   Other Mixed   
Relationships status:  
Single         
Married      
Divorced    
Widowed  
Other                    Please state: 
Asian or Asian British 
   Indian    
   Pakistani   
   Bangladeshi   
   Other Asian   
Medication: 
 
Black or Black British 
   Caribbean   
   African     
   Other Black    
Co-morbidities: 
 
Chinese or other ethnic group 
   Chinese   
   Other ethnic group 
History of head injury:  
Date of injury: 
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Appendix 11: Sample of feedback report for participant 
 
Trent Doctorate of Clinical Psychology 
Institute of Work Health and Organisations  
University of Nottingham 
International House, B Floor 
Jubilee Campus 
Wollaton Road 
Nottingham 
NG8 1BB 
 
Tel:   
Date 
Address 
 
Dear  
I am writing to thank you for the valuable contribution you have made to my 
research. I understand that you have a review with your care co-ordinator soon 
and you requested for the outcomes of the assessments to be communicated to 
*. 
As you may recall, the research was about trying to find different forms of 
assessment for older people who were experiencing changes in their memory, 
attention or other areas of their mental processing. I carried out seven tests with 
you on Date. Each of these assessed different mental processes and as 
promised, I will provide some feedback below.  
Observations 
During our time together, you were pleasant and appropriate in your social 
interaction. You commented that you had enjoyed the assessment process as it 
was a challenge. You struck me as someone who had some insight and 
awareness about the difficulties you were experiencing and you were taking an 
active role in managing the care and treatment you were receiving from 
services. For instance, you were able to evaluate what assessments had been 
completed so far and were able to tell me that * would be repeating 
assessments with you in a year. You were able to tell me that this was to 
monitor if there had been any change, in the difficulties you are experiencing, 
over time. 
You had no problems with remembering that I was coming to see you or 
recalling the purpose of my research. Subsequently, you were assessed as 
having the capacity to consent to take part in this research.  
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Global cognitive ability 
The Mini-Mental State Examination (MMSE) was used as a general measure of 
your thinking processes. On this, you scored 29 out of 30, which is within the 
‘normal range’. Although this is one point lower than when you were assessed 
previously on this test, it does not necessarily mean that you have experienced 
a decline in your thinking ability, as there can be some variation in scores 
across different assessors. A one point difference is not significant.  
The Clock Drawing Test (CDT) was also administered. You completed this 
successfully without making any errors. This places you within the ‘normal’ 
range.  The symbol Digit Modalities Test was also used as a screening measure 
of difficulties in thinking ability. On this you scored 31, this is again within the 
‘Normal range’.  
As we discussed during our time together, people who are highly educated can 
achieve 30 out of 30 on the MMSE and make no errors on the CDT, but still 
have difficulties with their thinking ability. As you have 23 years of education, 
this would place you in the ‘high level of education range’. It is worth taking this 
into consideration when interpreting any results.   
Visuospatial Constructional ability and Visual Memory 
To assess how you process visual information and your visual memory, I 
administered the Rey Complex Figure Test. On this test you scored within the 
‘Normal range’ on visual-constructional ability. During our time together, you 
highlighted that your professional expertise lie in the field of Architecture. 
Therefore, we would expect someone with your experience to be highly skilled 
in drawing complex figures. When assessing how long it took you to copy the 
figure, your score again fell within the ‘Normal’ range. This suggests that your 
speed of information processing ability was adequate.  
For immediate and delayed visual memory, you scored within the ‘Above 
average range’. For recognition memory, you scored within the ‘Average’. 
These scores suggest that your visual memory processing is within the ‘Normal 
range’. 
Attention and speed of information processing 
The Colour Trails Test, part 1 and 2 were administered to assess your abilities 
in sustained visual attention, visual scanning and speed of information 
processing. Your scores were compared with a population of a similar age to 
you and with similar levels of education to you to interpret the score. On both of 
these tests you scored within the ‘Below Average’ range. 
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Executive processes 
The Brixton test was administered to assess your executive processes. These 
are thinking processes which are related to every-day functioning ability. Some 
examples are abstract reasoning ability, making decisions, showing good 
judgment, maintaining attention, appropriate social behaviour, devising and 
following plans.  
The Brixton test is a rule attainment test which can indicate if someone may 
have problems with executive processes that require further exploration. On this 
test you scored within the ‘Moderate average range’.  
Intellectual and reasoning ability 
The Ravens Colour Progressive Matrices were administered to assess 
intellectual ability and the ability to think clearly. On this measure you scored 35 
out of 36, this suggests that on this measure you scored within the ‘Intellectually 
superior’ range.  
Summary 
From the tests that were completed you presented with strengths in the area of 
visual-constructional ability, visual immediate, delayed and recognition memory 
and in reasoning ability. The scores for speed of information processing, 
attention and executive process were slightly weaker.   
Conclusion 
It is important to remember that the above assessments were completed as part 
of a research project. I collected the data in one visit with you and did not have 
access to a detailed history or any other relevant clinical information what is 
necessary to interpret test scores. In addition, I did not have any information to 
make comparisons about your abilities prior to the onset of your difficulties. 
Therefore, caution must be taken when interpreting the results.  
I have enclosed a copy of the assessment report, which contains all the raw 
scores. I have also enclosed a copy the consent form which you signed on the 
day. I will forward a copy of these documents, together with a copy of this letter 
to  * so that a copy can be placed within your clinical records.  
I would like to take this opportunity to thank you once again for your support 
with this research.  
Yours sincerely 
Sobia Khan 
Lead Researcher & Trainee Clinical Psychologist 
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Cc   
  
Enc  
Assessment Report 
Consent form 
 
Assessment Report 
Name:  
Address:  
Date of birth:  
Reason for referral: Research 
Referred by:  
Date assessed:  
 
Rey Complex Figure Test 
The purpose of this test is to assess visual-spatial constructional ability, speed 
of processing, visual immediate, delayed and recognition memory.  
 Copy Time to 
copy 
Immediate 
recall 
Delayed 
recall 
Recognition 
total 
correct 
Raw score 33 211 23.5 22.5 20 
T score - - 78 76 50 
Percentile >16 >16 >99 >99 50 
Suggested 
clinical 
interpretation 
Normal 
range  
Normal 
range on 
speed of 
processing 
Above 
Average  
Above 
Average 
Average 
 
                               Range of clinical interpretation 
T-score 
range 
Suggested clinical 
interpretation 
>55 Above average 
45 to 54 Average 
40 to 44 Below average 
35 to 39 Mildly impaired 
30 to 34 Mild- to- Moderately 
impaired 
25 to 29 Moderately impaired 
20 to 24 Moderately-to-severely 
impaired 
<19 Severely impaired 
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Mini-Mental State Examination 
This is a screening measure to assess for cognitive impairment particularly in 
older people.  
Domain Score 
Orientation to time 5 
Orientation to place 5 
Registration 3 
Attention and 
calculation 
5 
Recall 3 
Naming 2 
Repetition 0 
Comprehension 3 
Reading 1 
Writing 1 
Drawing 1 
Total 29/30 
 
Raven’s Coloured Progressive Matrices 
This test assesses reasoning ability within the visual modality and intellectual 
ability.  
Score Percentile Grade 
35/ 36 95 percentile Intellectually Superior 
 
Colour Trails Test 
This test assesses speed of attention, sequencing, mental flexibility, visual 
search, and motor function.  
 Raw score Standard 
score 
T score Percentile 
score 
Clinical 
Impression 
Colour 
Trails 1 
73 seconds 90 43 24 Below 
average 
Colour 
Trails 2 
143 
seconds 
83 39 14 Below 
Average 
 
 
 
 
 
Cut off Classification 
27-30 Normal 
21-26 Mild 
11-20 Moderate 
0-10 Severe 
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Brixton spatial anticipation test 
This is a concept (or ‘rule’) attainment task. This task measures one aspect of 
executive functioning.  
Raw score Scaled score Classification 
19 5 Moderate Rang 
 
Raw Score Scaled Score Classification 
0-7 10 Very superior 
8 9 Superior 
9-10 8 Good 
11-13 7 High Average 
14-17 6 Average 
18-20 5 Moderate Average 
21-23 4 Low average 
24-25 3 Poor 
26-31 2 Abnormal 
>31 1 Impaired 
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Symbol Digit Modalities Test 
This is a measure of attention, visual scanning, concentration, and motor and 
psychomotor speed.  
Total score Difference 
from 
sample 
mean  
SD (1) Interpretation Clinical 
Impression 
31 - No norms were available for age group. 
However, this score was equal to what was 
expected of someone between 65 -78 years. 
Mean score was 32.28 (SD 11.27). 
 
 
Score Interpretation 
Scores approximately 1 standard 
deviation (Number in brackets) below 
the mean for a particular age group at 
a particular education level.  
Low scores  
Scores approximately 1.5 standard 
deviations below the mean for a 
particular age group at a particular 
education level.  
Moderately low scores  
Scores approximately 2 standard 
deviations below the mean for a 
particular age group at a particular 
education level.  
Very low scores 
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Clock Drawing Test 
This tests assesses for dementia as well as for visual-spatial, constructional, 
and executive difficulties. Higher T score values indicate higher levels of 
cognitive impairment. The percentiles indicate what percentage of sample of 
older people would score more than what was achieved by participant.  
Errors T Score Percentile Clinical 
Impressions 
0 37 16 Very good 
performance 
 
Range of T scores 
Percentile equivalents for T-scores 
T Scores Approximate 
percentiles 
70 98 
65 93 
60 84 
55 69 
50 50 
45 31 
40 16 
35 7 
30 2 
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Appendix 12: Sample of feedback report for referrer 
 
Trent Doctorate of Clinical Psychology 
Institute of Work Health and Organisations  
University of Nottingham 
International House, B Floor 
Jubilee Campus 
Wollaton Road 
Nottingham 
NG8 1BB 
 
Tel:  
25th September 2009 
The cognitive assessment of dementia severity using non-verbal cognitive 
tests 
Dear  
Re:  
Thank you for approaching your client and contributing to the above research.  * 
provided consent for me to share her results on the cognitive tests with you. I 
have enclosed a copy of the consent form and I would appreciate it if you could 
place this within her clinical records.  
The assessment report will provide a brief outline of the cognitive domains 
which each of the tests measures. I have also included the scores for each test 
and have documented the clinical impressions where possible.  
Please do not hesitate to contact me on the number above should you want to 
discuss these results further.  
Yours sincerely 
 
Sobia Khan 
Lead researcher & Trainee Clinical psychologist  
 
Supervised by: 
 
Dr Roshan Das Nair  
Dr Helen Philpott 
 
 
 
  Page 205 of 209       
 
Assessment Report 
Name: 
Address: 
Date of birth: 
Reason for referral: Assessment of dementia severity research study 
Referred by: 
Date assessed:  
 
Observations: 
Rey Complex Figure Test 
The purpose of this test is to assess visual-spatial constructional ability, speed 
of information processing and visual memory.  
 Copy Time to 
copy 
Immediate 
recall 
Delaye
d recall 
Recognitio
n total 
correct 
Raw score 32 404 
Seconds 
2.5 0 15 
T score - - 21 <20 <20 
Percentile >16 11-16 <1 <1 <1 
Suggested 
clinical 
interpretatio
n 
Normal 
range - 
Intact 
visuospatial 
construction
al skills 
Slower 
speed of 
informatio
n 
processin
g 
Moderately
-to-
severely 
impaired 
Severel
y 
impaire
d 
Severely 
impaired 
 
                               Range of clinical interpretation 
T-score 
range 
Suggested clinical 
interpretation 
>55 Above average 
45 to 54 Average 
40 to 44 Below average 
35 to 39 Mildly impaired 
30 to 34 Mild- to- Moderately 
impaired 
25 to 29 Moderately impaired 
20 to 24 Moderately-to-severely 
impaired 
<19 Severely impaired 
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Mini-Mental State Examination 
This is a screening measure to assess for cognitive impairment particularly in 
older people.  
Domain Score 
Orientation to time 4 
Orientation to place 5 
Registration 3 
Attention and 
calculation 
4 
Recall 1 
Naming 2 
Repetition 0 
Comprehension 3 
Reading 1 
Writing 1 
Drawing 1 
Total 25/30 
 
 
Raven’s Coloured Progressive Matrices 
This test assesses reasoning ability within the visual modality.  
Score Percentile Grade 
11/ 36 5th percentile Intellectually impaired 
range 
 
 
Colour Trails Test 
This test assesses speed of attention, sequencing, mental flexibility, visual 
search, and motor function.  
 Raw score Standard 
score 
T score Percentile 
score 
Clinical 
Impression 
Colour 
Trails 1 
78 seconds 90 43 24 Below 
average 
Colour 
Trails 2 
200 
seconds 
78 35 7 Impaired 
range 
 
 
 
Cut off Classification 
27-30 Normal 
21-26 Mild 
11-20 Moderate 
0-10 Severe 
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Brixton spatial anticipation test 
This is a concept (or ‘rule’) attainment task. This task measures one aspect of 
executive functioning.  
Raw score Scaled score Classification 
21 4 Low average 
 
 
Symbol Digit Modalities Test 
This test is used to assess divided attention, visual scanning, tracking, and 
motor speed.  
Total score Difference 
from 
sample 
mean  
SD (1) Interpretation Clinical 
Impression 
13 32.28  -2.8 
(11.27) 
Very low scores Suggestive of 
cognitive 
difficulties 
 
 
Score Interpretation 
Scores approximately 1 standard 
deviation (Number in brackets) below 
the mean for a particular age group at 
a particular education level.  
Low scores  
Scores approximately 1.5 standard 
deviations below the mean for a 
particular age group at a particular 
education level.  
Moderately low scores  
Scores approximately 2 standard 
deviations below the mean for a 
particular age group at a particular 
education level.  
Very low scores 
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Clock Drawing Test 
This tests assesses for dementia as well as for visual-spatial, constructional, 
and executive difficulties. Higher T score values indicate higher levels of 
cognitive impairment.  
Errors T Score Percentile Clinical 
Impressions 
1 49 50 Quite good 
performance 
 
Range of T scores 
Percentile equivalents for T-scores 
T Scores Approximate 
percentiles 
70 98 
65 93 
60 84 
55 69 
50 50 
45 31 
40 16 
35 7 
30 2 
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Appendix 13: Flow chart of recruitment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
30 participants 
identified 
20 assessed 
and data 
analysed 
All 30 invited to 
take part 
Exclusions (n) 
 
Lack capacity to 
consent (6) 
Did not consent (2) 
Carer concerns (1) 
Mental health (1) 
 
